POSTERS
THU-001 – THU-519

Poster programme version as of 10.04.2020
### NAFLD: Clinical aspects except therapy

<table>
<thead>
<tr>
<th>THU-001</th>
<th>Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 10%</td>
<td>Amalia GASTALDELLI, Italy</td>
</tr>
<tr>
<td>THU-002</td>
<td>Natural history and prognostic factors of compensated cirrhosis secondary to non-alcoholic steatohepatitis in Catalonia</td>
</tr>
<tr>
<td>YI</td>
<td>Octavi BASSEGODA, Spain</td>
</tr>
<tr>
<td>THU-003</td>
<td>Non-alcoholic fatty liver disease fibrosis score predicts cardiovascular mortality in post percutaneous coronary intervention patients: 5-year results from an observational registry</td>
</tr>
<tr>
<td>Top 10%</td>
<td>Dongyoung LEE, Korea, Rep. of South</td>
</tr>
<tr>
<td>THU-004</td>
<td>The association between liver fibrosis and cognitive impairment in type 2 diabetes: a cross-sectional sub-study of the south London diabetes cohort</td>
</tr>
<tr>
<td></td>
<td>Calum MOULTON, United Kingdom</td>
</tr>
<tr>
<td>THU-005</td>
<td>A new vision of non-alcoholic fatty liver disease: a «cardiac» disease per se and a «vascular» disease only with hypertension</td>
</tr>
<tr>
<td>YI</td>
<td>Filippo CATTAZZO, Italy</td>
</tr>
<tr>
<td>THU-006</td>
<td>NASH is emerging as a leading cause of hospitalisation for cirrhosis: results from a real-life, prospective, consecutive cohort</td>
</tr>
<tr>
<td></td>
<td>Christiane STERN, France</td>
</tr>
<tr>
<td>THU-007</td>
<td>The paradigm of the two faced Janus: NAFLD and cardiovascular disease. An integrated and multidisciplinary new model to approach outpatients affected by diabetes type 2 and NAFLD</td>
</tr>
<tr>
<td></td>
<td>Diego CAROLI, Italy</td>
</tr>
<tr>
<td>THU-008</td>
<td>ALT levels for Asians with metabolic diseases: a meta-analysis of 86 studies with bootstrap modelling and individual patient data validation</td>
</tr>
<tr>
<td>YI</td>
<td>Daniel HUANG, Singapore</td>
</tr>
<tr>
<td>THU-009</td>
<td>Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response</td>
</tr>
<tr>
<td></td>
<td>Diane SHEVELL, United States</td>
</tr>
<tr>
<td>THU-010</td>
<td>PNPLA3 gene polymorphism and overall and cardiovascular mortality among non-alcoholic fatty liver disease in the United States</td>
</tr>
<tr>
<td>YI</td>
<td>Karn WIJARNPREECHA, United States</td>
</tr>
<tr>
<td>THU-011</td>
<td>Renal failure is associated with increased mortality, morbidity, and hospital charges in patients admitted with non-alcoholic steatohepatitis</td>
</tr>
<tr>
<td>YI</td>
<td>Debashis REJA, United States</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>THU-012</td>
<td>Cardiovascular and cerebrovascular co-morbidities in non-alcoholic steatohepatitis</td>
</tr>
<tr>
<td>THU-013</td>
<td>Extra-hepatic gastrointestinal malignancies in NAFLD: nationwide inpatient sample 2016</td>
</tr>
<tr>
<td>THU-014</td>
<td>Is liver fibrosis the forerunner of clinical cardiovascular disease in non-alcoholic fatty liver disease?</td>
</tr>
<tr>
<td>THU-015</td>
<td>Mesenchymal pattern of iron deposition is linked to adverse hepatic outcomes in non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>THU-016</td>
<td>Prevalence of non-alcoholic fatty liver in the Netherlands: the Netherlands Epidemiology of Obesity study</td>
</tr>
<tr>
<td>THU-017</td>
<td>Association between non-alcoholic fatty liver disease and nut consumption</td>
</tr>
<tr>
<td>THU-018</td>
<td>Myosteatosis and sarcopenia are prevalent in patients with NAFLD even in the absence of advanced fibrosis</td>
</tr>
<tr>
<td>THU-019</td>
<td>A cholestatic pattern predicts liver outcomes in patients with non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>THU-020</td>
<td>Impact of non-alcoholic fatty liver disease on cardiovascular risk in a general population</td>
</tr>
<tr>
<td>THU-021</td>
<td>Serum zinc level and liver fibrosis in male patients with non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>THU-022</td>
<td>Identification of factors associated with engagement and adherence to a very low calorie diet to achieve significant weight loss in patients with advanced non-alcoholic fatty liver disease: a qualitative evaluation</td>
</tr>
<tr>
<td>THU-023</td>
<td>Lack of histological steatohepatitis features in advanced fibrosis could impact in screening failure rate: a comparison with FDA clinical criteria</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>THU-024</td>
<td>Risk factors associated to NAFLD-related advanced fibrosis in patients with normal ALT levels</td>
</tr>
<tr>
<td>THU-025</td>
<td>Fibrosis quantification by image morphometry of liver fibrosis predicts clinical outcomes in patients with non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>THU-026</td>
<td>Non-alcoholic fatty liver disease phenotype and prevalence across the menopause spectrum in women living with HIV</td>
</tr>
<tr>
<td>THU-027</td>
<td>Non-alcoholic fatty liver disease: interface between hepatology clinics and primary care</td>
</tr>
<tr>
<td>THU-028</td>
<td>The association with low skeletal muscle mass and carotid atherosclerosis in patients with non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>THU-029</td>
<td>Gender difference and hepatocellular carcinoma incidence in non-alcoholic steatohepatitis patients with advanced liver fibrosis</td>
</tr>
<tr>
<td>THU-030</td>
<td>Advanced liver fibrosis predicts poor cardiovascular outcomes in patients with type 2 diabetes</td>
</tr>
<tr>
<td>THU-031</td>
<td>Histological renal damage and eligibility for kidney donation are worse in patients with biopsy-proven non-alcoholic steatohepatitis compared with simple steatosis</td>
</tr>
<tr>
<td>THU-032</td>
<td>Evolution of hepatic fibrosis and steatosis during long-term use of metformin in patients with type 2 diabetes</td>
</tr>
<tr>
<td>THU-033</td>
<td>Incidence and risk factors for cardiovascular events in patients with advanced fibrosis due to non-alcoholic steatohepatitis: data from the phase 3 STELLAR trials</td>
</tr>
<tr>
<td>THU-034</td>
<td>A substantial number of patients with non-alcoholic fatty liver disease and type 2 diabetes have advanced liver fibrosis with a normal serum alanine transaminase</td>
</tr>
</tbody>
</table>
THU-035 YI Unlike HbA1c level and the amount of visceral adipose tissue, the presence and severity of NAFLD do not predict the occurrence of major adverse cardiovascular events in an obese Belgian population
Mikhail VAN HERCK, Belgium

THU-036 Association of FIB-4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US clinical practice
Michelle LAI, United States

THU-037 Association of FIB-4 score with major cardiovascular events (MACE) in real-world populations diagnosed with NASH or NAFLD in US clinical practice
Michelle LAI, United States

THU-038 Relevance of social support and severity of liver disease in biopsychosocial profiles of patients with non-alcoholic fatty liver disease
Manuel ROMERO GOMEZ, Spain

THU-039 NAFLD is a rising cause of HCC in women in a prospective populational cohort spanning 24 years (1990-2014)
Nicolas GOOSSENS, Switzerland

THU-040 Muscle fat infiltration in obese patients is associated with NAFLD related fibrosis severity – results from a prospective imaging study
Nicolas LANTHIER, Belgium

THU-041 Exercise performance in patients with non-alcoholic steatohepatitis
Oliver GLASS, United States

THU-042 Non-alcoholic fatty liver disease all cause mortality is associated with the metabolic syndrome, BMI and the severity of liver disease in hospital admitted patients using big data analytics
Oranit COHEN EZRA, Israel

THU-043 Obesity and alcohol intake modify the impact of genetic variants on the risk for incident liver disease in the general population
Panu LUUKKONEN, Finland

THU-044 Non-alcoholic steatohepatitis is associated with liver mitochondrial DNA damage and genome instability of cytochrome b, a component of the cellular respirasome supercomplex
Carlos PIROLA, Argentina

THU-045 Barriers and motivators to engaging in physical activity in individuals with NAFLD: implications for physical activity adherence
Philip O’GORMAN, Ireland

THU-046 Serious complications due to study-mandated liver biopsies in phase 3 trials for patients with advanced fibrosis due to non-alcoholic steatohepatitis
Quentin ANSTEE, United Kingdom
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-048</td>
<td>The burden of disease associated with non-alcoholic steatohepatitis patients under standard of care</td>
<td>Raluca PAIS, France</td>
</tr>
<tr>
<td>THU-049</td>
<td>Insulin secretion is an independent predictor of hepatic ballooning in non-diabetic subjects with non-alcoholic fatty liver disease</td>
<td>Ramy YOUNES, Italy</td>
</tr>
<tr>
<td>THU-050</td>
<td>NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients</td>
<td>Rosa LOMBARDI, Italy</td>
</tr>
<tr>
<td>THU-051</td>
<td>Association of non-alcoholic fatty liver disease with incident type 2 diabetes mellitus in men with chronic hepatitis B</td>
<td>Rei-Chi HSUEH, Taiwan</td>
</tr>
<tr>
<td>THU-052</td>
<td>Clinical and economic impact of non-alcoholic fatty liver disease in Spain</td>
<td>Salvador AUGUSTIN, Spain</td>
</tr>
<tr>
<td>THU-053</td>
<td>Europe's largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4)</td>
<td>Salvatore PETTA, Italy</td>
</tr>
<tr>
<td>THU-054</td>
<td>Patients receiving liver transplant for NASH cirrhosis have greater muscle loss compared to transplant and non-transplant control</td>
<td>Samarth PATEL, United States</td>
</tr>
<tr>
<td>THU-055</td>
<td>A national cross-sectional survey of health-related quality of life in Chinese patients with non-alcoholic fatty liver disease</td>
<td>Rui HUANG, China</td>
</tr>
<tr>
<td>THU-056</td>
<td>Risk factors associated with subclinical atherosclerosis in the patients with biopsy-proven non-alcoholic fatty liver disease</td>
<td>Taeang ARAI, Japan</td>
</tr>
<tr>
<td>THU-057</td>
<td>Progression of non-alcoholic fatty liver disease is rare in a Danish tertiary liver centre</td>
<td>Tea Lund LAURSEN, Denmark</td>
</tr>
<tr>
<td>THU-058</td>
<td>Health-care burden of NAFLD in European hospital-based outpatient hepatology clinics: real-world prospective data from the CONSTANS study</td>
<td>Vlad RATZIU, France</td>
</tr>
<tr>
<td>THU-059</td>
<td>Factors associated with increased overall and cause-specific mortality in non-alcoholic fatty liver disease in an ethnically diverse cohort in the United States</td>
<td>Veronica SETIAWAN, United States</td>
</tr>
</tbody>
</table>
THU-060 First 1-year follow up data from the German NAFLD prospective real-life cohort (FLAG study) show low frequencies of lifestyle changes
Wolf Peter HOFMANN, Germany

THU-061 Fibrosis non-invasive tests capture changes in patient-reported outcomes of patients with advanced non-alcoholic steatohepatitis
Zobair YOUNOSSI, United States
## Alcoholic liver disease

<table>
<thead>
<tr>
<th>Poster Code</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-062</td>
<td>Gut transcriptomics reveals potential therapeutic strategies for the restoration of epithelial barrier repair in alcohol-related liver cirrhosis</td>
<td>Antonio RIVA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-063</td>
<td>Specific alterations of the immune checkpoint secretome are linked with antibacterial immunity in alcohol-related liver disease</td>
<td>Antonio RIVA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-064</td>
<td>Proton pump inhibitors increase the risk of oral cancer among patients with alcoholic cirrhosis</td>
<td>Astrid Højmark ANDERSEN, Denmark</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>THU-065</td>
<td>Analysis of the influence of alcoholic abstinence on mortality in patients with alcoholic liver cirrhosis</td>
<td>Ángela SUÁREZ-NOYA, Spain</td>
<td></td>
</tr>
<tr>
<td>THU-066</td>
<td>Non-invasive criteria for diagnosis of alcoholic hepatitis: use in clinical practice and correlation with prognosis</td>
<td>Emma AVITABILE, Spain</td>
<td></td>
</tr>
<tr>
<td>THU-067</td>
<td>Early life ethanol exposure has long-term impacts on the transcriptome and epitranscriptome of rat liver</td>
<td>Shu-Huei HSIAO, Taiwan</td>
<td></td>
</tr>
<tr>
<td>THU-068</td>
<td>Alcohol recurrence and outcome in patients transplanted for alcoholic cirrhosis: impact of the 6-month rule</td>
<td>Claire-Anna PERIGNON, France</td>
<td>France</td>
</tr>
<tr>
<td>THU-069</td>
<td>Early liver transplantation in active drinkers with and without alcoholic hepatitis: a monocentric case series</td>
<td>Debora ANGRISANI, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>THU-070</td>
<td>Long-term outcome of symptomatic alcoholic hepatitis with a Maddrey discriminant function &lt; 32</td>
<td>Degré DELPHINE, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>THU-071</td>
<td>Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways</td>
<td>Eleonora PATSENKER, Switzerland</td>
<td></td>
</tr>
<tr>
<td>THU-072</td>
<td>Delisting of liver transplant candidates after improvement in alcohol-related decompensated cirrhosis: a multicentric study on incidence and outcomes</td>
<td>Elisa POSE, Spain</td>
<td></td>
</tr>
<tr>
<td>THU-073</td>
<td>A novel lymphocyte proliferation assay accurately predicts 90-day survival in severe alcoholic hepatitis patients</td>
<td>Euan YATES, United Kingdom</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>
THU-074  Alcohol use disorder and liver fibrosis – cases are missed through failure to test
Freya RHODES, United Kingdom

THU-075  Decreasing incidence of alcoholic liver disease in Denmark: a nationwide study
Frederik KRAGLUND, Denmark

THU-076  Fibroblast growth factor 21 response in a preclinical model of alcohol induced acute-on-chronic liver injury
Christidis GRIGORIOS, Germany

THU-077  Mortality in biopsy-proven alcohol-related liver disease: population-based cohort study of 3,453 individuals
Hannes HAGSTRÖM, Sweden

THU-078  Inhibition of cytochrome P-4502E1 by clomethiazole improves alcoholic liver disease in alcohol-dependent patients: a short-term, randomized, controlled clinical trial
Helmut SEITZ, Germany

THU-079  Metabolic synapse between hepatocytes and stellate cells drives endocannabinoid-mediated alcoholic steatosis
Hee-Hoon KIM, Korea, Rep. of South

THU-080  Role of fecal microbiota transplantation in severe alcoholic hepatitis: assessment of impact on prognosis and short-term outcomes
Radha DHIMAN, India

THU-081  In alcoholic hepatitis, cytokeratin 18 serum fragments reflect its severity and predict responsiveness to prednisolone
Jane GROVE, United Kingdom

THU-082  Multi-modal training of specialty clinical trainees improves the detection and subsequent interventions for alcohol use disorder
Jasmohan S BAJAJ, United States

THU-083  Temporal change in the plasma metabolome profile is indicative of outcome in severe alcoholic hepatitis
Jaswinder MARAS, India

THU-084  Pharmacokinetics of DUR-928 in alcoholic hepatitis patients – a phase 2a study
Jaymin SHAH, United States

THU-085  Alterations and role of bioactive lipid metabolites (oxylipins) in human and experimental ALD: associations with disease severity
Jeffrey WARNER, United States
### Alcoholic liver disease (Cont.)

| THU-086 | Alcohol-induced liver injury is attenuated by human beta defensin in experimental ALD via improvements in the gut-liver axis  
Jeffrey WARNER, United States |
|---|---|
| THU-087 | Type III interferon lambda derangements are associated with susceptibility to infection in alcohol-related liver disease  
Jennifer RYAN, United Kingdom |
| THU-088 | The role of PNPLA3, MBOAT7 and TM6SF2 during alcohol detoxification: different mechanisms of fibrosis and steatosis development  
Johannes MUELLER, Germany |
| THU-089 | Loss of the resolvin D1-formula peptide receptor 2 signaling axis leads to pro-inflammatory transcriptional reprogramming in alcoholic liver disease  
Josiah HARDESTY, United States |
| THU-090 | High risk of futile over-referrals or late under-referrals among patients suspected of alcohol-related or non-alcohol-related fatty liver disease: real-world evidence reveal opportunities to optimize referral patterns to secondary care  
Katrine PRIER LINDVIG, Denmark |
| THU-091 | Patients with alcoholic hepatitis present strong Th1 cellular immune responses to alcohol dehydrogenase related to impairment of the PD-1/PD-L1 pathway due to high circulating levels of soluble PD-1  
Laura BLACKMORE, United Kingdom |
| THU-092 | Differential roles of receptor interacting protein 3 and mixed lineage kinase like in murine models and patients with alcohol- and non-alcohol related liver disease  
Laura NAGY, United States |
| THU-093 | High throughput plasma proteomics in 459 patients reveals patterns of protein dynamics in alcoholic associated liver disease: a biopsy-controlled study  
Lili NIU, Denmark |
| THU-094 | Defective gut adaptive immunity during early alcoholic liver disease  
Luca MACCIONI, Belgium |
| THU-095 | Metabolic and genetic risk factors predict advanced alcohol-related liver fibrosis regardless of drinking pattern  
Mads ISRAELSEN, Denmark |
| THU-096 | The Stanford integrated psychosocial assessment for transplantation (SIPAT) is an effective tool at identifying limited sobriety candidates with alcohol-related liver disease and low risk of relapse  
Mai SEDKI, United States |
THU-097 YI  The development and severity of alcoholic hepatitis is associated with decreased intestinal microbiome-derived secondary bile acid isoursodeoxycholic acid
Mark MUTHIAH, Singapore

THU-098 YI  H2O2, the major reactive oxygen species produced during alcohol metabolism in liver induces autophagy without involving mTOR
Cheng CHEN, Germany

THU-099 YI  Early diagnosis of alcohol-related liver disease and timely intervention: the role of alcohol care teams
Naina SHAH, United Kingdom

THU-100 YI  A scoring system to predict infection in alcohol-associated hepatitis
Daniel PENRICE, United States

THU-101 YI  Unexpected protective role of the chemokine lix after Gao-binge ethanol feeding in mice
Kyle POULSEN, United States

THU-102 YI  Shedding light on BASH: a novel experimental model of advanced liver damage
Raquel BENEDÉ, Spain

THU-103 YI  Duration of alcohol abstinence as a predictor of alcohol relapse – the more the better?
Ricardo CRESPO, Portugal

THU-104 YI  Alcohol-related liver cirrhosis patients have higher-disease severity, one-year morbidity and mortality after index hospitalisation- followup of a cohort of 5,138 patients
S Muralikrishna SHASTHRY, India

THU-105 YI  Comparative hepatic proteome analysis in low and high dose ab libitum alcohol mice model of liver injury
Sudrishti CHAUDHARY, India

THU-106 YI  Neuro-immunological pathway alters the phenotype of bone marrow F4/80+CD11b+ macrophages during chronic alcohol consumption
Young-Ri SHIM, Korea, Rep. of South

THU-107 YI  Epigenetic basis of monocyte dysfunction in severe alcoholic hepatitis
Thierry GUSTOT, Belgium

THU-108 YI  Plasma protein glycomics combined with circulating fragments of cytokeratin-18 are reliable biomarkers to diagnose alcoholic hepatitis
Verhelst XAVIER, Belgium

THU-109 YI  Role of NOX1 on hepcidin signaling in the crosstalk between macrophages and hepatocytes
Linna YU, Germany
## Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology

**THU-110**  
Single-cell analysis of self-antigen-specific CD4 T cells reveals the B helper signature and the peripheral reservoir of autoreactive T cells in autoimmune hepatitis  
Amédée RENAND, France

**THU-111**  
Top 10%  
FXR agonists repress innate and adaptive effector cytokine production in primary sclerosing cholangitis  
Asthana MALIK, United States

**THU-113**  
Absence of BSEP (ABCB11) protects MDR2 (ABCB4) K0 mice from cholestatic liver and bile duct injury through modulating hepatic and intestinal inflammatory signaling  
Claudia FUCHS, Austria

**THU-114**  
Predicted risk of end stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of obeticholic acid for 60 months in patients with primary biliary cholangitis  
David JONES, United Kingdom

**THU-115**  
YI  
Cell specific transcriptomic analysis reveals a disassociation between treatment response and peripheral markers of immune activation in primary biliary cholangitis  
Evaggelia LIASKOU, United Kingdom

**THU-116**  
YI  
Distinct intrahepatic molecular signature between relapse and sustained remission of autoimmune hepatitis before initiation of immunosuppression withdrawal  
Finn DERBEN, Germany

**THU-117**  
Top 10%  
Metagenomic sequencing in primary sclerosing cholangitis highlights microbial metabolism of essential nutrients and multiple altered species  
Johannes R. HOV, Norway

**THU-118**  
YI  
Obeticholic acid but not bezafibrate treatment improves cholestasis-induced cognitive decline  
Lucy GEE, United Kingdom

**THU-119**  
Negative immune regulator LNK/SH2B3 contributes to the development of autoimmune liver disease in mice under fatty-metabolic stress  
Taizo MORI, Japan

**THU-120**  
YI  
Mast cell activation mediates biliary immunobiology and subsequent immune response in a model of primary biliary cholangitis  
Lindsey KENNEDY, United States
<table>
<thead>
<tr>
<th>THU-121</th>
<th>MSCs attenuate cona-induced autoimmune hepatitis in mice through Nrf2/HO-1 pathway by altering macrophage polarization</th>
<th>WENTIAN LIU, China</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-122</td>
<td>Klebsiella in the mucosal gut microbiota in primary sclerosing cholangitis is associated with more severe disease</td>
<td>Mikal Jacob HOLE, Norway</td>
</tr>
<tr>
<td>THU-123</td>
<td>Downregulation of the bile acid receptor TGR5 in livers of PSC patients and ABCB4-/- mice</td>
<td>Maria REICH, Germany</td>
</tr>
<tr>
<td>THU-124</td>
<td>Insufficient deletion of autoreactive CD4 T cells and plasticity of Tregs drive spontaneous autoimmune hepatitis in mice</td>
<td>Max PRETI, Germany</td>
</tr>
<tr>
<td>THU-125</td>
<td>MIR-506 as one of potential determinants of different phenotypic presentation of ulcerative colitis in patients with primary sclerosing cholangitis (PSC)</td>
<td>Malgorzata MILKIEWICZ, Poland</td>
</tr>
<tr>
<td>THU-126</td>
<td>Co-stimulatory molecules OX40 and CD30 mediates the regeneration of the liver epithelium in a mouse primary sclerosing cholangitis model</td>
<td>Naruhiro KIMURA, United Kingdom</td>
</tr>
<tr>
<td>THU-127</td>
<td>Developing antigen-specific immunotherapy for autoimmune hepatitis type 2 by identification of T cell epitopes</td>
<td>Naomi RICHARDSON, United Kingdom</td>
</tr>
<tr>
<td>THU-128</td>
<td>Relevance of epidermal growth factor receptor kinase activity in a model of cholestatic liver injury</td>
<td>Nerea LAZCANOITURBURU, Spain</td>
</tr>
<tr>
<td>THU-129</td>
<td>The role of cellular senescence in the natural course of primary sclerosing cholangitis</td>
<td>Nora CAZZAGON, Italy</td>
</tr>
<tr>
<td>THU-130</td>
<td>Upregulation of hepatic TH17 response is associated with large duct disease and advanced hepatic fibrosis in pediatric autoimmune liver disease</td>
<td>Simon LAM, United States</td>
</tr>
<tr>
<td>THU-131</td>
<td>Elevated levels of systemic bacterial vesicles in autoimmune hepatitis are associated with non-response to corticosteroid therapy</td>
<td>Sukriti SUKRITI, India</td>
</tr>
<tr>
<td>THU-132</td>
<td>Single cell RNA sequencing reveals naive T cells ready for effector function in livers of patients with primary sclerosing cholangitis</td>
<td>Tobias POCH, Germany</td>
</tr>
</tbody>
</table>
**Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology (Cont.)**

**THU-133**  Integrated analysis of GWAS and mRNA microarray identified IFN-α and CD40I as the central upstream-regulators in primary biliary cholangitis  
Kazuko UENO UENO, *Japan*

**THU-134**  FcRL4⁺ b cells are associated with inflamed bile ducts in patients with primary biliary cholangitis and locally capture IGA immune complexes  
Yuxin Susan LIU, *United Kingdom*

**THU-135**  Bile from patients with chronic liver diseases activates MAIT cells  
Fei ZHENG, *Norway*
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-136</td>
<td>Inhibition of toll-like receptor 4 signaling reduces hyperammonemia by modulating urea cycle function</td>
<td>Annarein KERBERT, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-137</td>
<td>Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis</td>
<td>Alberto ZANETTO, Italy</td>
<td></td>
</tr>
<tr>
<td>THU-138</td>
<td>Different inflammasome activation predisposes for acute-on-chronic liver failure depending on hepatic compensation in human and experimental liver cirrhosis</td>
<td>Sofia MONTEIRO, Portugal</td>
<td></td>
</tr>
<tr>
<td>THU-139</td>
<td>Impaired splenic function in liver cirrhosis: a study in 69 patients with cirrhosis from outpatient hepatology clinic in a tertiary hospital in northern Greece</td>
<td>Lamprini KIRKINESKA, Greece</td>
<td></td>
</tr>
<tr>
<td>THU-140</td>
<td>Histological characterization of muscle and adipose tissue in patients with cirrhosis receiving liver transplant</td>
<td>Maryam EBADI, Canada</td>
<td></td>
</tr>
<tr>
<td>THU-141</td>
<td>A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals</td>
<td>Elisabetta DEGASPERI, Italy</td>
<td></td>
</tr>
<tr>
<td>THU-142</td>
<td>The bone marrow pool of megakaryocytes and their ability to proliferate are preserved in rats with advanced cirrhosis</td>
<td>Iris ASENSIO, Spain</td>
<td></td>
</tr>
<tr>
<td>THU-143</td>
<td>Bile acids modify ROS production, impair chemotaxis and delay apoptosis of neutrophils in vitro</td>
<td>Irina KOMAROVA, Austria</td>
<td></td>
</tr>
<tr>
<td>THU-144</td>
<td>Neuro and hepatic inflammation and steatosis are modulated by gut microbial changes after isolated hepatic vagotomy and antibiotics in cirrhosis</td>
<td>Jasmohan S BAJAJ, United States</td>
<td></td>
</tr>
<tr>
<td>THU-145</td>
<td>Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis</td>
<td>Maurizio BALDASSARRE, Italy</td>
<td></td>
</tr>
<tr>
<td>THU-146</td>
<td>SLU7 downregulation potentiates liver damage through hepatic de-differentiation</td>
<td>María GÁRATE-RASCÓN, Spain</td>
<td></td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Authors</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>THU-147</td>
<td>Endotrophin predicts clinical outcome and mortality in patients with compensated cirrhosis</td>
<td>Mette Juul NIELSEN, Denmark</td>
<td></td>
</tr>
<tr>
<td>THU-148</td>
<td>Characterization of lymphocyte subsets in ascites during spontaneous bacterial peritonitis: MAIT cells show the strongest increase</td>
<td>Christian NIEHAUS, Germany</td>
<td></td>
</tr>
<tr>
<td>THU-149</td>
<td>Immune cell response in progressing liver cirrhosis is dominated by neutrophil granulocytes</td>
<td>Rhea VEELKEN, Germany</td>
<td></td>
</tr>
<tr>
<td>THU-150</td>
<td>Proagio: a protein designed to target integrin alpha V beta 3 outside ligand binding site is an effective way to target activated hepatic stellate cells</td>
<td>Ravi Chakra TURAGA, United States</td>
<td></td>
</tr>
<tr>
<td>THU-151</td>
<td>Hepatocytes undergo pyroptosis in response to lipopolysaccharide exposure, and can be sensitised to cell death by ER stress</td>
<td>Ugo SOFFIENTINI, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-152</td>
<td>Faecal cytokines provide novel insights into the role of gut mucosal inflammation in acute decompensation of cirrhosis</td>
<td>Vishal C PATEL, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-153</td>
<td>Hypofibrinolysis as a contributing mechanism of cirrhotic portal vein thrombosis as evidenced by rotational thromboelastometry (ROTEM)</td>
<td>Vladimir MARQUEZ, Canada</td>
<td></td>
</tr>
<tr>
<td>THU-154</td>
<td>Lecithin-cholesterol acyltransferase deficiency as an explanatory mechanism for both relative adrenal insufficiency and spur cell anemia in cirrhosis</td>
<td>Zachary HENRY, United States</td>
<td></td>
</tr>
</tbody>
</table>
Acute liver failure and drug induced liver injury

THU-155  Plasma perfusion combined with plasma exchange improved survival in chronic hepatitis B related acute-on-chronic liver failure patients
Tao CHEN, China

THU-156  The role of urea on the prognosis of severe acute liver injury and acute liver failure
Top 10%
Ana CRACIUN, Portugal

THU-157  Idiosyncratic drug-induced liver injury in the elderly: an analysis of cases from the Spanish DILI registry
Top 10%
Raul J. ANDRADE, Spain

THU-158  Use of the molecular adsorbent recirculating system in acute liver failure: a North American multicenter experience
Andrew MACDONALD, Canada

THU-159  MELD score is the best predictor for transplant-free survival in patients with acute liver injury
Carolina SIMÕES, Portugal

THU-160  Ketamine for maintenance sedation in critically ill burned patients is associated with liver dysfunction and acute kidney injury
Christian DE TYMOWSKI, France

THU-161  The therapeutic role of iNOS-expressed myeloid derived suppressor cells in acetaminophen induced acute liver failure
Chien-Hao HUANG, Taiwan

THU-162  Prevalence, incidence, and characteristics of hepatorenal syndrome-related acute kidney injury in the United States
Manfred BILZER, Denmark

THU-163  Bioenergetics defect of CD14+ monocytes are associated with increased mortality in acute liver failure
Dhananjay KUMAR, India

THU-164  Ferroptosis related regulatory protein NCOA4 and its IncRNA-mRNA co-expression network in patients with anti-tuberculosis drug-induced liver injury
Jun CHEN, China

THU-165  AARC score has better accuracy at predicting 90-day mortality in drug induced acute-on-chronic liver failure (DILI – ACLF)
Top 10%
Sushrut SINGH, India

THU-166  Clinical characteristics and prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by gynura segetum
Jing ZHANG, China
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-167</td>
<td>Umbilical cord-derived mesenchymal stem cells regulate ferroptosis via the activation of NRF2 are signaling pathway for the treatment of acute liver failure</td>
<td>Cong DU, China</td>
</tr>
<tr>
<td>THU-168</td>
<td>Novel in vivo tracing of the hepatocyte origin of extracellular vesicles in mice with experimental liver disease</td>
<td>Elena BLÁZQUEZ-LÓPEZ, Spain</td>
</tr>
<tr>
<td>THU-169</td>
<td>Markers of neutrophil extracellular traps are associated with poor outcome in patients with acute liver failure</td>
<td>Fien VON MEIJENFELDT, Netherlands</td>
</tr>
<tr>
<td>THU-170</td>
<td>Activation of the aryl hydrocarbon receptor sensitizes to acetaminophen-induced acute liver failure</td>
<td>Fenja SCHURAN, Germany</td>
</tr>
<tr>
<td>THU-171</td>
<td>Human bone marrow mesenchymal stem cell’s small extract vesicles promote hepatocyte regeneration in acute liver failure</td>
<td>Juan GAO, China</td>
</tr>
<tr>
<td>THU-172</td>
<td>Cut-off level of serum cytokeratin 18 for diagnosis of acute-on-chronic liver failure in chronic hepatitis C cirrhosis</td>
<td>Hany SHABANA, Egypt</td>
</tr>
<tr>
<td>THU-173</td>
<td>Air-liquid interactive bioartificial liver embedded with 3D-layered human hepatocyte-derived liver progenitor-like cells rescues pocine acute liver failure</td>
<td>Hexin YAN, China</td>
</tr>
<tr>
<td>THU-174</td>
<td>Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: a multicenter experience</td>
<td>Ilker TURAN, Turkey</td>
</tr>
<tr>
<td>THU-175</td>
<td>Expression of microRNA-124 in Kupffer cells modulates liver injury</td>
<td>Jinyu WANG, China</td>
</tr>
<tr>
<td>THU-176</td>
<td>Predictors of acute liver failure and death among patients with dengue-induced severe hepatitis</td>
<td>Tongluk TEERASARNTIPAN, Thailand</td>
</tr>
<tr>
<td>THU-177</td>
<td>Clinical and radiological features for early identification of malignancy induced acute liver failure</td>
<td>Liane RABINOWICH, United Kingdom</td>
</tr>
</tbody>
</table>
THU-178  Deletion of XBP1 in liver parenchymal cells ameliorates acetaminophen (APAP)-induced hepatotoxicity via activation of IRE1alpha-JNK1-ATG5-dependent autophagy
Hui YE, Spain

THU-179  Larazotide acetate reduces the frequency of bacterial translocation in the thioacetamide-induced liver failure in rats
Muhsin Murat HARPUTLUOGLU, Turkey

THU-180  The protective effects of a sense oligonucleotide drug targeting inducible nitric oxide synthase for a rat model of acute liver injury
Richi NAKATAKE, Japan

THU-181  Hasi-iquest: investigating viral etiologies of acute liver failure of unknown cause
Nicolas GILLE, France

THU-182  Poly(adp-ribose) polymerase plays a critical role in oxidative stress- and hypoxia/reoxygenation-induced programmed cell death in mouse liver cells
Michitaka OZAKI, Japan

THU-183  Investigation into the cut-off point for chronicity of drug-induced liver injury through metabolomic profiling
Jia-bo WANG, China

THU-184  Hepatic steatosis predicts fibrosis in long-term methotrexate use
Alnoor RAMJI, Canada

THU-185  Novel therapy with anti-miR-873-5p at late stages of acetaminophen overdose
Rubén RODRÍGUEZ AGUDO, Spain

THU-186  A novel HER2-targeted liposomal formulation for reducing the risk of liposome-induced hepatotoxicity
Sara DE MARTIN, Italy

THU-187  Combination of sivelestat and n-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury
Sarah RAEVENS, Belgium
Gut microbiota and liver disease

THU-189  Administration of lactobacillus alleviates experimental NASH by reducing miR-21 in the liver  
André A. SANTOS, Portugal

THU-190  Disease severity and proton pump inhibitor use impacts strongest on faecal microbiome composition in cirrhosis  
Angela HORVATH, Austria

THU-191  Deoxycholic acid-producing clostridium scindens influences host metabolism  
Annika WAHLSTRÖM, Sweden

THU-192  Alteration of the gut microbiota in patients with primary sclerosing cholangitis and concomitant dominant strictures  
Christian RUPP, Germany

THU-193  Gut microbiota and metabolites associated with response to ursodesoxycholic acid in patients with primary biliary cholangitis  
Bin GAO, China

THU-194  Gut microbiota are associated with minimal hepatic encephalopathy (MHE) in cirrhosis regardless of country of origin  
Jasmohan S BAJAJ, United States

THU-195  Microbiota modulates ischemia-reperfusion injury in mouse liver transplantation  
Shoichi KAGEYAMA, United States

THU-196  Gut microbiota composition is difference between HCV mono-infection and HCV/HIV co-infection  
Natthaya CHUAYPEN, Thailand

THU-197  Transplantation of gut microbiota derived from MCJ-KO genotype determines a protective profile against non-alcoholic fatty liver disease in germ-free mice  
Naroa GOIKOETXEA, Spain

THU-198  Effects of anti-TNF? treatment on Crohn’s disease induced hepatic steatosis  
Paul Peter MANKA, Germany

THU-199  Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease  
Paula BOEIRA, United Kingdom

THU-200  Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for alfafermin (NGM282) in patients with non-alcoholic steatohepatitis  
Rohit LOOMBA, United States
THU-201  Novel metagenomic signature of fungal mycobiome in NAFLD-cirrhosis with validation in a geographically independent cohort
Rohit LOOMBA, United States

THU-202  Lactobacillus rhamnosus GG improve fungal dysbiosis on liver cirrhotic rats
Ding SHI, China

THU-203  Protective effects of akkermansia muciniphila against non-alcoholic fatty liver disease through modulation of gut microbiota
Wenrui WU, China

THU-204  Identification of gut bacterial candidates involved in hepatic encephalopathy by the analysis of feces DNA from patients administered rifaximin
Yoshimi MUTO, Japan
## Liver development, physiology and regeneration

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-205</td>
<td>Modulation of native decellularized liver matrix enhances hepatic cells proliferation, viability and functions on 3D-bioscaffolds</td>
<td>Abhishak GUPTA</td>
<td>India</td>
</tr>
<tr>
<td>THU-206</td>
<td>Hepatocyte-targeted R-spondin mimetic for liver regeneration</td>
<td>Helene BARIBAULT</td>
<td>United States</td>
</tr>
<tr>
<td>THU-207</td>
<td>Primed liver regeneration in protein convertase subtilisin/kexin type 9 knockout mice is associated with increased lipids uptake and hypercholesterolemia</td>
<td>Jacopo GAVINI</td>
<td>Switzerland</td>
</tr>
<tr>
<td>THU-208</td>
<td>Targeting the embryonic liver with ultrasound-guided in utero nano-injection to manipulate gene expression during liver development and hematopoiesis</td>
<td>Jingyan HE</td>
<td>Sweden</td>
</tr>
<tr>
<td>THU-209</td>
<td>Development and automation of 3D innovative hiPSC-based liver organoids including the microenvironment for phenotyping screening – application on metabolic diseases</td>
<td>Karim SI-TAYEB</td>
<td>France</td>
</tr>
<tr>
<td>THU-210</td>
<td>Dynamic characterization of revascularization in decellularized whole-liver scaffold</td>
<td>Jun LI</td>
<td>China</td>
</tr>
<tr>
<td>THU-211</td>
<td>Optimal liver metabolism and proliferation require the tight junction protein claudin-3</td>
<td>Felix Alexander BAIER</td>
<td>Switzerland</td>
</tr>
<tr>
<td>THU-212</td>
<td>Liver disease modelling with human pluripotent stem cells derived organoids</td>
<td>Nadzim RAMLI</td>
<td>Singapore</td>
</tr>
<tr>
<td>THU-213</td>
<td>Serum transferrin levels reflect hepatocyte nuclear factor 4 alpha activity in the liver</td>
<td>Nurdan GULDIKEN</td>
<td>Germany</td>
</tr>
<tr>
<td>THU-214</td>
<td>Macrophage regulation of PKM2 during liver regeneration process</td>
<td>Nicolas MELIN</td>
<td>Switzerland</td>
</tr>
<tr>
<td>THU-216</td>
<td>Diploid hepatocytes drive physiological liver renewal in adult humans</td>
<td>Paula HEINKE</td>
<td>Germany</td>
</tr>
<tr>
<td>THU-217</td>
<td>Imaging human liver regeneration by multiphoton microscopy</td>
<td>Scott DAVIES</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>
**THU-218**  
**YI**  
**Thyroid hormone and TGF-β inhibition drive functional maturation of human pluripotent stem cell-derived hepatocytes**  
Sarah Withey, Australia

**THU-219**  
**Nicotinamide riboside promotes liver regeneration by enhancing mitochondrial fatty acid oxidation**  
Sarmistha Mukherjee, United States

**THU-220**  
**Potential role of two novel agonists of thyroid hormone receptor-beta on liver regeneration**  
Simona Onali, Italy
Liver transplantation and hepatobiliary surgery: Clinical aspects

THU-221 Parenchyma-sparing hepatectomy improves salvageability and survival for solitary small intrahepatic cholangiocarcinoma
Hui LI, China

THU-222 Reducing length of stay in patients following a liver transplant
Abdulrhman ALAMR, Canada

THU-223 The presence and outcome of biliary sphincter disorders in liver transplant recipients according to the Rome IV classification
Andres CARDENAS, Spain

THU-224 Impact of sarcopenia in patients awaiting simultaneous liver and kidney transplantation: a cohort of study on clinical outcomes
Alessandra MAZZOLA, France

THU-225 Recent trends and intention-to-treat survival of liver transplantation for non-alcoholic steatohepatitis: an Italian liver transplant registry study.
On behalf of AISF, FIRE, SITO and CNT
Alessandro VITALE, Italy

THU-226 The application of immunoglobulins after liver transplantation influences the occurrence of donor-specific antibody associated complications
Alexandra FREY, Germany

THU-227 A new score including anthropometric measurement for weight improved prediction of mortality in adolescents on the liver transplantation waiting list: a US nationwide study
Abdel-Aziz SHAHEEN, Canada

THU-228 Post-transplant lymphoproliferative disease after adult liver transplantation has a higher incidence after primary sclerosing cholangitis and can be prevented by surveillance of Epstein-Barr viral load with a pre-emptive strategy – a long-term study
Bart VAN HOEK, Netherlands

THU-229 De novo metabolic syndrome after liver transplantation: a prospective, longitudinal study
Chiara BECCHETTI, Switzerland

THU-230 Phase angle is a prognostic nutritional marker in patients on the waiting list and after liver transplantation
Berenice M. ROMÁN-CALLEJA, Mexico

THU-231 Differences of bile microbiology and antibiotic susceptibilities in liver transplant recipients from a non-transplant population with acute biliary infection
Sukwon SUH, Korea, Rep. of South
THU-232  Transplantation of hepatitis C virus (HCV) infected livers into HCV uninfected recipients  
Natalie BZOWEJ, United States

THU-233  Safety of marginal grafts in liver transplantation: a single-center experience  
Hui TANG, China

THU-234  Severe obesity increases death and dropout from liver waiting list: French liver transplant cohort  
Claire DELACÔTE, France

THU-235  The effect of the six-month waiting rule on liver transplant patients with hepatocellular carcinoma  
Dilip MOONKA, United States

THU-236  Liver transplantation assessment: what are the factors associated with contraindication for listing or delayed activation on waiting list?  
Domitille ERARD-POINSOT, France

THU-237  Anticoagulation in liver transplant candidates: a case control study  
Domitille ERARD-POINSOT, France

THU-238  Pre-transplant sarcopenic obesity worsens the survival after liver transplantation: a meta-analysis and systematic review  
Péter Jenő HEGYI, Hungary

THU-239  Women benefit more from having a potential living liver donor than men  
Ravikiran SINDHUVALADA KARNAM, Canada

THU-240  Transmission and impact of donor allergies in living donor liver transplantation  
Ravikiran SINDHUVALADA KARNAM, Canada

THU-241  Postreperfusion biopsy as predictor of outcomes after liver transplantation  
Esteban FUENTES VALENZUELA, Spain

THU-242  Sarcopenia HIBA score predicts the presence of sarcopenia and mortality in patients on the waiting list for liver transplant  
Ezequiel MAURO, Argentina

THU-243  A novel nomogram based on liver stiffness to predict the comprehensive complication index after liver resection in patients with hepatocellular carcinoma  
Federico RAVAIOLI, Italy

THU-244  Physical frailty predicts liver transplant waiting list mortality: United Kingdom experience  
Felicity WILLIAMS, United Kingdom
Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.)

THU-245  Early versus late hepatocellular carcinoma (HCC) recurrence after liver transplantation for HCC: patterns and long-term outcome  
Faouzi SALIBA, France

THU-246  Epidemiology, features and outcome of patients transplanted for hepatocellular carcinoma in the last decade: a single-center experience  
Federica INVERNIZZI, Italy

THU-247  Early recurrence of hepatocellular carcinoma after liver transplantation can be predicted by FDG-PET and microvascular invasion at explant pathology  
Federica INVERNIZZI, Italy

THU-248  Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage  
George THERAPONDOS, United States

THU-249  Predictors of success in the treatment of anastomotic biliary stricture after liver transplantation  
Helena KATCHMAN, Israel

THU-250  Survival after liver transplant in recipients of different age groups: a systematic review and meta-analysis  
Ho Ming CHENG, Hong Kong

THU-251  Prophylactic rifaximin use in liver transplant candidates is associated with false positive results of the alcohol biomarker, ethyl sulphate  
Ian WEBZELL, United Kingdom

THU-252  Predictive factors of symptomatic nodular regenerative hyperplasia after liver transplantation  
Ilias KOUNIS, France

THU-253  Transplanting livers from hepatitis C positive donors: is it worth the risk?  
Jacobs MENSINK, Netherlands

THU-254  Long-term outcomes of persistently positive hepatitis B surface antigen after liver transplantation for chronic hepatitis B  
Yan Yue James FUNG, China

THU-255  Living donor liver transplantation should be considered cautiously in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection  
Jong Man KIM, Korea, Rep. of South

THU-256  NASH is the leading indication for liver transplantation in elderly patients  
Justin STEGGERDA, United States
THU-257  
**Hepatitis B immunoglobulin prophylaxis for prevention of de novo Hepatitis B infection from hepatitis B core antibody-positive donors**  
Kyeongdeok KIM, Korea, Rep. of South

THU-258  
**Improved patient and graft survival from kidney transplantation in liver transplants for congenital hepatic fibrosis and Caroli’s disease**  
Khalid KHAN, United States

THU-259  
**Outcomes of liver transplantation for metabolic disorders in children**  
Khalid KHAN, United States

THU-260  
**Assessment of long-term risk of cardiovascular disease after liver transplantation**  
Kirsty MILES, United Kingdom

THU-261  
**Hypertension prevalence, treatment and control among liver transplant recipients and associations with cardiovascular events and mortality**  
Madeline BERTHA, United States

THU-262  
**Portal venous thrombosis and liver transplant: incidence and evolution in the 1st year after transplant**  
Maria Angeles LOPEZ GARRIDO, Spain

THU-263  
**Utility of anticoagulation in portal venous thrombosis before and after liver transplant**  
Maria Angeles LOPEZ GARRIDO, Spain

THU-264  
**Safety and efficacy of a cardiac risk stratification protocol based on traditional cardiac risk-factors in patients undergoing liver transplantation**  
Marcus ROBERTSON, Australia

THU-265  
**Projection of liver transplant activity per indication in France and United Kingdom**  
Mark CONNOLLY, Netherlands

THU-266  
**The impact of gender and comorbidity burden on liver transplant eligibility and patient survival**  
Marwan GHABRIL, United States

THU-267  
**Risk factors for fatty liver of donors after living donor liver transplantation**  
Hisamitsu MIYAAKI, Japan

THU-268  
**Accuracy of triple echo MRI in predicting hepatic steatosis in potential liver donors**  
Mohammed ALJAWAD, Saudi Arabia

THU-269  
**Preliminary results of a prospective pilot program for transplantation of patients with alcohol-related liver disease and less than 6 months abstinence**  
Nazia SELZNER, Canada
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Abstract Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-270</td>
<td>Positive complement-dependent cytotoxicity crossmatch results do not influence long-term graft or patient survival following liver transplantation</td>
<td>Neil HALLIDAY, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-271</td>
<td>Pregnancy outcomes after liver transplantation: a systematic review and meta-analysis</td>
<td>Nelson VALENTIN, United States</td>
<td></td>
</tr>
<tr>
<td>THU-272</td>
<td>Clostridium difficile infection in liver transplant recipients is uncommon and does not impact long-term survival: a case-control study</td>
<td>Nicholas KORTT, Australia</td>
<td></td>
</tr>
<tr>
<td>THU-273</td>
<td>Pure laparoscopic versus open right hepatectomy in live liver donors: a propensity score matched analysis</td>
<td>Suk Kyun HONG, Korea, Rep. of South</td>
<td></td>
</tr>
<tr>
<td>THU-274</td>
<td>Patient social and lifestyle factors associated with cardiovascular risk affect decisions regarding transplant candidacy more than factors associated with psychological and financial well-being</td>
<td>Oliver TAVABIE, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-275</td>
<td>Inequality in access to liver transplant: are satellite liver transplant centres the answer?</td>
<td>Oliver TAVABIE, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-276</td>
<td>Usefulness of phosphatidylethanol and urinary ethyl glucuronide to monitor alcohol abstinence in patients awaiting liver transplantation</td>
<td>Olivier MENARD, France</td>
<td></td>
</tr>
<tr>
<td>THU-277</td>
<td>Poor dental health is a risk factor for infections by streptococci after liver transplant</td>
<td>Philipp GÖBEL, Germany</td>
<td></td>
</tr>
<tr>
<td>THU-278</td>
<td>Pre-formed donor specific antibodies and aetiology of liver disease are associated with increased incidence of acute cellular rejections after liver transplantation</td>
<td>Preya PATEL, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-279</td>
<td>Sustained virological response with DAAs decreases glucose level but do not improve renal function, lipid metabolism and blood pressure in liver transplanted patients: a 3-year, long-term follow up</td>
<td>Raffaella LIONETTI, Italy</td>
<td></td>
</tr>
<tr>
<td>THU-280</td>
<td>Prospective multicenter study of sofosbuvir-velpatasvir (SOF/VEL) in hepatitis C virus (HCV) negative liver (LT) and kidney transplant (KT) recipients receiving HCV viremic donors</td>
<td>Raymond RUBIN, United States</td>
<td></td>
</tr>
<tr>
<td>THU-281</td>
<td>Incidence and prognostic impact of cancer after liver transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Manuel RODRÍGUEZ-PERÁLVAREZ, Spain</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-282</th>
<th>Gender disparity in cardiovascular morbidity and mortality post liver transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Samarth PATEL, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-283</th>
<th>GFR reset point at 3 months after liver transplant is a superior predictor of liver and kidney disease related outcomes: analysis from a large cohort of NASH patients (nail NASH consortium)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sanjaya SATAPATHY, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-284</th>
<th>Is hepatitis B immunoglobulin necessary for hepatitis D prophylaxis after liver transplantation? A retrospective multicenter study of a cohort of 174 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sergio RODRÍGUEZ-TAJES, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-285</th>
<th>Pre-transplant diabetes independently predicts atherosclerotic vascular event and death due to cardiovascular disease in liver transplant recipients: a long term multicenter observational study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stefano GITTO, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-286</th>
<th>A novel scoring system for predicting risk of relapse following referral for liver transplantation in patients with alcohol-related liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stephanie TURNER, Australia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-287</th>
<th>Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Thomas HORVATITS, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-288</th>
<th>An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Teng-Yu LEE, Taiwan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-289</th>
<th>Proximal splenorenal shunt as a secondary prophylaxis for isolated gastric bleeding in patients with non-cirrhotic portal hypertension: a report from a single-center case-series</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Utpal ANAND, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-289</th>
<th>Usefulness of the «AFP model» to predict recurrence tumor in patients transplanted with carcinoma hepatocellular within Milan criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Victor J BELTRÁN, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-291</th>
<th>Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vito SANSONE, Italy</td>
</tr>
</tbody>
</table>
Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.)

THU-292 Geographic disparities and socioeconomic determinants in liver transplantation referral at the Scottish Liver Transplant Unit
Wilson SIU, United Kingdom

THU-293 Pre-operative biliary drainage in perihilar cholangiocarcinoma: an overview of systematic reviews
Xinwei CHANG, Netherlands

THU-294 Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR
Amare AREGAY, Germany

THU-295 The FOXO1-hedgehog signaling axis regulates NLRP3 inflammasome activation in liver ischemia and reperfusion injury
Bibo KE, United States

THU-296 Mesenchymal stem cells-derived extracellular vesicles carried IncRNA-CEP95 ameliorates acute liver rejection by modulating phenotype of natural killer cells
Liang CHEN, China

THU-297 Hepatic ischemia induces a time-dependent increase in SERPINB3 gene expression
Cristian TURATO, Italy

THU-298 Esomeprazole attenuates hepatic ischemia/reperfusion injury by modulation of TLR4-mediated signaling in mice
Min SUNG KIM, Korea, Rep. of South

THU-299 MSC-EVs induce liver transplantation tolerance by promoting CD8+CD28- T cells differentiation and immunomodulatory function via IncRNA MALAT1/IRF4 signaling
Xin SUI, China

THU-300 Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate hepatic ischemia-reperfusion injury by regulating neutrophils polarization and suppressing neutrophil extracellular traps formation
Xiaomei ZHANG, China

THU-301 Antibodies against huntingtin interacting protein 1-related protein are more prevalent in patients with antibody-mediated rejection after liver transplantation
Bastian ENGEL, Germany
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-302</td>
<td>Inhibition of gamma glutamyl transpeptidase ameliorates hepatic/reperfusion injury in rats with fatty liver</td>
<td>Joseph GEORGE, Japan</td>
</tr>
<tr>
<td>THU-303</td>
<td>Influence of PML, RASSF6 and NLRP12 on growth and recurrence of human hepatocellular carcinoma</td>
<td>Natalie VOGEL, Germany</td>
</tr>
<tr>
<td>THU-304</td>
<td>Serum glycomics early after liver transplantation relate to graft loss 3 months after liver transplantation independently of early allograft dysfunction</td>
<td>Verhelst XAVIER, Belgium</td>
</tr>
<tr>
<td>THU-305</td>
<td>YAP attenuates hepatic ischemia reperfusion injury by inducing autophagy through p38/ERK MAPK pathway</td>
<td>Shuguang ZHU, China</td>
</tr>
<tr>
<td>THU-306</td>
<td>Extracellular vesicles derived from human umbilical cord mesenchymal stem cell protect liver ischemia/reperfusion injury by reducing CD154 expression on CD4+ T cells via CCT2.</td>
<td>Jun ZHENG, China</td>
</tr>
</tbody>
</table>
### Molecular and cellular biology

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-307</td>
<td>Decreased level of KEAP1 and activation of NRF2 contribute to sorafenib resistant in hepatocellular carcinoma</td>
<td>Shi JIANG</td>
<td>China</td>
</tr>
<tr>
<td>THU-308</td>
<td>Unravelling the molecular determinants of metabolic syndrome thanks to NMR-metabolomics of urine and serum samples</td>
<td>Chiara BRUZZONE</td>
<td>Spain</td>
</tr>
<tr>
<td>THU-309</td>
<td>The hedgehog effect: mediating crosstalk between liver and adipose tissue</td>
<td>Fritzi OTT</td>
<td>Germany</td>
</tr>
<tr>
<td>THU-310</td>
<td>MicroRNA-26b-5p sensitizes hepatocellular carcinoma CD133+ cancer stem cells to cisplatin through downregulation of Jag1-Hes1 and increased BBC3-mediated apoptosis</td>
<td>Hamed HEMATI</td>
<td>India</td>
</tr>
<tr>
<td>THU-311</td>
<td>TMBIM6 regulates ageing and high-fat diet-induced lipid accumulation</td>
<td>Han-Jung CHAE</td>
<td>Korea, Rep. of South</td>
</tr>
<tr>
<td>THU-312</td>
<td>Decreased expressions of p70S6K in NK cells of F4-NAFLD patients inhibited F-actin and was correlated with their impaired function</td>
<td>Johnny AMER</td>
<td>Israel</td>
</tr>
<tr>
<td>THU-313</td>
<td>A fatty acid amide hydrolase inhibitor, URB597, inhibits MICA and MICB shedding</td>
<td>Kazuma SEKIBA</td>
<td>Japan</td>
</tr>
<tr>
<td>THU-314</td>
<td>A trans-activator of transcription-fusion bone morphogenetic protein 7 polypeptide suppresses CCL4 induced-hepatic fibrogenesis in mice</td>
<td>Kyung Joo CHO</td>
<td>Korea, Rep. of South</td>
</tr>
<tr>
<td>THU-315</td>
<td>Dickkopf-1 enhances tumourigenic potential by inducing liver angiogenesis</td>
<td>Kyung Joo CHO</td>
<td>Korea, Rep. of South</td>
</tr>
<tr>
<td>THU-316</td>
<td>The FXR agonist obeticholic acid decreases matrix metalloproteinase activity via RECK and TIMP modulation in hepatic ischemia/reperfusion injury</td>
<td>Laura Giuseppina DI PASQUA</td>
<td>Italy</td>
</tr>
<tr>
<td>THU-317</td>
<td>Cross-linking of liver metabolism – hedgehog as a key regulator of energy metabolism, regulating mechanistic target of rapamycin activity</td>
<td>Luise SPORMANN</td>
<td>Germany</td>
</tr>
<tr>
<td>THU-318</td>
<td>Functional consequences of metabolic zonation in murine livers: new insights for an old story</td>
<td>Madlen MATZ-SOJA</td>
<td>Germany</td>
</tr>
</tbody>
</table>
THU-319  PXB-cells for the study of lipid metabolism: robust and human-specific lipid profile in human hepatocytes freshly isolated from chimeric mice with humanized liver
Masaki TAKAHASHI, Japan

THU-320  Ductular reaction and its microenvironment is aetiology driven
Matthias VAN HAELE, Belgium

THU-321  Increased autophagy is linked to exosomes secretion in ductular cells of cirrhosis
Tzu-Min HUNG, Taiwan

THU-322  Screening of components involved in activation of innate immune responses and inflammation in NEMO KO mice
Mick FRISSEN, Netherlands

THU-323  Establishment of murine model of acute-on-chronic liver failure
Nidhi NAUTIYAL, India

THU-324  The method of spheroid formation for 3D cultures of primary hepatocytes influences hepatocellular functions and hepatotoxicity
Natalia SANCHEZ-ROMERO, Spain

THU-325  Bioengineering of 3D bile ducts from 2D micropatterns by self-organogenesis
Pascale DUPUIS-WILLIAMS, France

THU-326  Histidine triad nucleotide-binding protein-2 is present at the cross-road of ER-mitochondria interactions and modulates adaptive stress response in hepatocytes
Pavitra KUMAR, Switzerland

THU-327  Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease
Peter REVILL, Australia

THU-328  Tolerogenic dendritic cells modulate pathogenic CD4+ T cells in an ex vivo co-culture system in a concanavalin A -mice model of type-I autoimmune hepatitis
Prabhsimran SINGH, India

THU-329  Hepatic inflammation upregulates netrin-1 in mice and in vitro through translational activation and transcript topology alteration in a LA-related protein-1 (LARP1)-dependent manner
Romain BARNAUT, France

THU-330  Cirrhotic extracellular matrix affects Hic-5 expression in primary human hepatic stellate cells
Simona ONALI, Italy
### Molecular and cellular biology (Cont.)

<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-331</td>
<td>Phenotypic characterization of ABCG5/G8 deficiency: selective knockout in liver or intestine leads to genocopies</td>
<td>Susanne N WEBER, Germany</td>
<td></td>
</tr>
<tr>
<td>THU-332</td>
<td>Synthesis and comparative assessment of bile acid C3-hydroxyl stereoisomers as farnesoid X receptor modulators</td>
<td>Tarek MOUSTAFA, Austria</td>
<td></td>
</tr>
<tr>
<td>THU-333</td>
<td>Upregulation of CCNB1, CDC20 and CENPF genes is associated with poor prognosis in hepatocellular carcinoma (HCC)</td>
<td>Tengfei SI, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-334</td>
<td>Bax inhibitor-1 inhibits acetaminophen induced hepatotoxicity by reducing the drug induced ER stress through regulating the RIDD activity of IRE1 alpha</td>
<td>Thoufiqul Alam RIAZ, Korea, Rep. of South</td>
<td>Top 10%</td>
</tr>
<tr>
<td>THU-335</td>
<td>Circular RNA circ-TEX2 acts as the sponge of miR-182 and miR-184 to suppress hepatocellular carcinoma proliferation and invasion</td>
<td>Rong LI, China</td>
<td>YI</td>
</tr>
<tr>
<td>THU-336</td>
<td>CircRNA_104797 mediates acquired sorafenib resistance in hepatocellular carcinoma through regulating ROS</td>
<td>Junjie XU, China</td>
<td>YI</td>
</tr>
<tr>
<td>THU-337</td>
<td>Ubiquilin 1 mediates sorafenib resistance in hepatocellular carcinoma through targeting mitochondrial biogenesis via regulating PGC1?</td>
<td>Junjie XU, China</td>
<td>YI</td>
</tr>
<tr>
<td>THU-338</td>
<td>Investigating the mechanism of treating acute-on-chronic liver failure with human bone marrow-derived mesenchymal stem cells via hepatocytes exosomal miRNAs</td>
<td>Jing ZHANG, China</td>
<td>YI</td>
</tr>
</tbody>
</table>
# Viral hepatitis C: Clinical aspects except therapy

<table>
<thead>
<tr>
<th>Poster Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-339</td>
<td>A novel hepatitis C intervention in Denmark to test and treat people who inject drugs</td>
<td>Anne ØVREHUS, Denmark</td>
</tr>
<tr>
<td>THU-341</td>
<td>Kidney transplant from hepatitis C positive donors to hepatitis C negative recipients: report on the first experience in the UK</td>
<td>Brendan HEALY, United Kingdom</td>
</tr>
<tr>
<td>THU-342</td>
<td>Pharmacy-based molecular point-of-care testing for hepatitis C (HCV) in high-risk patients: feasibility and linkage to care</td>
<td>Benedict ROGERS, United Kingdom</td>
</tr>
<tr>
<td>THU-343</td>
<td>Improving female street sex worker (FSSW) access to hepatitis C testing and treatment</td>
<td>Catherine WIGGLESWORTH, United Kingdom</td>
</tr>
<tr>
<td>THU-344</td>
<td>Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center</td>
<td>Cristina MARCOS FOSCH, Spain</td>
</tr>
<tr>
<td>THU-345</td>
<td>Integrating hepatitis C virus screening by dry blood spot test into colorectal cancer screening: a randomized controlled trial</td>
<td>María Cristina REYGOSA CASTRO, Spain</td>
</tr>
<tr>
<td>THU-346</td>
<td>Ethnic disparities in the risk of hepatitis C virus-related diabetes in a large population-based cohort in Canada</td>
<td>Dahn JEONG, Canada</td>
</tr>
<tr>
<td>THU-347</td>
<td>The electronegative low-density lipoprotein in patients with chronic hepatitis C infection</td>
<td>Chia-Yen DAI, Taiwan</td>
</tr>
<tr>
<td>THU-348</td>
<td>Telemedicine and decentralized treatment dispensation to rescue patients in a hepatitis C micro-elimination program based on on-site dried blood spot testing in drug addiction centers</td>
<td>Dalia MORALES ARRAEZ, Spain</td>
</tr>
<tr>
<td>THU-349</td>
<td>The success of outreach hepatitis C screening among a Belgian population of drug users in a rural and urban setting</td>
<td>Dana BUSSCHOTS, Belgium</td>
</tr>
<tr>
<td>THU-350</td>
<td>Angiopoietin 2 levels decrease with SVR and correlate with dynamics of portal hypertension in patients with HCV-induced advanced chronic liver disease</td>
<td>David JM BAUER, Austria</td>
</tr>
</tbody>
</table>
### Viral hepatitis C: Clinical aspects except therapy (Cont.)

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-351</td>
<td>A program of hepatitis C surveillance with linkage to care for inpatients from non-infectious departments in two tertiary hospitals from Jiangsu, China</td>
<td>Chao WU, China</td>
<td></td>
</tr>
<tr>
<td>THU-352</td>
<td>Feasibility and acceptability of self-testing for hepatitis C infection among the general population in Egypt</td>
<td>Elena IVANOVA, Switzerland</td>
<td></td>
</tr>
<tr>
<td>THU-353</td>
<td>The HSD17B13 rs6834314 variant is associated with liver stiffness measurement in untreated HCV-3 patients with cirrhosis</td>
<td>Enrico GALMOZZI, Italy</td>
<td></td>
</tr>
<tr>
<td>THU-354</td>
<td>The impact of universal access to DAA and real-world treatment outcome amongst genotype 3 hepatitis C virus-infected prisoners</td>
<td>YU JUN WONG, Singapore</td>
<td></td>
</tr>
<tr>
<td>THU-355</td>
<td>Hepatitis C reflex testing in Spain in 2019: a story of success</td>
<td>Federico GARCIA GARCIA, Spain</td>
<td></td>
</tr>
<tr>
<td>THU-356</td>
<td>Cracks in the hepatitis C cascade of care: real-life outreach data from four Central London services</td>
<td>Hui Mei WONG, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>THU-357</td>
<td>Seroprevalence of hepatitis B virus co-infection among HCV infected patients screened during the national campaign for HCV eradication in Egypt</td>
<td>Hadeel GAMAL ELDEEN, Egypt</td>
<td></td>
</tr>
<tr>
<td>THU-358</td>
<td>Risk of liver and non-liver-related mortality among hepatitis C virus and human immunodeficiency virus co-infected persons in a cohort of Brazilian blood donors: a twenty-year study</td>
<td>Helio Ranes FILHO, Brazil</td>
<td></td>
</tr>
<tr>
<td>THU-359</td>
<td>Emergency department screening for hepatitis C carriers does not improve linkage to care – a single-center prospective study</td>
<td>Inbal HOURI, Israel</td>
<td></td>
</tr>
<tr>
<td>THU-360</td>
<td>Treating patients with DAAs helped to save €1 billion in France – a budget impact model from 2014 to 2018</td>
<td>Ingrid RODRIGUEZ, France</td>
<td></td>
</tr>
<tr>
<td>THU-361</td>
<td>Outcomes of community and prison-based hepatitis C treatment using an eHealth model of care</td>
<td>James HARIDY, Australia</td>
<td></td>
</tr>
<tr>
<td>THU-362</td>
<td>Testing and linkage to treatment programme for hepatitis C in different homeless locations in Greater Manchester, UK</td>
<td>F Javier VILAR, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
THU-363  Achieving micro elimination of hepatitis C across a network of prisons in the north-west of England covered by a single treatment provider  
F Javier VILAR, United Kingdom

THU-364  Hepatitis C virus care cascade assessment: one step closer to micro-elimination  
Jehan CHOWDHURY, United States

THU-365  Global timing of hepatitis C virus elimination in high-income countries: an updated analysis  
Jean-Michel PAWLOTSKY, France

THU-366  Anticipated timing of elimination of hepatitis C virus in Canada’s four most populous provinces  
Jordan FELD, Canada

THU-367  Acute hepatitis C virus infection: a prospective ten-year observational study of HCV-mono and HCV/HIV-coinfected patients  
Julia DIETZ, Germany

THU-368  Improving the referral of hepatitis C virus positive patients to specialists through an electronic «pop-up» alert system  
Kamil OZDIL, Turkey

THU-369  Predictors of disengagement or delay after hepatitis C assessment  
Kathleen BRYCE, United Kingdom

THU-370  Predictors of workload in a hepatitis C treatment pathway  
Kathleen BRYCE, United Kingdom

THU-371  Micro-elimination of hepatitis C in mental health care settings  
Kristen MCKEE, Australia

THU-372  Triple E (engagement, education and eradication) for patients with chronic hepatitis C infection: > 2 years of results of a successful, collaborative US model for improving education, screening and linkage to care in an underserved population  
Marcelo KUGELMAS, United States

THU-373  Prevalence of hepatitis C in a gastrointestinal endoscopy unit. An active search for asymptomatic subjects  
Laura GOMEZ-ESCOBAR VIEJO, Spain

THU-374  Why didn’t I see you in my clinic? Patients with HCV positive serology but never a confirmed infection. A retrospective analysis at 10 years  
Matias ESTEVEZ, Spain

THU-375  Timing of hepatitis C elimination in the United States: estimating the year each state will meet the World Health Organization’s elimination targets  
Nancy S REAU, United States
Viral hepatitis C: Clinical aspects except therapy (Cont.)

THU-376 Managing hepatitis C in people who inject drugs (PWID) using the internist-addiction medicine-hepatology (IAHC) model to achieve Hep C micro-elimination
Naren Srinath NALLAPETA, United States

THU-377 Testing and treatment for hepatitis C in the community pharmacy setting: an opportunity not to be missed?
Nicki PALMER, United Kingdom

THU-378 Hepatitis C virus antigen detection as a tool for diagnosis of acute hepatitis C in patients with negative hepatitis C virus antibody
Rajneesh KUMAR, Singapore

THU-379 Screening for chronic liver diseases in the general population reveals an unexpectedly high prevalence of hepatitis C and advanced NAFLD
Sebastian BACHMAYER, Austria

THU-380 Does additional information obtained from multiple visits change the timing of HCV treatment decisions
Shawn GREENAN, Canada

THU-381 Missed linkage to care for patients with chronic hepatitis C virus infection in a tertiary care center: results of the telepass project
Francesco SANTOPAOLO, Italy

THU-382 Epidermal growth factor gene polymorphism in hepatitis C virus patients with hepatocellular carcinoma
Sara ASAR, Egypt

THU-383 Impact of dysmetabolism on liver damage severity and evolution in a real-life cohort of patients treated for chronic hepatitis C
Serena PELUSI, Italy

THU-384 Direct-acting antivirals have substantially modified the profile of patients with cirrhosis who require hospitalization in Spain
Sergio RODRIGUEZ-TAJES, Spain

THU-386 Patients with hepatitis C (Redpath): a randomised controlled trial of telephone contact or offer of an incentive, in addition to a standard letter
Stephen BARCLAY, United Kingdom

THU-387 Overdose events among active drug users successfully treated for HCV: the impact of homelessness
Tianna MAGEL, Canada

THU-388 Micro-elimination in prisons: a high-intensity test and treat (HITT) programme
Tracey STIRRUP, United Kingdom
THU-389  Oncogenic implications of sofosbuvir on the development of hepatocellular carcinoma  
Wei-Lun TSAI, Taiwan

THU-390  Epidemiological evolution of viral hepatitis in uremic patients in Taiwan – the Formosa like group  
Yu-Ju WEI, Taiwan
**Viral hepatitis C: Therapy and resistance**

**THU-391**  Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial  
Xiaoyu WEN, China

**THU-392**  Expansion of a multidisciplinary support program for patients with addictions and hepatitis C: strategies for an effective approach  
Montserrat GARCIA-RETORTILLO, Spain

**THU-393**  Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program  
Alessandra MANGIA, Italy

**THU-394**  Real-life efficacy and safety of direct-acting antivirals in patients with liver cirrhosis and history of hepatic decompensation: EpiTer-2 study  
Aleksandra BERKAN-KAWINSKA, Poland

**THU-395**  Concomitant use of direct-acting antivirals (DDAs) and central nervous system drugs in current chronic hepatitis C patient profile  
Antoni SICRAS, Spain

**THU-396**  Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: the grand plan study  
Brian CONWAY, Canada

**THU-397**  Direct-acting antiviral treatment in patients infected with a non-epidemic hepatitis C genotype in the Netherlands: results from a nationwide cohort study  
Cas ISFORDINK, Netherlands

**THU-398**  A real-world study of treating advanced liver cirrhosis due to chronic HCV infection genotype 1b with sofosbuvir+ ledipasvir with or without ribavirin: results from a cohort of 349 patients  
Carmen Monica PREDA, Romania

**THU-399**  Alcohol use does not influence treatment uptake or outcomes in the DAA era  
Curtis COOPER, Canada

**THU-400**  Influence of baseline resistance on treatment outcome in patients treated for chronic hepatitis C in Denmark: a nationwide study  
Christina SØLUND, Denmark

**THU-401**  Inadvertent «off label» DAA treatment in the real-world and importance for virologic outcome – data from the German hepatitis C-Registry (DHC-R)  
Christoph SARRAZIN, Germany
THU-402 Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir
David A SMITH, United Kingdom

THU-403 Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C
Velia Chiara DI MAIO, Italy

THU-404 Grazoprevir/elbasvir for treatment of hepatitis C virus genotype 4 post kidney transplant
Faisal ABAALKHAIL, Saudi Arabia

Ekaterina NABATCHIKOVA, Russian Federation

THU-406 Integrated efficacy and safety analysis of GT1-6 treatment-naive, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir
Eli ZUCKERMAN, Israel

THU-407 Hepatitis C micro-elimination pilot strategy in Pakistani migrants in Catalonia through the implementation of a community intervention: interim results of the HepC-link study
Elisa MARTRÓ, Spain

THU-408 Characteristics of adults with difficult-to-treat hepatitis C virus genotype subtype 4r infection in Rwanda: a secondary analysis of a clinical trial in Sub-Saharan Africa (shared study)
Fredrick KATEERA, Rwanda

THU-409 The importance of medical specialists and services coordination to effectively treat hepatitis C infection in patients who inject drugs: the Trieste model of care
Mauro GIUFFRÉ, Italy

THU-410 The outcome of re-treatment of relapsed hepatitis C virus infection after direct acting antiviral treatment failure in resource-limited settings
Gina NAGUIB, Egypt

THU-411 Resistance-associated variants conferring quite a high level of resistance to all approved NS5A inhibitors in genotype 2 hepatitis C virus
Goki SUDA, Japan

THU-412 A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection
Rui HUA, China
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-413</td>
<td>Health-related quality of life (HRQOL) before and after treatment of genotype 1 (GT1) infection with elbasvir/grazoprevir (EBR/GZR): results from the German hepatitis C registry (DHC-R)</td>
<td>Dietrich HÜPPE, Germany</td>
</tr>
<tr>
<td>THU-414</td>
<td>Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort</td>
<td>Irene CACCIOLA, Italy</td>
</tr>
<tr>
<td>THU-415</td>
<td>Use of sofosbuvir based direct acting antiviral regimens is associated with reduced mortality in liver transplant candidates with hepatitis C</td>
<td>Jeffrey WANG, United States</td>
</tr>
<tr>
<td>THU-416</td>
<td>Factors associated with efficacy of retreatment with grecaprevir/pibrentasvir therapy in prior DAA failed patients – nationwide multicenter study in Japan</td>
<td>Jun ITAKURA, Japan</td>
</tr>
<tr>
<td>THU-417</td>
<td>Impact of the universal access to direct-acting antivirals in the profile of hepatitis C treated patients</td>
<td>Jordi LLANERAS, Spain</td>
</tr>
<tr>
<td>THU-418</td>
<td>Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease – data from the German hepatitis C-registry (DHC-R)</td>
<td>Johannes WIEGAND, Germany</td>
</tr>
<tr>
<td>THU-419</td>
<td>HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C</td>
<td>Joss O’LOAN, Australia</td>
</tr>
<tr>
<td>THU-420</td>
<td>Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naive hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry</td>
<td>Juan TURNES, Spain</td>
</tr>
<tr>
<td>THU-421</td>
<td>Baseline features of hepatitis C patients associated to prescription of pangenotypic antiviral treatments: results from the real-world Spanish Hepa-C registry</td>
<td>Juan TURNES, Spain</td>
</tr>
<tr>
<td>THU-422</td>
<td>The English hepatitis C registry shows only a modest effect from non-completion of directly-acting antivirals for hepatitis C: SVR rates over 80% in genotype 1, 2 or 3 HCV if more than one third of planned treatment is completed</td>
<td>Kate DRYSDALE, United Kingdom</td>
</tr>
</tbody>
</table>
THU-423  Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany – analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)
Karl-Georg SIMON, Germany

THU-424  The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review
Katherine DAVIDSON, United Kingdom

THU-425  Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection
Lisette KRASSENBURG, Canada

THU-426  Virological patterns of HCV-patients with failure to second generation direct-acting antivirals
Laura OCCHIELLO, Italy

THU-427  Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness
Lisa BARRETT, Canada

THU-428  Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees
Lorenzo ONORATO, Italy

THU-429  Elimination of hepatitis C in a remand prison using a rapid point of care driven test and treat pathway
Louise DAVIES, United Kingdom

THU-430  Dermatological manifestations in the era of new direct acting antivirals: a single-center experience
Mohamed TALKHAN, Egypt

THU-431  Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction services in Kenya
Matthew AKIYAMA, United States

THU-432  Real-life experience of direct acting antiviral treatment for chronic hepatitis C infection in adolescent patients in a low prevalence setting
Mary FLANAGAN, Ireland

THU-433  Treatment of hepatitis C at the Stockholm needle syringe program – treatment success, reinfection rates and challenges for HCV elimination
Martin KÅBERG, Sweden

THU-434  Epidemiological and clinical analysis of foreign patients treated with direct antivirals for hepatitis C in a high immigration area
Matias ESTEVEZ, Spain
### Viral hepatitis C: Clinical aspects except therapy (Cont.)

**THU-435**  
Drug-drug interactions (DDIs) with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C; understanding the populations at risk and real-world care management  
Michael CURRY, *United States*

**THU-436**  
Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR  
Olav DALGARD, *Norway*

**THU-437**  
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment  
Naveed JANJUA, *Canada*

**THU-438**  
A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects  
Ounisha MUNGUR, *Mauritius*

**THU-439**  
Frequency and characteristics of DAAs failure in hepatitis C therapy  
Pablo FLOREZ DÍEZ, *Spain*

**THU-440**  
Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries  
Pietro LAMPERTICO, *Italy*

**THU-441**  
Fast-track-consultation protocol: an interdisciplinary and useful tool for treating drug user hepatitis C infection in addiction out-patient units  
Silvia ACOSTA-LÓPEZ, *Spain*

**THU-442**  
Achieving hepatitis C elimination in people who inject drugs – interim results of an innovative screen-and-treat program in Austria  
Caroline SCHMIDBAUER, *Austria*

**THU-443**  
Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as a tailored microelimination strategy in PWIDs with a high risk of non-adherence – real-world data from Vienna, Austria  
Caroline SCHMIDBAUER, *Austria*

**THU-444**  
Externalized HCV linkage-to-care cascade in the biggest harm reduction center in Barcelona: approaching a high-risk PWID population  
Sabela LENS, *Spain*

**THU-445**  
In-depth molecular characterization of inherently resistant African HCV genotype 1, subtype 1l, in patients failing DAA-based therapy  
Slim FOURATI, *France*
THU-446 YI  Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment
Igor STARINSKIJ, United Kingdom

THU-447  Microelimination beyond prison walls: subjects sentenced to non-custodial sentences, screening and immediate assisted treatment with «navigator» figure and telemedicine
Susana LLERENA, Spain

THU-448 YI  Efficacy of sofosbuvir/velpatasvir (s/v): impact of treatment adherence
Tianna MAGEL, Canada

THU-449  Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis
Tim PAPALUCA, Australia

THU-450  Management of hepatitis C in primary healthcare in the country of Georgia
Tengiz TSERTSVADZE, Georgia

THU-451  HCV DAA treatment failure is associated to hepatocellular carcinoma presence
Ubaldo Visco COMANDINI, Italy

THU-452 YI  Challenges in hepatitis C elimination despite highly effective antiviral agents – experience of a tertiary hepatology centre
Christian URAK, Austria

THU-453  Reasons for hepatitis C direct acting antiviral failure: experience from the field
Vincent THIBAULT, France

THU-454 Top 10%  Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience
Vincenzo MESSINA, Italy

THU-455 Top 10%  Hepatitis C positive organ transplantation to negative recipients at a multi-organ Canadian transplant centre: ready for prime time
Waleed ALGHAMDI, Canada
Liver tumours: Clinical aspects except therapy

THU-458 Neutrophil-lymphocyte ratio predicts the risk of developing hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B under antiviral therapy
Ke SHI, China

THU-459 Differentiation and management of hepatobiliary mucinous cystic neoplasms: a single-center experience for 10 years
Junhao ZHENG, China

THU-460 Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection
Hui LI, China

THU-461 Serum and urine extracellular vesicles contain specific RNAs with diagnostic capacity for cholangiocarcinoma, being possibly involved in disease pathogenesis
Ainhoa LAPITZ, Spain

THU-462 Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC)
Ainhoa LAPITZ, Spain

THU-463 Investigating the impact of extrahepatic metastasis in patients with HCC: does location matter?
Aline MAEHINGER-KUNZ, Germany

THU-464 Combination of AFP, AFP-l3 and PIVKA-II levels improves diagnostic accuracy of hepatocellular carcinoma (ALPS score)
Han Ah LEE, Korea, Rep. of South

THU-465 The PNPLA3 G-allele is common in patients with HCC but does not affect tumor characteristics and tumor biology
Benedikt SCHAEFER, Austria

THU-466 Long-term risk of HCC in persons with cirrhosis: national, population-based cohort study of 7,322 individuals
Bonnie BENGTTSSON, Sweden

THU-467 Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma
Gian Paolo CAVIGLIA, Italy

THU-468 Contrast-enhanced ultrasound using sonazoid in liver imaging reporting and data system category 3 and 4 observations on gadoxetate-enhanced magnetic resonance imaging
Yeun-Yoon KIM, Korea, Rep. of South
THU-469  Active chronic hepatitis B increases the risk of liver metastasis – a retrospective observational study of 7,187 consecutive newly diagnosed colorectal cancer
Yue YANG, China

THU-470  Identification and etiology-dependent evaluation of diagnostic algorithms for early detection of hepatocellular carcinoma
Dave MORGENSTERN, United States

THU-471  Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (TNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC)
David J. PINATO, United Kingdom

THU-472  Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma
David J. PINATO, United Kingdom

THU-473  MALDI-imaging mass spectrometry of N-glycan profiles of molecular subclasses of human hepatocellular carcinoma
Andrew DELACOURT, United States

THU-474  The burden of percutaneous liver biopsy use in hepatocellular carcinoma
Ahmad KHAN, United States

THU-475  Epidemiological trends of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease in Italy. On behalf of the ITA.LI.CA study group
Fabio FARINATI, Italy

THU-476  Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization
Filippo PELIZZARO, Italy

THU-477  Natural history of hepatobiliary-hypointense only nodules found at magnetic resonance imaging with Gd-EOB-DTPA: time-dependent effects of dimensional increase and diffusion weighted imaging alterations
Francesca BENEVENTO, Italy

THU-478  Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study
Giovanni MARASCO, Italy

THU-479  Prognostic and diagnostic role of angiogenesis biomarkers in hepatocellular carcinoma treated with chemoembolization
Giulia PESERICO, Italy
### Liver tumours: Clinical aspects except therapy (Cont.)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>THU-480</strong></td>
<td>Risk of hepatocellular carcinoma in hepatitis D co-infected patients compared to hepatitis B mono-infected patients: a systematic review and meta-analysis</td>
<td>Habiba KAMAL, <em>Sweden</em></td>
</tr>
<tr>
<td><strong>THU-481</strong></td>
<td>The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma</td>
<td>Johann VON FELDEN, <em>Germany</em></td>
</tr>
<tr>
<td><strong>THU-482</strong></td>
<td>Intratumoral EpCAM-positive cancer stem cell heterogeneity in patients with hepatocellular carcinoma and its impact on clinical outcome</td>
<td>Jenny KRAUSE, <em>Germany</em></td>
</tr>
<tr>
<td><strong>THU-483</strong></td>
<td>Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer</td>
<td>John CONNELL, <em>United Kingdom</em></td>
</tr>
<tr>
<td><strong>THU-484</strong></td>
<td>Care pathway for patients with hepatocellular carcinoma in France in 2017: management overview, description of nurse coordinators’ role and its impact</td>
<td>Julie DEVICTOR, <em>France</em></td>
</tr>
<tr>
<td><strong>THU-485</strong></td>
<td>Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides</td>
<td>Julien CALDERARO, <em>France</em></td>
</tr>
<tr>
<td><strong>THU-486</strong></td>
<td>Deep learning for cost-effective accurate diagnosis of liver tumor based-on magnetic resonance imaging and clinical information: a retrospective study</td>
<td>Shihui ZHEN, <em>China</em></td>
</tr>
<tr>
<td><strong>THU-487</strong></td>
<td>Elevated serum myostatin level is associated with development of hepatocellular carcinoma in patients with alcoholic liver cirrhosis: a multicenter study</td>
<td>Ji Hyun KIM, <em>Korea, Rep. of South</em></td>
</tr>
<tr>
<td><strong>THU-488</strong></td>
<td>The risk of hepatocellular carcinoma recurrence following resection or ablation is dependent on underlying etiology</td>
<td>Laura TELEP, <em>United States</em></td>
</tr>
<tr>
<td><strong>THU-489</strong></td>
<td>High subcutaneous tissue density correlates negatively with survival in patients with hepatocellular carcinoma</td>
<td>Leona VON KOECKRITZ, <em>Switzerland</em></td>
</tr>
<tr>
<td><strong>THU-490</strong></td>
<td>The protective role of urea-containing cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma</td>
<td>Young-Sun LEE, <em>Korea, Rep. of South</em></td>
</tr>
</tbody>
</table>
THU-491 YI  Applicability of the «six and twelve model» in patients with hepatocellular carcinoma treated with DEB-TACE
Maria PIPA MUÑIZ, Spain

THU-492 YI  Application of acoustic radiation force impulse elastography in non-invasive diagnosis of focal nodular hyperplasia
Mariana FORLINO, Italy

THU-493 YI  Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma
Natthaya CHUAYPEN, Thailand

THU-494 YI  Incidence of hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors: impact on outcomes and tissue biomarker analysis
Nicola PERSONENI, Italy

THU-495 YI  External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients
Osman Cavit OZDOGAN, Turkey

THU-496 YI  Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2
Peter GALLE, Germany

THU-497 YI  AFP is elevated more than 10 years before hepatocellular carcinoma development is detected: this observation leads to a practical risk stratification strategy
Philip JOHNSON, United Kingdom

THU-498 YI  The prognostic and diagnostic significance of the neutrophil to lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study
Philip JOHNSON, United Kingdom

THU-499 YI  Quantitative assessment of the impact of viral state on the rate of tumour progression in patients receiving sorafenib for advanced hepatocellular carcinoma
Philip JOHNSON, United Kingdom

THU-500 YI  Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis
Pietro GUERRA, Italy

THU-501 Top 10% Refining the immune class of hepatocellular carcinoma
Roser PINYOL, Spain
## Liver tumours: Clinical aspects except therapy (Cont.)

<table>
<thead>
<tr>
<th>THU-502</th>
<th>Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation</th>
<th>Sabine URBAN, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-503</td>
<td>Cholangiocarcinoma miscoding in hepatobiliary centres</td>
<td>Shaun SELVADURAI, United Kingdom</td>
</tr>
<tr>
<td>THU-504</td>
<td>Non-alcoholic steatohepatitis is a risk factor for intrahepatic cholangiocarcinoma and affects its long-time outcome: results from a multicenter international case-control study</td>
<td>Stefania DE LORENZO, Italy</td>
</tr>
<tr>
<td>THU-505</td>
<td>Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic hepatitis B and C patients</td>
<td>Stijn VAN HEES, Belgium</td>
</tr>
<tr>
<td>THU-506</td>
<td>TERT mutated circulating tumor DNA is a useful biomarker and predicts prognosis in Danish HCC patients</td>
<td>Stine KARLSEN, Denmark</td>
</tr>
<tr>
<td>THU-507</td>
<td>Comparison of hepatocellular carcinoma between the current decade and the past – a study of 3,013 cases</td>
<td>Chee-Kiat TAN, Singapore</td>
</tr>
<tr>
<td>THU-508</td>
<td>Cholangiocarcinoma in England – a national study examining changes in incidence, diagnostic routes and overall survival</td>
<td>Tracey GENUS, United Kingdom</td>
</tr>
<tr>
<td>THU-509</td>
<td>Reduced incidence of hepatobiliary cancers in helicobacter pylori infected persons in a population-based cohort study</td>
<td>Hendrik VILSTRUP, Denmark</td>
</tr>
<tr>
<td>THU-510</td>
<td>Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model</td>
<td>Vito SANSONE, Italy</td>
</tr>
<tr>
<td>THU-511</td>
<td>Identifying core fucosylated glycopeptides via LC-MS in hepatocellular carcinoma tissue specifically using a targeted approach from dual enzymatic MALDI-MSI</td>
<td>Connor WEST, United States</td>
</tr>
<tr>
<td>THU-512</td>
<td>Use of a novel thyroid-stimulating hormone model for predicting the progression of hepatocellular carcinoma</td>
<td>ZhiYun YANG, China</td>
</tr>
</tbody>
</table>
THU-513  A scoring system based on artificial neural network for predicting progression in HBV-related hepatocellular carcinoma
ZhiYun YANG, China

THU-514  Prediction of long-term survival of patients with hepatocellular carcinoma based on NK cells count novel model
ZhiYun YANG, China

THU-515  Chronological improvement in long-term outcomes of surgical resection for patients with hepatocellular carcinoma: two large-volume center studies
Yun Bin LEE, Korea, Rep. of South

THU-516  Glucose variability and risk of hepatocellular carcinoma in diabetic patients: a nationwide population-based study
Su Jong YU, Korea, Rep. of South

THU-517  Estimation of hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance
Yewan PARK, Korea, Rep. of South

THU-518  Indeterminate nodules in hepatocellular carcinoma surveillance: an analysis of the frequency, outcomes and costs
Yu Meng LI, United Kingdom

THU-519  Serum creatinine / cystatin C ratio has a potential as a useful surrogate marker for evaluation of muscle mass volume in patients with hepatocellular carcinoma
Kazufumi KOBAYASHI, Japan
<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-001</td>
<td>The development of the naf3 score to accurately predict the presence of active NASH with advanced fibrosis&lt;br&gt;Naim ALKHOURI, United States</td>
</tr>
<tr>
<td>FRI-002</td>
<td>Advanced transcriptomics identifies the tweak receptor as a novel biomarker in non-alcoholic steatohepatitis: biomarker discovery from gene expression signature to plasma protein&lt;br&gt;Anja BENGTSSON, Denmark</td>
</tr>
<tr>
<td>FRI-003</td>
<td>Machine learning models identify novel histologic features predictive of clinical disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis&lt;br&gt;Andrew BECK, United States</td>
</tr>
<tr>
<td>FRI-004</td>
<td>Serum proteomics identifies biomarkers of fibrotic severity in NASH patients&lt;br&gt;Arathi KRISHNAKUMAR, United States</td>
</tr>
<tr>
<td>FRI-005</td>
<td>Performance of non-invasive fibrosis tests among non-alcoholic fatty liver disease (NAFLD) patients with normal alanine aminotransferase (ALT): data from a large North American primary care NAFLD pathway&lt;br&gt;Abdel-Aziz SHAHEEN, Canada</td>
</tr>
<tr>
<td>FRI-006</td>
<td>Non-invasive detection of NASH and significant fibrosis in NAFLD patients with low FIB-4&lt;br&gt;Heike BANTEL, Germany</td>
</tr>
<tr>
<td>FRI-007</td>
<td>Impact of elevated liver stiffness and hepatic steatosis on maximum liver function capacity&lt;br&gt;Valentin BLANK, Germany</td>
</tr>
<tr>
<td>FRI-008</td>
<td>Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH)&lt;br&gt;Brenda REINHART, Switzerland</td>
</tr>
<tr>
<td>FRI-009</td>
<td>Non-invasive tests for assessing fibrosis in patients with non-alcoholic fatty liver disease: an evaluation of combining test results&lt;br&gt;Amy LAW, United States</td>
</tr>
<tr>
<td>FRI-010</td>
<td>13c-octanoate breath test in a predictive score for the diagnosis of non-alcoholic steatohepatitis&lt;br&gt;Carmen FIERBINTEANU BRATICEVICI, Romania</td>
</tr>
<tr>
<td>FRI-011</td>
<td>Interplay between metabolic derangement, biomarkers of collagen remodeling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease&lt;br&gt;Chiara ROSSO, Italy</td>
</tr>
</tbody>
</table>
| FRI-012 | Comparison of diagnostic accuracy of magnetic resonance ideal-iq sequence and controlled attenuation parameter for detecting liver steatosis  
Xiaoling CHI, China |
| FRI-013 | Mack-3: an accurate blood test for the diagnosis of fibrotic NASH and a candidate biomarker to monitor disease progression  
Clémence CANIVET, France |
| FRI-014 | Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD score) on NAFLD in a mixed Latin American population  
Claudia OLIVEIRA, Brazil |
| FRI-015 | Identification of significant fibrosis in patients with non-alcoholic steatohepatitis using non-invasive tests: determination of optimal thresholds based on cross-sectional analyses of patients screened for a phase 3 randomised controlled trial  
Darshini SHAH, United States |
| FRI-016 | Patients with non-alcoholic fatty liver disease referred from primary care have a significant serum fibrosis marker and liver stiffness measurement discordance  
David HARMAN, United Kingdom |
| FRI-017 | Comparison of point-shear wave elastography (elastPQ) and fibroscan transient elastography (F-TE) for liver fibrosis staging in patients with NAFLD.  
Davide ROCCARINA, United Kingdom |
| FRI-018 | Digital image analysis for quantitative evaluation of fibrosis, steatosis, inflammation and iron overload in patients with non-alcoholic fatty liver disease  
David MARTI-AGUADO, Spain |
| FRI-019 | 2d-shear wave elastography and attenuation imaging: a novel non-invasive method for assessment of non-alcoholic steatohepatitis  
Dong Ho LEE, Korea, Rep. of South |
| FRI-020 | Metabolomics composite biomarkers selected by machine learning predicts NASH  
Elizabeth BROWN, United States |
| FRI-021 | Diagnostic accuracy of acoustic radiation force impulse elastography for the staging of hepatic fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis  
Emmanuel SELVARAJ, United Kingdom |
| FRI-022 | Three is enough: optimization of regions of interest selection for accurate estimation of proton density fat fraction in liver from magnetic resonance images  
Florent ROCHE, France |
**NAFLD: Diagnostics and non-invasive assessment (Cont.)**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-023</td>
<td>Diagnostic accuracy of magnetic resonance elastography for the staging of fibrosis and diagnosis of steatohepatitis in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis</td>
<td>Ferenc MOZES, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-024</td>
<td>Investigation of a composite imaging biomarker for identification of non-alcoholic steatohepatitis (NASH) patients in a Japanese population</td>
<td>Filza ASLAM, Singapore</td>
<td></td>
</tr>
<tr>
<td>FRI-025</td>
<td>External validation of hepatic estimated steatosis index using magnetic resonance image</td>
<td>Dong Hwi RIM, Korea, Rep. of South</td>
<td></td>
</tr>
<tr>
<td>FRI-026</td>
<td>The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus</td>
<td>Geert ROBAEYS, Belgium</td>
<td></td>
</tr>
<tr>
<td>FRI-027</td>
<td>Validation of interleukin-32 as a new circulating fatty liver biomarker</td>
<td>Guido Alessandro BASELLI, Italy</td>
<td></td>
</tr>
<tr>
<td>FRI-028</td>
<td>Simple non-invasive prediction of advanced fibrosis in NAFLD – a stepwise approach and external validation study to reduce indeterminates and biopsy</td>
<td>Heather M KOSICK, Canada</td>
<td></td>
</tr>
<tr>
<td>FRI-029</td>
<td>Adherence to established process measures in the evaluation of hepatic steatosis on imaging in a large tertiary care network</td>
<td>Hersh SHROFF, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-030</td>
<td>Value of FIB-4 and NAFLD fibrosis scores for screening of liver fibrosis in the general population</td>
<td>Isabel GRAUPERA, Spain</td>
<td></td>
</tr>
<tr>
<td>FRI-031</td>
<td>Utilizing pre-existing imaging and data lake technology in the search of clinically neglected non-alcoholic fatty liver disease (NAFLD)</td>
<td>Iiro KARHIAHO, Finland</td>
<td></td>
</tr>
<tr>
<td>FRI-032</td>
<td>Factors associated with NAFLD and advanced liver fibrosis and accuracy of liver biopsy in patients with diabetes mellitus type 2: a cross sectional study</td>
<td>Ivana MIKOLASEVIC, Croatia</td>
<td></td>
</tr>
<tr>
<td>FRI-033</td>
<td>FIB-4 first strategy for non-alcoholic fatty liver disease might not be appropriate for ruling-out advanced liver fibrosis with current cut-off values in patients with type 2 diabetes mellitus</td>
<td>Ivica GRGUREVIC, Croatia</td>
<td></td>
</tr>
<tr>
<td>FRI-034</td>
<td>Accuracy of cytokeratin-18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis</td>
<td>Jenny LEE, Netherlands</td>
<td></td>
</tr>
</tbody>
</table>
FRI-035  Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160,000 blood samples
Johannes WIEGAND, Germany

FRI-036  Composite biomarkers selected by machine learning predict severe fibrosis in NASH
John THOMPSON, United States

FRI-037  Low transient elastography score appropriately identifies patients that can stay within primary care practice
Jaspreet SURI, United States

FRI-038  Phenome-wide association study of the FIB-4 index in a large, populational-based study in the United States
Karen SCHLAUCH, United States

FRI-039  A combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels
Kenneth I. ZHENG, China

FRI-040  Macrophage markers do not add to the prediction of liver fibrosis by transient elastography in patients with non-alcoholic fatty liver disease
Konstantin KAZANKOV, Denmark

FRI-041  Diagnostic accuracy of controlled attenuation parameter compared to ultrasound for detecting steatosis in children with obesity
Laura DRAIJER, Netherlands

FRI-042  ELF test should be used concurrently with elastography in NAFLD to maximize diagnostic accuracy
Laura IOGNA PRAT, United Kingdom

FRI-043  Evaluation of a novel histology-based fibrosis phenotypic composite score and its correlation with NASH-CRN fibrosis scores in patients with NASH
Li CHEN, United States

FRI-044  Serum exosomal miRNA-4668-5p as potential biomarker for advanced fibrosis in non-alcoholic fatty liver disease
Young-Sun LEE, Korea, Rep. of South

FRI-045  Mitochondrial ferritin as a biomarker for the diagnosis of non-alcoholic steatohepatitis
Miwa KAWANAKA, Japan

FRI-046  Patient-reported symptoms and impact in non-alcoholic steatohepatitis: an evaluation of the NASH-check, a novel prom in NASH
Maria Magdalena BALP, Switzerland
## NAFLD: Diagnostics and non-invasive assessment (Cont.)

| FRI-047 | The FGF19 analogue aldafermin improves non-invasive tests in patients with non-alcoholic steatohepatitis  
Marno RYAN, Australia
| FRI-048 | Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis  
Matthew BRECKONS, United Kingdom
| FRI-049 | Systematic review and meta-analysis of FIB-4 for the diagnosis of advanced fibrosis due to non-alcoholic steatohepatitis  
Mazen NOUREDDIN, United States
| FRI-050 | Liver incytes: assessment of fibrosis and steatosis in patients and healthy volunteers  
Michael CURRY, United States
| FRI-051 | Analysis of the prevalence of metabolic syndrome components and other factors as predictors of disease progression among an urban population with NAFLD and/or NASH  
Magdy ELKHASHAB, Canada
| FRI-052 | The impact of ethnicity on incidence of NAFLD/NASH among patients referred to the Toronto liver centre for non-invasive evaluation with transient elastography  
Magdy ELKHASHAB, Canada
| FRI-053 | Drivers of diagnosis and referral decisions in non-alcoholic fatty liver disease patients  
Michael RODEN, Germany
| FRI-054 | Validation of the accuracy of the fast score for detecting non-alcoholic steatohepatitis patients at high risk of becoming cirrhotic in a North American cohort  
Mariana LAZO, United States
| FRI-055 | Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population  
Monika LEWINSKA, Denmark
| FRI-056 | Difference between antinuclear antibody-positive non-alcoholic steatohepatitis and autoimmune hepatitis based on differential patterns of peripheral T lymphocytes  
Akira KADO, Japan
| FRI-057 | Utility of metabolomic biomarkers to identify non-alcoholic fatty liver disease in liver transplant recipients  
Christopher MOWRY, United States
FRI-058  YI  Cost-effectivity analysis of several non-invasive test strategies for detection and referral of patients with non-alcoholic fatty liver disease at risk of advanced fibrosis
Manuel ROMERO GOMEZ, Spain

FRI-059  Prediction of advanced fibrosis with transient elastography is superior to gut microbiota-based approaches in non-alcoholic fatty liver disease
Münevver DEMIR, Germany

FRI-060  The accuracy of the fast score in predicting NASH with significant fibrosis
Nabil NOUREDDIN, United States

FRI-061  Pnfp – a new predictor for pediatric NAFLD fibrosis
Nibin NAHAZ, India

FRI-062  Expanding the use of the vibration controlled transient elastography in morbid obese patients: validation of a new automated adaptive measurement depths algorithm in a large pooled NAFLD cohort
Philip N NEWSOME, United Kingdom

FRI-063  A diagnostic approach of non-alcoholic fatty liver disease with a machine learning model using parameters derived from ultrasound B-mode examination
Pavlos ZOUMPOULIS, Greece

FRI-064  Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH
Peter MESENBRINK, United States

FRI-065  Liver derived apoptotic microparticles as biomarkers to detect transition from simple steatosis to steatohepatitis in non-alcoholic fatty liver disease
Rocio MUNOZ HERNANDEZ, Spain

FRI-066  Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial
Rohit LOOMBA, United States

FRI-067  Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease
Salvatore PETTA, Italy

FRI-068  Glympse liver test for noninvasive monitoring of combination drug therapy in a rat model of non-alcoholic steatohepatitis (NASH)
Sophie CAZANAVE, United States

FRI-069  Too many to refer? FIB-4 scores in primary care patients with abnormal liver tests
Andrew SCHREINER, United States
NAFLD: Diagnostics and non-invasive assessment (Cont.)

FRI-070  Circulating pcsk9 levels correlated with advanced disease in patients with biopsy-proven non-alcoholic fatty liver disease
Sheila GATO ZAMBRANO, Spain

FRI-071  Non-invasive liver fibrosis markers, FIB-4, PRO-C3 and ADAPT, are significantly elevated in biopsy confirmed NAFLD patients at high risk of developing coronary heart disease and cardiovascular disease and are promising clinical decision making tools
Samuel DANIELS, Denmark

FRI-072  The FIB-8 score: validation of a model to screen patients with non-alcoholic fatty liver disease for significant fibrosis
Pimsiri SRIPONGPUN, United States

FRI-073  Continuous CAP algorithm: reduced variability in a prospective cohort
Stephen HARRISON, United States

FRI-074  Ultrasound small vessel imaging and deep learning; a novel approach to FLD screening
Tim HOOGENBOOM, United Kingdom

FRI-075  Individual patient data meta-analysis on controlled attenuation parameter for the XL probe in obese patients
Thomas KARLAS, Germany

FRI-076  Metabolomics approaches to identify biomarkers of non-alcoholic fatty liver disease
Tuulia HYÖTYLÄINEN, Sweden

FRI-077  Optimal non-invasive screening strategy for non-alcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes
Veeral AJMERA, United States

FRI-078  The acNASH index – a novel, non-invasive test for accurately identifying non-alcoholic steatohepatitis in individuals with biopsy-proven NAFLD
Xi-Xi WU, China

FRI-079  Use of the fibrosis-4 score to estimate fibrosis stage for patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in retrospective real-world datasets: a targeted literature review and feasibility assessment
Ying QIU, United States

FRI-080  Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study
Zobair M. YOUNOSSI, United States

FRI-081  Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians
Zobair YOUNOSSI, United States
NAFLD: Therapy

FRI-082  A randomized, double blind, placebo-controlled trial of htd1801 (berberine ursodeoxycholate, budc ) in patients with hypercholesterolemia: implications for its use in non-alcoholic steatohepatitis (NASH)
Adrian DI BISCEGLIE, United States

FRI-083  Weight loss and change in alanine aminotransferase (ALT) among patients with non-alcoholic fatty liver disease (NAFLD) receiving standard care in real world clinical practice: TARGET-NASH
Andrew MOON, United States

FRI-084  Gw9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease
Anja BAUMANN, Austria

FRI-085  Obesity management during the rise of NAFLD: real world outcomes of the medical weight loss approach using a very low energy diet
Ann FARRELL, Australia

FRI-086  Supplementing diet with olive oil does not prevent the progression of non-alcoholic fatty liver disease
Annette BRANDT, Austria

FRI-087  Sustained FXR agonist MET642 shows improved potency and efficacy relative to MET409 in a diet-induced obese biopsy-confirmed mouse model of NASH and in non-human primate pharmacodynamics
Brandee WAGNER, United States

FRI-088  Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in healthy participants
Christopher JONES, United States

FRI-089  Decline in NASH and atherosclerosis-associated oxidised phospholipids and 7-ketocholesterol in response to icosabutate therapy
David A. FRASER, Netherlands

FRI-090  Aramchol improves glucose and lipid homeostasis in NASH via regulation of AMPK and mTOR
José M. MATO, Spain

FRI-091  Saroglitazar for the treatment of NAFLD patients: a single- center observational study at 52 weeks follow up
Santosh D. HAJARE, India
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-092</td>
<td>The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment</td>
<td>Elijah WEBER, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-093</td>
<td>Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor</td>
<td>Elijah WEBER, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-094</td>
<td>The safety and pharmacokinetics of fenofibrate in patients with advanced fibrosis including those with non-alcoholic steatohepatitis (NASH)</td>
<td>Elijah WEBER, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-095</td>
<td>Novel strategies to optimize animal models of human non-alcoholic steatohepatitis for drug development</td>
<td>Francois BRIAND, France</td>
<td></td>
</tr>
<tr>
<td>FRI-096</td>
<td>A randomized, double-blind, placebo-controlled, first-in-human single ascending dose, multiple ascending dose, and food effect study to evaluate the safety, tolerability, and pharmacokinetic profile of FM101 in healthy volunteers</td>
<td>Seon-Ah HA, Korea, Rep. of South</td>
<td></td>
</tr>
<tr>
<td>FRI-097</td>
<td>Direct access lifestyle training improves liver biochemistry and causes weight loss but uptake is suboptimal in patients with NAFLD</td>
<td>Imran PATANWALA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-098</td>
<td>Motile sperm domain-containing protein 2: a novel therapeutic target for the treatment of non-alcoholic steatohepatitis</td>
<td>Itzhak MENDEL, Israel</td>
<td></td>
</tr>
<tr>
<td>FRI-099</td>
<td>The efficacy of vitamin D supplementation on NAFLD: a randomized, double-blind, placebo-controlled 12- month trial on 311 patients</td>
<td>Ivana MIKOLASEVIC, Croatia</td>
<td></td>
</tr>
<tr>
<td>FRI-100</td>
<td>Molecular, cellular, and pharmacological characterization of beta-selective partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis</td>
<td>Jerome DEVAL, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-101</td>
<td>The first double-blind randomized placebo-controlled phase 2 study to assess the efficacy and safety of insulin sensitizer in patients with non-alcoholic steatohepatitis in Asia- an interim report</td>
<td>Jee-Fu HUANG, Taiwan</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Author(s)</td>
<td>Country</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>FRI-102</td>
<td>Efficacy and feasibility of a very low calorie diet to achieve 10% weight loss in patients with advanced non-alcoholic fatty liver disease</td>
<td>Kate HALLSWORTH</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-103</td>
<td>IDL-2965: a selective, highly potent, clinical-stage integrin antagonist for treatment of non-alcoholic steatohepatitis</td>
<td>Karl KOSSEN</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-104</td>
<td>The effectiveness of Mediterranean diet versus calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review with clinical implications</td>
<td>Laura HAIGH</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-105</td>
<td>Therapeutic efficacy of the chitotriosidase inhibitors in STAM model of non-alcoholic steatohepatitis</td>
<td>Michal MLACKI</td>
<td>Poland</td>
</tr>
<tr>
<td>FRI-106</td>
<td>Endoscopic gastric plication (endosleeve) improves hepatic steatosis and liver fibrosis in patients with grade 1-2 obesity, preliminary results at 6 months</td>
<td>Michel BLE CASO</td>
<td>Mexico</td>
</tr>
<tr>
<td>FRI-107</td>
<td>Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practice</td>
<td>Michelle LAI</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-108</td>
<td>BIO89-100, a novel glycopegylated FGF21 analog, reduces body weight and fat mass in naive CD-1 mice through an increase in energy expenditure despite an increase in food consumption</td>
<td>Moti ROSENSTOCK</td>
<td>Israel</td>
</tr>
<tr>
<td>FRI-109</td>
<td>EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis</td>
<td>Mozhdeh SOJOODI</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-110</td>
<td>Characterization of EYP001 a novel, potent and selective FXR agonist in vitro 3D human liver models of NASH</td>
<td>Pauline RADREAU – PIERINI</td>
<td>France</td>
</tr>
<tr>
<td>FRI-111</td>
<td>Synergistic effect of clostridium butyricum miyairi on rifaximin in mice model of non-alcoholic steatohepatitis by methionine choline-deficient diet</td>
<td>Ryo YAMAUCHI</td>
<td>Japan</td>
</tr>
<tr>
<td>FRI-112</td>
<td>Methylaltrexone and rifaximin treatments significantly improve chronic «leaky gut» in a diet-induced mouse model of non-alcoholic fatty liver disease</td>
<td>Rebecca CAFFREY</td>
<td>United States</td>
</tr>
</tbody>
</table>
### NAFLD: Therapy (Cont.)

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-113</td>
<td>Recombinant glutamine synthetase (AM-535): a novel therapeutic approach for the treatment of hyperammonaemia and its deleterious effects on multiple systems</td>
<td>Antria SIAKALLI, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-114</td>
<td>Co-administration of PF-05221304 and PF-06865571 delivers robust whole liver fat reduction and mitigation of acetyl-coa carboxilase inhibitor induced hypertriglyceridemia in patients with NAFLD</td>
<td>Roberto CALLE, United States</td>
<td></td>
</tr>
<tr>
<td>Top 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-115</td>
<td>A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects</td>
<td>Seungjae BAEK, Korea, Rep. of South</td>
<td></td>
</tr>
<tr>
<td>FRI-116</td>
<td>Change in hepatic output of palmitic acid after weight loss in type 2 diabetes</td>
<td>Shaden MELHEM, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Top 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-117</td>
<td>GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model</td>
<td>M. Scott HARRIS, United States</td>
<td></td>
</tr>
<tr>
<td>Top 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-118</td>
<td>Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study</td>
<td>Sven FRANCQUE, Belgium</td>
<td></td>
</tr>
<tr>
<td>FRI-119</td>
<td>Novel autophagy inducer, a4368 improves non-alcoholic steatohepatitis in mice</td>
<td>Seung-Woo YEON, Korea, Rep. of South</td>
<td></td>
</tr>
<tr>
<td>Top 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-120</td>
<td>Intrahepatic microcirculation disorders and increased blood ammonia at the chronic liver diseases with initial stage of liver fibrosis</td>
<td>Tatiana ERMOLLOVA, Russian Federation</td>
<td></td>
</tr>
<tr>
<td>FRI-121</td>
<td>Composite targeting of nuclear receptors protects against diet-induced NAFLD</td>
<td>Tawhidul ISLAM, Portugal</td>
<td></td>
</tr>
<tr>
<td>Top 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-122</td>
<td>Patient-reported benefits for future non-alcoholic steatohepatitis therapy: a global real-world study among 1,035 patients across 12 countries</td>
<td>Victoria HIGGINS, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Top 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-123</td>
<td>Effects of kaempferol on CFLAR-JNK pathway in mice with non-alcoholic steatohepatitis</td>
<td>Yue SHEN, China</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Abstract</td>
<td>Author(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>FRI-124</td>
<td><strong>Top 10%</strong> Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase</td>
<td>Alessio GERUSSI, Italy</td>
<td></td>
</tr>
<tr>
<td>FRI-125</td>
<td><strong>Top 10%</strong> Ursodeoxycholic acid and/or ciprofibrate for treating patients with presumptive diagnosis of low phospholipid cholelithiasis, a clinical spectrum of progressive familial intrahepatic cholestasis type 3</td>
<td>Ana CARDOSO, Brazil</td>
<td></td>
</tr>
<tr>
<td>FRI-126</td>
<td><strong>Top 10%</strong> Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients</td>
<td>Anna REIG, Spain</td>
<td></td>
</tr>
<tr>
<td>FRI-127</td>
<td><strong>Top 10%</strong> Histological features of non-alcoholic steatohepatitis are common in patients with autoimmune hepatitis who have advanced fibrosis at diagnosis</td>
<td>Ashleigh LIMA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-128</td>
<td><strong>Top 10%</strong> Histological primary biliary cholangitis changes in patients with positive serology and normal alkaline phosphatase</td>
<td>Benedetta TERZIROLI, Switzerland</td>
<td></td>
</tr>
<tr>
<td>FRI-129</td>
<td><strong>Top 10%</strong> Ursodeoxycholic acid response in primary biliary cholangitis is associated with a significant reduction in decompensation and mortality in compensated cirrhosis</td>
<td>Binu JOHN, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-130</td>
<td><strong>Top 10%</strong> Male gender is associated with a high rate of decompensation and mortality in primary biliary cholangitis with well compensated cirrhosis</td>
<td>Binu JOHN, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-131</td>
<td><strong>Top 10%</strong> Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease</td>
<td>Brandon FOSTER, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-132</td>
<td><strong>Top 10%</strong> Effectiveness of obeticholic acid (OCA) in southern European patients with primary biliary cholangitis (PBC) as a second line therapy. A multicenter, international, real-world cohort</td>
<td>Conrado Manuel FERNANDEZ RODRIGUEZ, Spain</td>
<td></td>
</tr>
<tr>
<td>FRI-133</td>
<td>Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study</td>
<td>Cynthia LEVY, United States</td>
<td></td>
</tr>
</tbody>
</table>
Autoimmune and chronic cholestatic liver disease: Clinical aspects

<table>
<thead>
<tr>
<th>FRI-134</th>
<th>Hepatocellular carcinoma in patients with autoimmune hepatitis: prevalence and risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 10%</td>
<td>Débora TERRABUIO, Brazil</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-135</th>
<th>Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) - TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase 2 study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yanhua DING, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-136</th>
<th>Temporal trends of autoimmune hepatitis related hospitalizations: a descriptive study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 10%</td>
<td>Ahmad KHAN, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-137</th>
<th>Ursodeoxycholic acid reduces cholestatic hepatitis and maternal bile acid levels in intrahepatic cholestasis of pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Madhumita PREMKUMAR, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-138</th>
<th>Poor diagnostic accuracy of blood IgG4/IgG RNA ratio for discriminating IgG4-related disease from pancreatic or biliary cancer (DIPAC): a prospective cohort study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 10%</td>
<td>Elsemieke DE VRIES, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-139</th>
<th>Glucuronidation directs systemically available norursodeoxycholic acid (norUDCA) to the kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Emina HALILBASIC, Austria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-140</th>
<th>Predictive factors of response to corticosteroid therapy in acute severe autoimmune hepatitis: a national multicentric study</th>
</tr>
</thead>
<tbody>
<tr>
<td>YI</td>
<td>Eugenia SÁNCHEZ RODRÍGUEZ, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-141</th>
<th>Antibodies against glycoprotein 2 and anti-neutrophil cytoplasmic antibodies targeting the serine proteinase 3 are markers of severe primary sclerosing cholangitis (PSC) and progression to cholangiocarcinoma (CCA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 10%</td>
<td>Ewa WUNSCH, Poland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-142</th>
<th>Analysis of 1,776 patients with primary sclerosing cholangitis from a laboratory database</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Friedrich MITTERMAYER, Austria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-143</th>
<th>The treatment response and corticosteroid therapy was predicted by GGT, chol, and fibrosis in patients of PBC-AIH overlap syndrome: a real-world study</th>
</tr>
</thead>
<tbody>
<tr>
<td>YI</td>
<td>Xiaoli FAN, China</td>
</tr>
</tbody>
</table>
FRI-144  Risks and benefits of percutaneous transhepatic cholangiodrainage in patients with primary sclerosing cholangitis
   Gustav BUESCHER, Germany

FRI-145  Antimitochondrial antibodies in patients with autoimmune hepatitis: a large multicenter study
   Nikolaos GATSELIS, Greece

FRI-146  Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with primary biliary cholangitis who did not achieve the poise criteria
   Gideon HIRSCHFIELD, Canada

FRI-147  Enhanced liver fibrosis test and liver stiffness variation over time in a prospective cohort of primary sclerosing cholangitis patients
   Guri FOSSDAL, Norway

FRI-148  An international perspective on cholestatic pruritus in primary biliary cholangitis (PBC)
   Helen SMITH, United Kingdom

FRI-149  Magnetic resonance imaging features of primary biliary cholangitis
   Ilkay S. IDILMAN, Turkey

FRI-150  Comparison of liver stiffness measurement with MRE and liver and spleen volumetry for prediction of disease severity and hepatic decompensation in patients with primary sclerosing cholangitis
   Ilkay S. IDILMAN, Turkey

FRI-151  The inter-relationship between primary sclerosing cholangitis and socioeconomic status
   Jessica DYSON, United Kingdom

FRI-152  Change in risk of primary biliary cholangitis is associated with the evolution of coal mining
   Jessica DYSON, United Kingdom

FRI-153  The simple cholestatic complaints score is a valid and reliable questionnaire for cholestatic symptoms in PSC patients
   Kim N. VAN MUNSTER, Netherlands

FRI-154  The clinical significance of programmed cell death-1 rs11568821 and interleukin-28b rs12979860 polymorphisms in autoimmune hepatitis
   Kalliopi AZARIADI, Greece

FRI-155  Histological characteristics of primary biliary cholangitis with an incomplete response to ursodeoxycholic acid
   Kenichi HARADA, Japan
### Autoimmune and chronic cholestatic liver disease: Clinical aspects (Cont.)

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-156</td>
<td>Maternal and foetal outcomes, biochemistry and immunology changes during pregnancy in patients with autoimmune hepatitis</td>
<td>Kathryn OLSEN</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-157</td>
<td>Impaired sulfation capacity may deteriorate clinical course in patients with primary sclerosing cholangitis (PSC)</td>
<td>Karolina Maria WRONKA</td>
<td>Poland</td>
</tr>
<tr>
<td>FRI-158</td>
<td>Accuracy of liver stiffness measurement in assessing liver fibrosis in naive patients with primary biliary cholangitis</td>
<td>Laura CRISTOFERI</td>
<td>Italy</td>
</tr>
<tr>
<td>FRI-159</td>
<td>Ciprofibrate: a new option of fibrate for primary biliary cholangitis with incomplete response to ursodeoxycholic acid</td>
<td>Laura GUEDES</td>
<td>Brazil</td>
</tr>
<tr>
<td>FRI-160</td>
<td>Utility of thiopurine metabolite testing in autoimmune hepatitis: defining an optimal therapeutic range for disease management and measurement may avert relapse and adverse drug reactions</td>
<td>Lena Susanna CANDELS</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-161</td>
<td>Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis</td>
<td>Lei LING</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-162</td>
<td>Higher prevalence of hepatitis E virus in autoimmune hepatitis: the role of false positive antibodies</td>
<td>Laura Patricia LLOVET</td>
<td>Spain</td>
</tr>
<tr>
<td>FRI-163</td>
<td>Development and validation of a novel risk score predicting long-term survival in autoimmune hepatitis</td>
<td>Maaike BIEWENGA</td>
<td>Netherlands</td>
</tr>
<tr>
<td>FRI-164</td>
<td>Safety and efficacy of temporary placement of fully covered metallic stent for dominant stricture among primary sclerosing cholangitis patients</td>
<td>Mahmud MAHAMID</td>
<td>Israel</td>
</tr>
<tr>
<td>FRI-165</td>
<td>Understanding of central and peripheral fatigue in primary biliary cholangitis</td>
<td>Naw April PHAW</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-166</td>
<td>Genetic variant c.711 in the hepatobiliary phospholipid transporter ABCB4 is associated with clinically relevant liver stiffness in chronic liver diseases</td>
<td>Marcin KRAWCZYK</td>
<td>Poland</td>
</tr>
</tbody>
</table>
Response to treatment in autoimmune hepatitis determines the health-related quality of life
Maurice MICHEL, Germany

Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis
Michael TRAUNER, Austria

Removal of fibrosis-related genes identifies a hepatic gene expression signature that identifies canonical signaling pathways and is correlated with clinical outcomes in patients with primary sclerosing cholangitis
Michael TRAUNER, Austria

Hepatic transcriptomic analysis identifies a mast cell gene expression signature that correlates with fibrosis stage and is prognostic in patients with primary sclerosing cholangitis
Michael TRAUNER, Austria

Simultaneous liver and spleen stiffness measurements as complementary methods for fibrosis quantification in autoimmune hepatitis
Maciej K. JANIK, Poland

Pregnancy outcomes for women with primary sclerosis cholangitis and primary binary cholangitis
Matthew CAULDWELL, United Kingdom

Machine learning models accurately interpret liver histology and are associated with disease progression in patients with primary sclerosing cholangitis
Nate TRAVIS, United States

CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2-/- mouse model.
Neta BARASHI, Israel

Belimumab: a promising third line treatment option for refractory autoimmune hepatitis
Pinelopi ARVANITI, Greece

European Association for the Study of the Liver primary biliary cholangitis guideline clinical care standards: the patient experience as recorded by PBC Foundation app and International Patient Registry
Robert MITCHELL THAIN, United Kingdom

A multi-disciplinary approach to IgG4 related disease aids in diagnosis and management
Rory PETERS, United Kingdom
Autoimmune and chronic cholestatic liver disease: Clinical aspects (Cont.)

FRI-178 Long-term prevalence of gastro-oesophageal varices in early primary biliary cholangitis patients with good response to treatment
Toru SETSU, Japan

FRI-179 Symptom burden in patients living with primary biliary cholangitis: indigenous Canadians report significantly higher PBC-40 quality of life scores
Surain ROBERTS, Canada

FRI-180 Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study
Leroy VINCENT, France

FRI-181 Lost in the system: identification of patients with undiagnosed primary biliary cholangitis
Jorge YEBRA CARMONA, Spain
Cirrhosis: ACLF and Critical illness

FRI-182  Low growth hormone levels predict poor outcome of hepatitis B virus-related acute-on-chronic liver failure
YI Lingjian ZHANG, China

FRI-183  Mesenchymal stem cells regulated DX5 – liver natural killer cells in rescuing acute-on-chronic liver failure murine
YI Jing XIONG, China

FRI-184  Selecting patients with decompensated cirrhosis and acute-on-chronic liver failure (ACLF) admitted to the intensive care unit for liver transplantation
YI Sophie-Caroline SACLEUX, France

FRI-185  Improving the survival rate of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis
YI Jinjun CHEN, China

FRI-186  Soluble immune checkpoints are involved in the immunopathogenesis of ACLF
Top 10% YI Douglas CORRIGALL, United Kingdom

FRI-187  Prevalence, profile and predictors of invasive fungal infections in acute-on-chronic liver failure; analysis of Asia Pacific Association for Study of the Liver, Acute-on-Chronic Liver Failure Research Consortium (AARC) data base
YI Pratibha RAMCHANDRA KALE, India

FRI-188  Differential hepatic mRNA and miRNA expression patterns in a novel mouse model of bacterial infection related to acute-on-chronic liver injury
YI Ersin KARATAYLI, Germany

FRI-189  The prevalence of multi-resistant bacterial infections in patients with decompensated cirrhosis admitted to the intensive care unit
YI Fischer PETRA, Romania

FRI-190  Acute-on-chronic liver failure as defined by the European (EASL-CLIF) versus North American (NACSELD) diagnostic criteria in their prediction of short-term prognosis in patients with decompensated cirrhosis admitted into hospital
YI Florence WONG, Canada

FRI-191  Novel experimental animal models for acute decompensation and acute-on-chronic liver failure
YI Frank USCHNER, Germany

FRI-192  Artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure patients
YI Tao HAN, China
# Cirrhosis: ACLF and Critical illness (Cont.)

| FRI-193 | Global hemostatic status in patients with acute-on-chronic liver failure and patients with sepsis without underlying liver disease  
Ton LISMAN, Netherlands |
| FRI-194 | Muscle quality as assessed by computed tomography-derived skeletal muscle density is associated with 28-day mortality in mechanically ventilated critically ill patients with cirrhosis  
Jaya BENJAMIN, India |
| FRI-195 | Refining the renal failure criteria of the EASL-CLIF diagnostic model for defining acute- on- chronic liver failure (ACLF)  
Joana CALVÃO, Portugal |
| FRI-196 | Regulation of IL-22 in a rat model for acute-on-chronic liver failure (ACLF)  
Katharina Maria SCHWARZKOPF, Germany |
| FRI-197 | Thymosin alpha 1 for patients with hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial  
Bingliang LIN, China |
| FRI-198 | Derivation and validation of prognostic nomogram for HBV-related acute-on-chronic liver failure  
Bingliang LIN, China |
| FRI-199 | Efficacy evaluation of artificial liver support system (ALSS) in treatment of HBV-ACLF patients based on metabolomics  
Jie WANG, China |
| FRI-200 | Mesenchymal stem cells regulate hepatocytes excessive autophagy and apoptosis through miR-125b/TRAF6 pathway in acute- on- chronic liver failure  
Dengna LIN, China |
| FRI-201 | Predictors and outcome of emergent liver transplantation for patients with acute-on-chronic liver failure  
Ji Eun KIM, Korea, Rep. of South |
| FRI-202 | Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives  
Nagel MICHAEL, Germany |
| FRI-203 | Reversal of immune paralysis to immune homeostasis: effect of plasma exchange on monocyte merTK and HLA-DR expression in patients with acute-on-chronic liver failure  
Siddharth MITTAL, India |
FRI-204  Different transcriptome characteristics of peripheral blood mononuclear cells are associated with survival outcome in hepatitis B-related acute-on-chronic liver failure
Shanshan MA, China

FRI-205  Granulocyte colony-stimulating factor in acute-on-chronic liver failure: systematic review and meta-analysis
Rosa MARTIN-MATEOS, Spain

FRI-206  Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells
Sabrina RUESCHENBAUM, Germany

FRI-207  Functional activin-HNF4A-coagulation axis in liver progenitor cells determines MELD score and outcome of acute-on-chronic liver failure
Tao LIN, Germany

FRI-208  Serum cholinesterase, an underestimated marker in the prediction of acute-on-chronic liver failure, organ failure and LTx-free survival in patients with liver cirrhosis?
Tammo Lambert TERGAST, Germany

FRI-209  Low eosinophil count: a predictor of in-hospital mortality in cirrhotic patients with sepsis
Tharun OOMMEN, India

FRI-210  Single-centre experience of implementing a hepatology outreach service to improve patient care for emergency admissions of acutely decompensated cirrhosis
Tomi ASHAYE, United Kingdom

FRI-211  Using bilirubin to define hepatotropic insult in patients with chronic liver disease and acute exacerbation: a prospective multicenter cohort study
Liang QIAO, China

FRI-212  Clinical features and natural history of acute-on-chronic liver failure precipitated by any indeterminate factor: single-center observational study
Hitomi HOSHI, Japan

FRI-213  Granulocytic myeloid-derived suppressor cells contribute to HBV-related acute-on-chronic liver failure infection and mortality by inducing T cell exhaustion
Xueping YU, China
<table>
<thead>
<tr>
<th>Poster</th>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-214</td>
<td>FRI-214</td>
<td>Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis</td>
<td>Naim ALKHOURI, United States</td>
</tr>
<tr>
<td>FRI-215</td>
<td>FRI-215</td>
<td>Diagnostic accuracy of a pocket-size ultrasound device in identifying liver surface nodularity for fibrosis staging in chronic liver disease</td>
<td>Andrea COSTANTINO, Italy</td>
</tr>
<tr>
<td>FRI-216</td>
<td>FRI-216</td>
<td>Combination of an acetyl CoA carboxylase inhibitor with therapeutics that promote fatty acid oxidation moderately improves efficacy in a preclinical NASH model</td>
<td>Archana VIJAYAKUMAR, United States</td>
</tr>
<tr>
<td>FRI-217</td>
<td>FRI-217</td>
<td>PBI-4050 promotes hepatic stellate cell deactivation by shifting energy metabolism</td>
<td>Brigitte GROUIX, Canada</td>
</tr>
<tr>
<td>FRI-218</td>
<td>FRI-218</td>
<td>Diagnostic accuracy of WFA+ – M2BP for significant hepatic fibrosis determined by MR elastography</td>
<td>Mi Mi KIM, Korea, Rep. of South</td>
</tr>
<tr>
<td>FRI-219</td>
<td>FRI-219</td>
<td>ZLN005, PGC-1? activator, induces oxidative phosphorylation and lipogenesis in myofibroblasts to reverse liver fibrosis</td>
<td>Jianye CAI, China</td>
</tr>
<tr>
<td>FRI-220</td>
<td>FRI-220</td>
<td>Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population</td>
<td>Kyung A KANG, Korea, Rep. of South</td>
</tr>
<tr>
<td>FRI-221</td>
<td>FRI-221</td>
<td>GLI1, but not smoothened-dependent, signaling in hepatic progenitor cells promotes a ductular reaction, which aggravates liver fibrosis</td>
<td>Jiamei CHEN, China</td>
</tr>
<tr>
<td>FRI-222</td>
<td>FRI-222</td>
<td>Enigma proteins control YAP1 related mechano-transduction in hepatic stellate cells</td>
<td>Dina ABDELMOTTALEB, United Kingdom</td>
</tr>
<tr>
<td>FRI-223</td>
<td>FRI-223</td>
<td>Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells</td>
<td>Zhen DAI, Germany</td>
</tr>
<tr>
<td>FRI-224</td>
<td>FRI-224</td>
<td>The IL-17a and IL-22 cytokines like triggers of human liver fibrosis</td>
<td>Daria KARTASHEVA-EBERTZ, France</td>
</tr>
<tr>
<td>FRI-225</td>
<td>FRI-225</td>
<td>Fib-4 score for assessment of liver fibrosis is useful in general practice</td>
<td>Denis OUZAN, France</td>
</tr>
<tr>
<td>FRI-226</td>
<td>Analysis of PNPLA3 SNP variants in human hepatic stellate cells in 3D human liver extracellular matrix scaffolds reveals key PNPLA3-dependent pro-fibrogenic features</td>
<td>Elisabetta CAON, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>FRI-227</td>
<td>An HSV-TK / valganciclovir mouse model enables the study of fibrocytes in liver fibrosis</td>
<td>Felix HEMPEL, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-228</td>
<td>Factors predicting liver histological changes under long-term follow-up chronic hepatitis C patients treated with pegylated-interferon-alpha plus ribavirin</td>
<td>Jung-Ta KAO, Taiwan</td>
<td></td>
</tr>
<tr>
<td>FRI-230</td>
<td>TGF-beta3 plays a prominent role in murine parenchymal liver fibrosis</td>
<td>Hiroyuki ABE, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-231</td>
<td>MUDENG (mu-2 related death-inducing gene) overexpression accelerates liver fibrosis in carbon tetrachloride-induced cirrhosis</td>
<td>Ju-Yeon CHO, Korea, Rep. of South</td>
<td></td>
</tr>
<tr>
<td>FRI-232</td>
<td>Thrombofibrosis: inherited thrombophilia as a cause of significant liver fibrosis</td>
<td>Iranzu EZCURRA, Spain</td>
<td></td>
</tr>
<tr>
<td>FRI-233</td>
<td>C-Rel acts as a metabolic switch controlling macrophage and hepatocyte phenotype in response to liver injury and is required for fibrosis</td>
<td>Jack LESLIE, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-234</td>
<td>An improved method for liver fibrosis assessment using magnetic resonance elastography</td>
<td>JunSheng, Jaryl CHENG, Singapore</td>
<td></td>
</tr>
<tr>
<td>FRI-235</td>
<td>Expression of cyclin E1 and CDK2 in hepatic stellate cells is critical for initiation and progression of liver fibrosis in mice</td>
<td>Julia HENNINGS, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-236</td>
<td>Non-canonical autophagy in myeloid cells constrains hepatic and systemic inflammation and limits fibrosis</td>
<td>JingHong WAN, France</td>
<td></td>
</tr>
<tr>
<td>FRI-237</td>
<td>Reduction in types I and III collagen gene expression by an alphavbeta1 integrin inhibitor correlates with a decrease in PRO-C1 and PRO-C3 levels in precision-cut liver tissue slices from cirrhotic non-alcoholic steatohepatitis patients</td>
<td>Johanna SCHAUB, United States</td>
<td></td>
</tr>
<tr>
<td>Poster</td>
<td>Title</td>
<td>Authors</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>FRI-238</td>
<td>Active role of sphingosine-1-phosphate in promoting peripheral-dominant liver fibrosis in mice model of congestive hepatopathy</td>
<td>Hironari KAWAI, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>FRI-239</td>
<td>CRV431 decreases diet- and chemical-driven fibrosis in livers of mice</td>
<td>Joseph KUO, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-240</td>
<td>Fibrosis progression in NASH: real- world data from the US population</td>
<td>Leonardo RUIZ CASAS, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-241</td>
<td>Nanoparticular bisphosphonate induces an anti-fibrotic response by modulation of fibrosis associated genes and pathways in (non-) parenchymal liver cells in CCL4 fibrotic mice</td>
<td>Leonard KAPS, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-242</td>
<td>Microscopy-based fibrosis phenotypic analysis of animal and human NASH cohorts reveal translational traits of fibrosis progression and severity</td>
<td>Li CHEN, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-243</td>
<td>Fibrosis phenotypic analysis of collagen stained liver histology sections discern anti-fibrotic agents in DDC- induced cholangitis mouse model</td>
<td>Li CHEN, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-244</td>
<td>Dietary wheat amylase trypsin inhibitors activate myeloid cell toll-like receptor 4 to enhance chronic liver disease in murine liver fibrosis and hepatocellular carcinoma</td>
<td>Muhammad ASHFAQ-KHAN, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-245</td>
<td>Epigenetic mechanism and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNA methyltransferase 1 for the inhibition of liver fibrosis</td>
<td>Maite G FERNANDEZ-BARRENA, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>FRI-246</td>
<td>FIB-4 and APRI scores re-validation; a cohort study of 69106 chronic hepatitis C patients</td>
<td>Mahasen MABROUK, Egypt</td>
<td>Egypt</td>
</tr>
<tr>
<td>FRI-247</td>
<td>Integrin alphaVbeta1 inhibition ameliorates liver fibrosis in mice</td>
<td>Min LU, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-248</td>
<td>AlphaVbeta6 inhibitor stabilizing the bent closed integrin conformation is effective in primary sclerosis cholangitis mouse model</td>
<td>Min LU, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-249</td>
<td>Endotrophin, a hormone derived from type VI collagen, activates fibroblasts and drives fibrosis in the liver, lung, kidney, and heart</td>
<td>Morten KARSDAL, Denmark</td>
<td>Denmark</td>
</tr>
</tbody>
</table>
FRI-250  YI  Hepatocytic C-jun NH2 terminal kinase activity confers protection against cholestatic liver injury in mice
Mohamed Ramadan MOHAMED, Germany

FRI-251  YI  Prevalence of heterogeneous fibrosis in liver biopsies with congestive hepatopathy: an institutional experience
Michelle LIN, United States

FRI-252  YI  Novel Rho associated coiled kinase inhibitor improves hepatic fibrosis in mice model of non-alcoholic steatohepatitis (NASH)
Quaisar ALI, United States

FRI-253  YI  Non-invasive test cut-offs for the identification of advanced liver fibrosis in a diabetes cohort with non-alcoholic steatohepatitis: data from the phase 3 AURORA study
Quentin ANSTEE, United Kingdom

FRI-254  YI  What did we learn from a large cohort of more than 24,000 patients evaluated by transient elastography in a single-center?
Roxana SIRLI, Romania

FRI-255  YI  The impact of LOXL2 inhibition on fibrosis progression in-vitro and in-vivo
Sarah A TOWNSEND, United Kingdom

FRI-256  YI  Hydrophobic bile acids promote proliferation and activation of hepatic stellate cells by PI3K-dependent mechanisms
Sebastian ZIMNY, Germany

FRI-257  YI  Modulation of liver fibrogenesis by interleukin-37
Steffeni MOUNTFORD, Germany

FRI-258  YI  Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients
Stephen HARRISON, United States

FRI-259  YI  Small extracellular vesicles from mesenchymal stem cells pre-conditioned with interferon-? can improve liver fibrosis by inducing anti-inflammatory macrophages with high migratory and phagocytotic abilities
Suguru TAKAUCHI, Japan

FRI-260  YI  Aspirin induces autophagy and alleviates liver fibrosis by reducing oxidative stress and inflammation in mice model of chronic liver injury
Adil BHAT, India

FRI-261  YI  Carabin deficiency promotes liver fibrosis via regulating RAS and calcineurin pathway in macrophage
Rong XUE, China
Fibrosis (Cont.)

FRI-262  (pro)renin receptor knockdown attenuates liver fibrosis through inactivation of ERK/TGF-β1/Smad3 pathway  
Yun-Cheng HSIEH, Taiwan

FRI-263  Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients  
Zeynep MELEKOGLU ELLIK, Turkey

FRI-264  Improvements in the ELF test are associated with widespread changes in the hepatic transcriptome in patients with advanced fibrosis due to non-alcoholic steatohepatitis  
Zobair M. YOUNOSSI, United States
### Imaging & drug targeting

| FRI-265 | Contrast-enhanced ultrasound algorithms for the non-invasive diagnosis of hepatocellular carcinoma in high-risk patients – a prospective multicentre study (DEGUM-CEUS HCC trial)  
Top 10%  
YI  
Barbara SCHELLHAAS, Germany |
|---|---|
| FRI-266 | Simultaneous multislice accelerated breath-holding diffusion weighted imaging of the liver using double air coils: comparison to standard diffusion weighted imaging  
Yedaun LEE, Korea, Rep. of South |
| FRI-267 | Evidence-based dilemma in the image-guided therapeutic management of uncomplicated amoebic liver abscess: a systematic review and meta-analysis  
Ramesh KUMAR, India |
| FRI-268 | Complementary role of computed tomography texture analysis for differentiation of hepatocellular carcinoma from intrahepatic peripheral cholangiocarcinoma on single portal-venous phase computed tomography  
Kaspar EKERT, Germany |
| FRI-269 | Ph-responsive polymersomes for matrix metalloproteinase-1 delivery as a promising therapeutic strategy for the treatment of liver fibrosis  
Eline GEERVLIET, Netherlands |
| FRI-270 | Diagnostic value of magnetic resonance elastography in cirrhotic portal hypertension  
Guanhua ZHANG, China |
| FRI-271 | Prognostic value of spleen volume obtained from preoperative computed tomography images in patients with hepatocellular carcinoma  
Jae Seok BAE, Korea, Rep. of South |
| FRI-272 | Predicting prognosis of hepatocellular carcinomas according to treatments by using hepatobiliary phase images of gadoxetic acid-enhanced magnetic resonance imaging  
Jae Seok BAE, Korea, Rep. of South |
| FRI-273 | Kahweol activates Nrf2/HO-1 by a pathway different from p62 and autophagy dependent degradation  
Byoung Kuk JANG, Korea, Rep. of South |
| FRI-274 | Role of Kupffer phase image using sonazoid on CEUS LI-RADS® and diagnostic performance for hepatocellular carcinoma  
Top 10%  
Jeong Ah HWANG, Korea, Rep. of South |
| FRI-275 | Impact of contrast-enhanced ultrasound on detection of colorectal liver metastases and therapeutic strategy in patients with newly diagnosed colorectal carcinoma after staging with computertomography. A prospective cohort study  
Top 10%  
Mikael SAWATZKI, Switzerland |
Rare liver diseases (including pediatric and genetic)

**FRI-276**  
The phenotype of compound heterozygous BSEP deficiency patients is determined by the combined residual function of the two ABCB11 mutations: results from the NAPPED consortium  
Antonia FELZEN, Netherlands

**FRI-277**  
Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease  
Top 10%  
Alvaro SANTOS-LASO, Spain

**FRI-278**  
Persistently low platelet count and splenomegaly after treatment with oxaliplatin as markers of development of portal sinusoidal vascular disease  
Angela PUENTE SANCHEZ, Spain

**FRI-279**  
Cross-talk between regulation of iron homeostasis and gluconeogenesis in a murine model of hereditary hemochromatosis  
Elena BUZZETTI, Italy

**FRI-280**  
Custom-designed next generation sequencing panel for genotype identification in cholestasis  
Carola DRÖGE, Germany

**FRI-281**  
ABCB4/MDR3 gene mutations in young patients with symptomatic cholelithiasis  
Catarina GOUVEIA, Portugal

**FRI-282**  
Efficacy of zinc on human hepatic copper uptake depending on zinc type and dose regimen quantified with 64-CuCl2 PET/CTscan  
Ditte Emilie MUNK, Denmark

**FRI-283**  
High burden of future liver disease in intrahepatic cholestasis of pregnancy patients  
Erica MONROSE, United States

**FRI-284**  
Impact of nitisinone treatment and discontinuation on the metabolome of wild type and hereditary tyrosinemia type 1 mice  
Haaike COLEMONTS-VRONINKS, Belgium

**FRI-285**  
Prognosis in persons with an HFE-mutation: population-based cohort study of 3,645 individuals  
Top 10%  
Hannes HAGSTRÖM, Sweden

**FRI-286**  
Cracking the notch code in alagille syndrome: single-cell receptor-ligand interactions and outcomes in vivo, and an emerging role of immune cells  
Jan MAŠEK, Sweden

**FRI-287**  
Real-world disease burden, treatment patterns, and outcomes of hospitalized patients with hepatic encephalopathy  
Top 10%  
Jan STANGE, United States
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-288</td>
<td>Liver ultrasonic transient elastometry (fibroscan (r)) in hepatic amyloidosis: results of a multicenter cohort of 26 cases</td>
<td>Jean-françois CADRANEL</td>
<td>France</td>
</tr>
<tr>
<td>FRI-289</td>
<td>Directed protein evolution as a tool to innovate gene therapy for hereditary tyrosinemia type 1</td>
<td>Jessie NEUCKERMANS</td>
<td>Belgium</td>
</tr>
<tr>
<td>FRI-290</td>
<td>Hospitalization rates of Budd Chiari syndrome in the United States</td>
<td>Joseph ALUKAL</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-291</td>
<td>Health care burden and in-hospital mortality of BCS in the United States between 1998 and 2016</td>
<td>Joseph ALUKAL</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-292</td>
<td>Genome-wide protective variants in MARC1 and HSD17B13 are associated with reduced inflammation and lower fibrosis stage on biopsy in children with NAFLD</td>
<td>Jake MANN</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-293</td>
<td>Non-invasive screening for liver fibrosis by acoustic radiation force impulse in patients with ciliopathies</td>
<td>Johanna BRESCH</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-294</td>
<td>Cholestatic phenotype of a mouse model for organic solute transporter ? (OST?/SLC51B) deficiency suggest a role of the beta subunit beyond an OST? chaperone</td>
<td>Stan VAN DE GRAAF</td>
<td>Netherlands</td>
</tr>
<tr>
<td>FRI-295</td>
<td>Comparative pharmacokinetic profile of two distinct trientine salt formulations used for treatment of Wilson’s disease</td>
<td>Karl Heinz WEISS</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-296</td>
<td>Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency</td>
<td>Kenneth SETCHELL</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-297</td>
<td>Clinical, histological, and biochemical liver phenotype of European adults with heterozygous alpha-1 antitrypsin deficiency (Pi*MZ genotype)</td>
<td>Karim HAMESCH</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-298</td>
<td>Customized xenograft model development: liver repopulation of FRG® KO mice with primary hepatocytes from donors carrying specific genetic variants</td>
<td>Lander FOQUET</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-299</td>
<td>Alpha-1-antitrypsin deficiency liver disease: patients lost in the system</td>
<td>Maria Angeles RUIZ-RAMIREZ</td>
<td>Spain</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
<td>Country</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>-----------------</td>
</tr>
<tr>
<td>FRI-300</td>
<td>Neurodegenerative patterns in Wilson's disease with hepatic or neurological manifestation assessed by morphometric magnetic resonance imaging</td>
<td>Marlene PANZER, Austria</td>
<td></td>
</tr>
<tr>
<td>FRI-301</td>
<td>Liver transplantation for acute intermittent porphyria in Europe</td>
<td>Mattias LISSING, Sweden</td>
<td></td>
</tr>
<tr>
<td>FRI-302</td>
<td>Magnetic resonance iron quantification facilitates venesection decision making in iron overload</td>
<td>Meha BHUVA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-303</td>
<td>Major depressive disorder in patients with Wilson’s disease: relationship with liver disease, neurological disease and quality of life</td>
<td>Michelle CAMARATA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-304</td>
<td>Mortality in patients with Wilson's disease in England: a national register-based study</td>
<td>Michelle CAMARATA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-305</td>
<td>Survival in HFE hemochromatosis: influence of polymorphisms in HSD17B13, GNPAT, and PCSK7</td>
<td>Moritz TOBIASCH, Austria</td>
<td></td>
</tr>
<tr>
<td>FRI-306</td>
<td>Analysis of survival and influence of genetic modifiers in HFE- and non-HFE-associated iron overload</td>
<td>Moritz TOBIASCH, Austria</td>
<td></td>
</tr>
<tr>
<td>FRI-307</td>
<td>Validation of the new proposed histological criteria for the diagnosis of porto-sinusoidal vascular disease in a single tertiary center</td>
<td>Oana NICOARA-FARCAU, Romania</td>
<td></td>
</tr>
<tr>
<td>FRI-308</td>
<td>Non-invasive diagnostic tools in porto sinusoidal vascular liver disease. A pilot study</td>
<td>Oana NICOARA-FARCAU, Romania</td>
<td></td>
</tr>
<tr>
<td>FRI-309</td>
<td>Simplification of Wilson’s disease maintenance therapy with a single daily dose: safety and efficacy in difficult to treat patients</td>
<td>Olivier GUILLAUD, France</td>
<td></td>
</tr>
<tr>
<td>FRI-310</td>
<td>A phase 1/2 open label extension study of givosiran, an investigational RNAi therapeutic, in patients with acute intermittent porphyria</td>
<td>Penelope STEIN, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-311</td>
<td>Good clinical outcomes after direct intrahepatic portocaval stent (DIPS) insertion for Budd-Chiari syndrome</td>
<td>Rosemary FAULKES, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
FRI-312  Clinical features and natural history of 1154 Alagille syndrome patients: results from the international multicenter GALA study group
Shannon M. VANDRIEL, Canada

FRI-313  Proteolytic immuno-srm-ms/ms analysis of ATP7b in dried blood spots: a potential application for the screening and diagnosis of Wilson’s disease
Shihoun HAHN, United States

FRI-314  Wilson’s disease: epidemiologic and therapeutic insights from German hospital and ambulatory invoicing data
Steffen WAHLER, Germany

FRI-315  The role of liver stiffness by ARFI elastography in the diagnosis of porto-sinusoidal vascular disease: comparison with patients with chronic portal vein thrombosis
Stefania GIOIA, Italy

FRI-316  Elevated serum bile acid and alanine aminotransferase concentrations in intrahepatic cholestasis of pregnancy are associated with increased fetal NT-proBNP which is ameliorated by ursodeoxycholic acid treatment
Tharni VASAVAN, United Kingdom

FRI-317  Penetrance, cancer incidence and survival of hemochromatosis in a long-term follow-up and epidemiological modelling study
Thomas KALLAB, Austria

FRI-318  Prevalence and characteristics of cystic fibrosis associated-liver disease in a cohort of cystic fibrosis patients
Zaina ISSA, Belgium

FRI-319  Liver cirrhosis development and value of transient elastography among a large cohort of Wilson’s disease patients with a long-term follow-up in Spain
Zoe MARIÑO, Spain
## Nurses and Allied Health Professionals research hepatology

<table>
<thead>
<tr>
<th>FRI-320</th>
<th>Employment after liver transplantation and contributing factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>YI</td>
<td>Anna VAN DEN BURG, Netherlands</td>
</tr>
<tr>
<td>FRI-321</td>
<td>Development of a district general hospital liver nurse service for patients with acute and chronic liver conditions</td>
</tr>
<tr>
<td>Top 10%</td>
<td>Amy THATCHER, United Kingdom</td>
</tr>
<tr>
<td>FRI-322</td>
<td>Managing decompensated cirrhosis – the importance of multidisciplinary engagement</td>
</tr>
<tr>
<td>YI</td>
<td>Dev KATAREY, United Kingdom</td>
</tr>
<tr>
<td>FRI-323</td>
<td>The first step towards comprehensive nurse-led hepatology care: evolution of the Hull specialist liver nurse service (SLNS)</td>
</tr>
<tr>
<td>Top 10%</td>
<td>Dianne BACKHOUSE, United Kingdom</td>
</tr>
<tr>
<td>FRI-324</td>
<td>Prospective study of therapeutic education (TE) designed with a multidisciplinary team and participation of patients to improve the adherence to treatment of the patients and their quality of life (QOL)</td>
</tr>
<tr>
<td>YI</td>
<td>Dominique LARREY, France</td>
</tr>
<tr>
<td>FRI-325</td>
<td>Hepatitis B testing in Bcr-Abl tyrosine kinase inhibitor therapy</td>
</tr>
<tr>
<td>YI</td>
<td>Fatema JESSA, United Kingdom</td>
</tr>
<tr>
<td>FRI-326</td>
<td>Impact of a nurse educational program for patient empowerment during sequential systemic therapy for hepatocellular carcinoma</td>
</tr>
<tr>
<td>YI</td>
<td>Gemma ISERTE, Spain</td>
</tr>
<tr>
<td>FRI-327</td>
<td>Treatment with sorafenib on hepatocellular carcinoma -10 years’ experience in a nursing-led outpatient clinic</td>
</tr>
<tr>
<td>YI</td>
<td>Gordana GRUJCIC, Sweden</td>
</tr>
<tr>
<td>FRI-328</td>
<td>Pilot of an advanced liver disease nurse education program and its intersection with emerging models of advanced hepatology nursing practice</td>
</tr>
<tr>
<td>FRI-329</td>
<td>Diet lifestyle management of non-alcoholic fatty liver disease (NAFLD): a cross-sectional survey of clinicians</td>
</tr>
<tr>
<td>YI</td>
<td>Laura HAIGH, United Kingdom</td>
</tr>
<tr>
<td>FRI-330</td>
<td>Development of clinical professional standards for liver transplant nursing</td>
</tr>
<tr>
<td>YI</td>
<td>Michelle CLAYTON, United Kingdom</td>
</tr>
<tr>
<td>FRI-331</td>
<td>Nurse assisted follow-up after admission with decompensation in cirrhosis: a systematic review and meta-analysis</td>
</tr>
<tr>
<td>YI</td>
<td>Malene BARFOD O’CONNELL, Denmark</td>
</tr>
</tbody>
</table>
FRI-332  Prospective evaluation of a non-alcoholic fatty liver disease assessment pathway; impact of clinical nurse specialist role
Marie MCGRATH, Ireland

FRI-333  Illustrations supporting patient counseling before and after liver transplantation
Patrizia KUENZLER-HEULE, Switzerland
# Immunology except viral hepatitis

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-334</td>
<td>Soluble CEACAM1 induces regulatory T cells in vitro</td>
<td>Andrea Horst, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-335</td>
<td>Activity of pyruvate kinase M2 regulates T cell polarization</td>
<td>Andrea Horst, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-336</td>
<td>Innate chemokine (C-C motif) ligand 3-expressing cells control early murine cytomegalovirus infection</td>
<td>Fernando Magdaleno, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-337</td>
<td>The alarmin IL-33 drives a ST2+ Treg-mediated anti-inflammatory immune response during immune-mediated hepatitis</td>
<td>Katrin Neumann, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-338</td>
<td>Plasmacytoid dendritic cells protect against acute liver injury via IL-35</td>
<td>Yuzo Koda, Japan</td>
<td></td>
</tr>
<tr>
<td>FRI-339</td>
<td>Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma</td>
<td>Luigi Buonaguro, Italy</td>
<td></td>
</tr>
<tr>
<td>FRI-340</td>
<td>High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients.</td>
<td>Maria Tagliamonte, Italy</td>
<td></td>
</tr>
<tr>
<td>FRI-341</td>
<td>Myeloid derived suppressor cells enhance regulatory T cell suppressive activity via IL-10, iNOS and PDL-2 in cirrhotic patients with sepsis</td>
<td>Rashi Sehgal, India</td>
<td></td>
</tr>
<tr>
<td>FRI-342</td>
<td>Neutrophils are recruited at the periportal area in alcoholic liver disease and promote ductular reaction expansion</td>
<td>Silvia Ariño Mons, Spain</td>
<td></td>
</tr>
<tr>
<td>FRI-343</td>
<td>Obeticholic acid suppresses expansion of hepatic immune cell populations in a diet-induced obese and biopsy-confirmed model of non-alcoholic steatohepatitis</td>
<td>Sanne Veidal, Denmark</td>
<td></td>
</tr>
<tr>
<td>FRI-344</td>
<td>Drug screening against complement disorders using human stem cell-derived endothelium and liver organoids</td>
<td>Yasunori Nio, Japan</td>
<td></td>
</tr>
<tr>
<td>FRI-345</td>
<td>Polarization of tissue-resident Tph cells by exosomal IL-10 in hepatocellular carcinoma bridges naive B cell inflammation and regulatory B cell polarization</td>
<td>Linsen Ye, China</td>
<td></td>
</tr>
<tr>
<td>FRI-346</td>
<td>Immune cells restricted C/EBPbeta deficiency is associated with distorted hepatic mononuclear phagocytes composition, weight loss and spontaneous hepatitis</td>
<td>Ehud Zigmund, Israel</td>
<td></td>
</tr>
</tbody>
</table>
### Viral Hepatitis A, B, C, D, E: Immunology

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-347</td>
<td><strong>YI</strong> Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis&lt;br&gt;Qirong JIANG, China</td>
</tr>
<tr>
<td>FRI-348</td>
<td><strong>YI</strong> Entecavir-induced interferon-lambda 1 suppresses innate lymphoid cells 2 in patients with hepatitis B virus-related liver cirrhosis&lt;br&gt;Siqi WANG, China</td>
</tr>
<tr>
<td>FRI-349</td>
<td><strong>Top 10%</strong> A new therapeutic candidate vaccine can overcome hepatitis B virus-induced immune tolerance in a mouse model of chronic infection&lt;br&gt;Babak BAYAT, Belgium</td>
</tr>
<tr>
<td>FRI-350</td>
<td>Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod&lt;br&gt;Diana CHEN, United States</td>
</tr>
<tr>
<td>FRI-351</td>
<td>Immunogenicity and efficacy of an HBV vaccine with an intrinsic checkpoint inhibitor&lt;br&gt;Hildegund ERTL, United States</td>
</tr>
<tr>
<td>FRI-352</td>
<td>Extracellular HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV pathogenesis&lt;br&gt;Valeria FUMAGALLI, Italy</td>
</tr>
<tr>
<td>FRI-353</td>
<td>Analysis of regulatory T cells frequency and phenotype in chronic hepatitis C patients undergoing interferon-free therapies&lt;br&gt;George KOUTSOUDAKIS, Spain</td>
</tr>
<tr>
<td>FRI-354</td>
<td>Characterization of the HBV-specific T cell pool reveals shared epitope usage but different phenotypes of HBV-reactive T cells across patients&lt;br&gt;Hassen KARED, Singapore</td>
</tr>
<tr>
<td>FRI-355</td>
<td><strong>YI</strong> Hepatitis B virus kinetics after nucleos(t)ide-analogue withdrawal in chronic HBeAg(-) hepatitis correlates with HBV-specific CD8+ response and HBsAg level&lt;br&gt;Julia PEÑA ASENSIO, Spain</td>
</tr>
<tr>
<td>FRI-356</td>
<td><strong>YI</strong> Interleukin-15 restores the reactivity of the peripheral memory-like pool in the exhausted hepatitis B virus-specific CD8+ T cell population during persistent HBeAg(-) infection&lt;br&gt;Julia PEÑA ASENSIO, Spain</td>
</tr>
<tr>
<td>FRI-357</td>
<td><strong>YI</strong> Hepatitis B virus-specific CXCR5+ CD8+ T cells may be related to hepatitis B virus clearance in chronic hepatitis B patients treated with pegylated interferon alpha&lt;br&gt;Li ZHANG, China</td>
</tr>
</tbody>
</table>
Viral Hepatitis A, B, C, D, E: Immunology (Cont.)

FRI-358  
Hepatitis B virus-specific CXCR5+ CD8+ T cells shows stronger functional activity in a mouse model of acute hepatitis B virus infection  
Li ZHANG, China

FRI-359  
Hepatitis D coinfection is associated with enhanced CXCR3 receptor expression of CD4 memory T cells and intrahepatic CXCR3 ligand expression compared to chronic hepatitis B patients.  
Jan-Hendrik BOCKMANN, Germany

FRI-360  
Magnitude and functionality of HEV-specific CD8+ and CD4+ T cell responses in asymptomatic blood donors resemble those in acute and symptomatic patients  
Janine KEMMING, Germany

FRI-361  
Peripheral soluble protein, transcriptomic, and methylation biomarkers associated with HBsAg loss in patients with chronic hepatitis B  
Jeffrey WALLIN, United States

FRI-362  
Tox expression on HBV-specific CD8+ T cells is linked to clinical stage of chronic HBV infection  
Kathrin HEIM, Germany

FRI-363  
Antigen modulation and re-activation of anti-viral immunity lead to control of chronic hepatitis B virus infection  
Katrin MANSKE, Germany

FRI-364  
Distinct serum HBsAg levels show minimal effect on gene expression profiles of blood leukocyte subpopulations in non-viremic chronic HBV patients.  
Noé Axel MONTANARI, Netherlands

FRI-365  
Hepatitis C virus chronicity is associated with a tox-1(high), Eomes(high), T-bet(dim) and PD1(high) phenotype of HCV-specific CD8+ T cells  
Nils WILDNER, Germany

FRI-366  
Targeting dysregulated intracellular signaling pathways can restore anti-viral HBV-specific T cell responses in chronic hepatitis B  
Paola FISICARO, Italy

FRI-367  
Profiles of expression of costimulatory molecules OX40 and OX40l in PBMCs and levels of soluble OX40/OX40l in plasma in chronic hepatitis B patients and health subjects  
Mengru ZHAN, China
FRI-368  Phenotypic variation among myeloid-derived suppressor cells (MDSC) in natural history phases of chronic HBV infection differentially impacts HBV-specific T cell response and homing: lack of functional normalization after anti-viral therapy
Sourina PAL, India

FRI-369  Integrated analysis of serum immunological biomarkers in patients with chronic hepatitis C upon direct-acting antiviral treatment
Rosângela TEIXEIRA, Brazil

FRI-370  Higher proportion of responders with hepatitis B antibody levels $\geq$100 miu/ml with the trivalent HepB vaccine, Sci-B-Vac, compared to Engerix-B: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)
Timo VESIKARI, Finland

FRI-371  Top 10%  Hepatocyte-derived l-carnitine impedes HBsAg clearance in chronic HBV infection
Yongyin Li, China

FRI-372  Interferon alpha-induced CXCL13 and IL-6 from intrahepatic monocytes facilitate HBV antigen seroconversion in chronic HBV infection
Yongyin Li, China
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-373</td>
<td>Serum levels of circulating DNA species can predict the development of hepatocellular carcinoma in chronic hepatitis B patients under long-term oral antiviral therapy</td>
<td>Alkistis Maria PAPATHEODORIDI, Greece</td>
</tr>
<tr>
<td>FRI-374</td>
<td>Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response?</td>
<td>Antonella OLIVERO, Italy</td>
</tr>
<tr>
<td>FRI-375</td>
<td>Comparison of the risk of hepatocellular carcinoma in nucleos(t)ide analogue-naive chronic hepatitis B patients treated with entecavir versus tenofovir: a systematic review and meta-analysis</td>
<td>Hyunwoo OH, Korea, Rep. of South</td>
</tr>
<tr>
<td>FRI-376</td>
<td>Is it possible to stop nucleus(t)die analogue safely in patients with preemptive or preventive therapy for HBV reactivation?</td>
<td>Akihiro TAMORI, Japan</td>
</tr>
<tr>
<td>FRI-377</td>
<td>Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: a multicenter study</td>
<td>Beom Kyung KIM, Korea, Rep. of South</td>
</tr>
<tr>
<td>FRI-378</td>
<td>Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era</td>
<td>David KAPLAN, United States</td>
</tr>
<tr>
<td>FRI-379</td>
<td>Excess body weight is associated with HBV-related HCC despite antiviral treatment</td>
<td>Jian SUN, China</td>
</tr>
<tr>
<td>FRI-380</td>
<td>Commonly used non-invasive markers do not reliably predict liver fibrosis in those patients of chronic hepatitis B who really need it: a prospective multi-centre study</td>
<td>Akash SHUKLA, India</td>
</tr>
<tr>
<td>FRI-381</td>
<td>Evaluation of dried plasma spot on the cobas(r) plasma separation card as a sample type for hepatitis B virus load quantification on the cobas(r) 6800 system</td>
<td>Ed G. MARINS, United States</td>
</tr>
<tr>
<td>FRI-382</td>
<td>Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years</td>
<td>Enrico GALMOZZI, Italy</td>
</tr>
</tbody>
</table>
FRI-383  PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy
George PAPATHEODORIDIS, Greece

FRI-384  Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection
Tetsuya HOSAKA, Japan

FRI-385  Plasma adipocyte fatty acid-binding protein and adiponectin levels are associated with fibrosis regression in nucleoside analogue-treated chronic hepatitis B: a prospective study with paired transient elastography
Rex Wan-Hin HUI, Hong Kong

FRI-386  Higher pregnancy hbcrag and pg HBV RNA concentrations are observed in treated and untreated chronic hepatitis B mothers with post-partum alt flares
Ivana CAREY, United Kingdom

FRI-387  Gender disparity in the association of interleukin-10 and interleukin-12 polymorphisms with the progression of hepatitis B virus infection in Caucasians
Janett FISCHER, Germany

FRI-388  Association between quantitative hepatitis B virus core antibody levels and surface antigen in chronic low viraemic patients
Jing LI, China

FRI-389  Risk of hepatitis flare in inflammatory bowel disease patients with previous hepatitis B virus exposure – results from a territory-wide Hong Kong ibd registry study
Joyce Wing Yan MAK, Hong Kong

FRI-390  Sarcopenia is associated with type 2 diabetes and sedentary lifestyle in patients with chronic hepatitis B
Luciana DINIZ SILVA, Brazil

FRI-391  Incidence of young-onset hepatocellular carcinoma in young adults with chronic hepatitis B virus infection: potential implication for surveillance
Myung Ji GOH, Korea, Rep. of South

FRI-392  Incidence and predictors of hepatitis B surface antigen clearance among people living with HIV and hepatitis B
Mamta JAIN, United States

FRI-393  Rituximab monotherapy in anti-HBC positive patients with multiple sclerosis or neuromyelitis optica spectrum disorders is not associated with HBV reactivation
Mar RIVEIRO BARCIELA, Spain
Viral hepatitis B/D: Clinical aspects except therapy (Cont.)

FRI-394  Not uncommon: HBV genotype g co-infection in HBeAg-negative chronic HBV infected patients  
Michael BASIC, Germany

FRI-395  Poor improvement of on-treatment FIB-4 index after initiation of nucleos(t)ide analogs is associated with development of hepatocellular carcinoma in both cirrhotic and non-cirrhotic chronic hepatitis B patients  
Miyako MURAKAWA, Japan

FRI-396  The integrated use of accurate virological and serological HBV markers can help identifying HBsAg-negative/anti-HBC-positive patients at higher risk of HBV-reactivation and optimizing the duration of prophylaxis in oncohematological setting  
Mohammad ALKHATIB, Italy

FRI-397  A comparative study of risks for hepatocellular carcinoma and mortality in chronic hepatitis B patients initially treated with entecavir or tenofovir  
Eileen YOON, Korea, Rep. of South

FRI-398  Reverse transcriptase droplet digital PCR versus reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification  
Natthaya CHUAYPEN, Thailand

FRI-399  Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium  
Özgür KOC, Belgium

FRI-400  Three HBsAg kinetic profiles in HBeAg negative infection and chronic hepatitis are associated with different chances of HBsAg clearance  
Piero COLOMBATTO, Italy

FRI-401  Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy  
Paolo FABRIS, Italy

FRI-402  Quantitative HBeAg varies in the different phases of HBV infection, and can predict therapeutic outcome in the setting of immunosuppression driven HBV reactivation  
Lorenzo PIERMATTEO, Italy

FRI-403  Development of a highly sensitive multiplex platform assay to monitor low levels of HBV DNA and pgRNA in samples from patients with chronic hepatitis B  
Qi HUANG, United States

FRI-404  Very low rates of receiving antiviral therapy among treatment eligible chronic hepatitis B virus infected patients  
Robert WONG, United States
Impact of hepatitis B virus-related immune reconstitution inflammatory syndrome on HBsAg loss in patients co-infected with human immunodeficiency virus
Sachiyo YOSHIO, Japan

Response to a double dose (40 mcg) and an accelerated schedule (0-1-2 months) of hepatitis B vaccine in patients with advance cirrhosis. A prospective study
Sergio RODRÍGUEZ-TAJES, Spain

Presence of significant histopathology in HBeAg-positive chronic infection patients identified by four international guidelines: a Chinese multi-center study
Yidi JIA, China

Detectable HBV DNA during nucleos(t)ide analogues is useful for stratification of page-b predictive hepatocellular carcinoma risk score
Shun KANEKO, Japan

Liver transplantation for hepatitis delta in the United States
Tatyana KUSHNER, United States

Evaluation of page-b and modified page-b scores to guide hepatocellular carcinoma surveillance in chronic hepatitis B patients on antiviral therapy – a territory-wide study of 32,150 subjects
Terry Cheuk-Fung YIP, Hong Kong

Clinical effectiveness of a newly developed and fully automated high-sensitive hepatitis B core-related antigen assay for monitoring nucleos(t)ide analogues therapy in hepatitis B envelope antigen-negative patients
Takako INOUE, Japan

Clinical efficacy of a newly developed high-sensitive hepatitis B core-related antigen assay for monitoring hepatitis B virus reactivation
Takako INOUE, Japan

Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort
Tongai Gibson MAPONGA, South Africa

Clonal expansion of hepatocytes and state of hepatitis B virus DNA integration in patients with nucleos(t)ide analogue therapy
Ning CHOW, Hong Kong

Machine learning identifies immune profile to predict virological relapse after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B
Maximilian WÜBBOLDING, Germany
Viral hepatitis B/D: Clinical aspects except therapy (Cont.)

**FRI-416**  Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis  
Yandi XIE, China

**FRI-417**  Prevalence of liver fibrosis in the natural course of chronic hepatitis B virus infection: a systematic review with meta-analysis  
Yan WANG, China

**FRI-418**  Estimating the clinical and economic burden of chronic hepatitis B (CHB) in the United States  
Zobair YOUNOSSI, United States
### Viral hepatitis C: Post SVR and long term follow up

<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-419</td>
<td>Exaggerated risk of vitamin B12 deficiency after HCV eradication with direct-acting antivirals</td>
<td>Diego CASAS DEZA, Spain</td>
</tr>
<tr>
<td>FRI-420</td>
<td>Risk of hepatocellular carcinoma recurrence in patients treated with direct acting antiviral therapy</td>
<td>Asmaa GOMAA, Egypt</td>
</tr>
<tr>
<td>FRI-421</td>
<td>Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy</td>
<td>Jisoo Amy KWON, Australia</td>
</tr>
<tr>
<td>FRI-422</td>
<td>HIV co-infection is associated with lower risk of liver cancer after HCV-cure</td>
<td>Anaïs CORMA-GÓMEZ, Spain</td>
</tr>
<tr>
<td>FRI-423</td>
<td>Statins use corrects the impact of direct acting antiviral agents on lipid profile in hepatitis C virus patients</td>
<td>Anna MANTOVANI, Italy</td>
</tr>
<tr>
<td>FRI-424</td>
<td>Medium-term outcomes of hepatitis C virus-infected patients with a sustained viral response according to albumin-bilirubin grade</td>
<td>Akihiro TAMORI, Japan</td>
</tr>
<tr>
<td>FRI-425</td>
<td>Identification of serum miRNAs whose expression were associated with and changed after HCV eradication</td>
<td>Atsumasa KOMORI, Japan</td>
</tr>
<tr>
<td>FRI-426</td>
<td>Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies</td>
<td>Bernhard SCHEINER, Austria</td>
</tr>
<tr>
<td>FRI-427</td>
<td>The severity of biopsy-proven fibrosis and sustained virologic response determine long-term outcomes in patients with chronic hepatitis C virus infection</td>
<td>Soon Kyu LEE, Korea, Rep. of South</td>
</tr>
<tr>
<td>FRI-428</td>
<td>HIV/HCV co-infected subjects show better thrombocytopenia improvement after sustained virologic response achievement than HCV mono-infected cirrhotics. Data from the hepaiCONA and PITER cohorts.</td>
<td>Roberto ROSSOTTI, Italy</td>
</tr>
<tr>
<td>FRI-429</td>
<td>Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DASSs-induced viral eradication</td>
<td>Chiara MANULI, Italy</td>
</tr>
</tbody>
</table>
Viral hepatitis C: Post SVR and long term follow up (Cont.)

FRI-430 Development of hepatocellular carcinoma by patients aged 75 years or over after HCV elimination by all-oral DAA therapy: results from a large-scale, multicenter cohort study
Eiichi OGAWA, Japan

FRI-431 Deteriorated lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication
Chung-Feng HUANG, Taiwan

FRI-432 Dynamic of cytokine profiles predicts risk of HCC among HCV patients with advanced fibrosis after successful antiviral therapy
Ming-Lung YU, Taiwan

FRI-433 Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis
Giordano SIGON, Italy

FRI-434 Direct-acting antivirals improve treatment outcomes in patients with chronic hepatitis C-related hepatocellular carcinoma treated with transarterial chemoembolization: a nationwide, multi-center, retrospective cohort study
Hye Kyung HYUN, Korea, Rep. of South

FRI-435 Patients treated for hepatitis C: an observational study with the French administrative healthcare database (SNDS)
Ingrid RODRIGUEZ, France

FRI-436 Role of pre- and post-treatment transient elastography measurements in predicting hepatocellular carcinoma (HCC) among hepatitis C patients treated with direct acting antivirals (DAAs)
Jacob CHARETTE, Canada

FRI-437 Non-invasive tests predict the risk of hepatocellular carcinoma in hepatitis C patients after sustained virological response: impact on HCC surveillance
Javier AMPUERO, Spain

FRI-438 Reinfection with hepatitis C following cure: results from the TraP Hep C program in Iceland – a prospective nationwide, population-based study
Jon M JOHANNESSON, Iceland

FRI-439 Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma
Frank JÜHLING, France

FRI-440 Simple blood test criteria for non-cirrhosis plus age and post-treatment AFP rule-out the risk of hepatocellular carcinoma development after SVR
Masayuki KUROSAKI, Japan
FRI-441  Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir
Laura TELEP, United States

FRI-442  The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort
Loreta KONDILI, Italy

FRI-443  Clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus
Marco DI PETRILLO, Italy

FRI-444  Identification of circulating microRNAs predictive of HCC in DAA-cured HCV-related cirrhosis
Marie-laure PLISSONNIER, France

FRI-445  Impact on health perception, quality of life and labor productivity of antiviral treatment for hepatitis C in patients without significant fibrosis
Matias ESTEVEZ, Spain

FRI-446  Sustained virologic response to direct-acting antivirals does affect the risk of portal vein thrombosis in patients with advanced chronic liver disease
Mattias MANDORFER, Austria

FRI-447  The one-year outcome of hepatitis B virus in Taiwanese patients with chronic hepatitis B and C co-infection after direct-acting antivirals
Ming-Lun YEH, Taiwan

FRI-448  Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland
Madeleine CAVEN, United Kingdom

FRI-449  Hepatitis C virus eradication with direct-acting agents elevates the serum small dense low-density lipoprotein cholesterol level
Naoyuki HINO, Japan

FRI-450  Influence of DAA treatment in patients with HCV-cirrhosis and esophageal varices on liver transplant free survival and risk of developing hepatocellular carcinoma
Noelia RODRÍGUEZ FERREIRO, Spain

FRI-451  Dynamic changes of serum M2BPGi as a fibrosis marker of patients with HCV mono-infection and HCV/HIV co-infection receiving direct-acting anti-viral therapy
Pisit TANGKIJVANICH, Thailand
### Viral hepatitis C: Post SVR and long term follow up (Cont.)

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-452</td>
<td>Non-invasive tests of fibrosis and risk of liver-related complications: observations following successful sofosbuvir-based treatment in patients with HCV cirrhosis</td>
<td>Rajender REDDY, United States</td>
<td></td>
</tr>
<tr>
<td>FRI-453</td>
<td>Hepatocellular carcinoma following direct acting antiviral therapy does not display an aggressive pattern: a prospective study</td>
<td>Reham SOLIMAN, Egypt</td>
<td></td>
</tr>
<tr>
<td>FRI-454</td>
<td>Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development</td>
<td>Riccardo NEVOLA, Italy</td>
<td></td>
</tr>
<tr>
<td>FRI-455</td>
<td>Hepatitis C virus infection, endogenous retrotransposons activation and cancer risk</td>
<td>Ruchi SHUKLA, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-456</td>
<td>Post-treatment wisteria floribunda agglutinin-positive mac-2-binding protein is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication</td>
<td>Shunsuke SATO, Japan</td>
<td></td>
</tr>
<tr>
<td>FRI-457</td>
<td>Eradication of HCV with direct-acting antivirals increased small LDL particle number in SVR48</td>
<td>Vanesa BERNAL MONTERDE, Spain</td>
<td></td>
</tr>
<tr>
<td>FRI-458</td>
<td>Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance</td>
<td>Vincenza CALVARUSO, Italy</td>
<td></td>
</tr>
<tr>
<td>FRI-459</td>
<td>Partial restoration of brain structural and connectivity changes after HCV cure with direct acting antivirals (DAA)</td>
<td>Zoe MARINO, Spain</td>
<td></td>
</tr>
</tbody>
</table>
Liver tumours: Experimental and pathophysiology

FRI-460  
YI  
**Glycogen synthase 2 (GYS2) restricts tumor metastatic ability via attenuating autophagy and breaking glycogenic homeostasis in hepatocellular carcinoma**  
Di WU, China

FRI-461  
YI  
**EIF4E BP3, methylated in gastric cancer, acts as a tumor suppressor restraining tumor proliferation and liver metastasis via targeting EIF4E/B-catenin axis**  
Zhongjie LIN, China

FRI-462  
Top 10%  
**Molecular characterization of hepatocellular carcinoma in Mongolia delineates unique genomic features**  
Marc PUIGVEHI, Spain

FRI-463  
YI  
**NK-cell dysfunction in hepatocellular carcinoma: modulatory approaches for functional restoration**  
Alessandra ZECCA, Italy

FRI-464  
**Global characterisation of tumour infiltrate of intrahepatic cholangiocarcinoma by single cell sequencing**  
Ana LLEO, Italy

FRI-465  
YI  
**New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma**  
Anne OLBRICH, Germany

FRI-466  
YI  
**Ganglioside patterns in the human cholangiocarcinoma stem cell subset**  
Benedetta PIOMBANTI, Italy

FRI-467  
YI  
**T cell exhaustion dynamics are linked to clinical outcomes in hepatocellular carcinoma**  
Bertram BENGSCH, Germany

FRI-468  
**Lactate promotes invasion and metastasis of hepatocellular carcinoma via changes in mitochondrial and histone acetylation**  
Jianye CAI, China

FRI-469  
YI  
**Dysregulation of aquaporin-1 in human CCA cells triggers epithelial-mesenchymal transition**  
César GASPARI, Argentina

FRI-470  
**Diagnostic performance of PIVKA-II in patients with hepatocellular carcinoma**  
Claudio GALLI, Italy

FRI-471  
Top 10%  
**TGF–beta-associated circular RNAs in cholangiocarcinoma: mechanisms and biomarkers**  
Corentin LOUIS, France
# Liver tumours: Experimental and pathophysiology (Cont.)

**FRI-472**  
**YI**  
Tracking neutrophils within the hepatocellular carcinoma microenvironment – development of relevant orthotopic and ex-vivo 3D liver-HCC culture models  
Daniel GEH, *United Kingdom*

**FRI-473**  
Identification of PD-L1- expressing exosome-derived microRNAs in human hepatocellular carcinoma  
Yu Rim LEE, *Korea, Rep. of South*

**FRI-474**  
Long interspersed nuclear element-1 (line-1) hypomethylation is associated with poor outcomes via the activation of ST18 in human hepatocellular carcinoma  
Yu Rim LEE, *Korea, Rep. of South*

**FRI-475**  
**Top 10%**  
Tristetraprolin is a key driver of hepatic inflammation, fibrosis and cancer development in vivo  
Dobrochna DOLICKA, *Switzerland*

**FRI-476**  
**YI**  
Identification of neoantigens as potential vaccines in hepatocellular carcinoma  
David REPARAZ, *Spain*

**FRI-477**  
**YI**  
SIMBA: a user-friendly high-throughput tool for spheroid invasion analysis of hepatocellular carcinoma cell lines  
Elias VAN DE WIJVER, *Belgium*

**FRI-478**  
**YI**  
Development of personalised human immunocompetent ex vivo models of primary and secondary liver cancers using precision cut tissue slice technology  
Ewald DOORNEBAL, *United Kingdom*

**FRI-479**  
Macrophage autophagy protects against hepatocellular carcinoma by modulation of the hepatic immune microenvironment  
Fatima TEIXEIRA-CLERC, *France*

**FRI-480**  
**Top 10%**  
Platelet activation promotes carcinogenesis and tumor growth in hepatocellular carcinoma  
Femke HEINDRYCKX, *Sweden*

**FRI-481**  
**YI**  
Blocking IRE1a-endoribonuclease activity in hepatic stellate cells decreases tumor cell proliferation and metastasis in hepatocellular carcinoma  
Femke HEINDRYCKX, *Sweden*

**FRI-482**  
Comprehensive analysis of cancer-related genes and AAV/hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection  
Fukiko KAWAI-KITAHATA, *Japan*
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors and Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-484</td>
<td>TIGIT and PD1 dual checkpoint blockade restores functionality of tumor-infiltrating T cells in hepatocellular carcinoma</td>
<td>Zhouhong GE, Netherlands</td>
</tr>
<tr>
<td>FRI-485</td>
<td>Regulation of the biology of cholangiocarcinoma (CCA) cells by the extracellular-signal regulated kinase 5 (ERK5)</td>
<td>Giulia LORI, Italy</td>
</tr>
<tr>
<td>FRI-486</td>
<td>Fatty acids regulate the biology of cholangiocarcinoma cells</td>
<td>Giulia LORI, Italy</td>
</tr>
<tr>
<td>FRI-487</td>
<td>Circulating exosomal microRNA-125b inhibits metastasis of hepatocellular carcinoma</td>
<td>Hye Seon KIM, Korea, Rep. of South</td>
</tr>
<tr>
<td>FRI-488</td>
<td>Modelling liver tumor organoids and cancer-associated fibroblasts interaction reveals the robust effects of stromal niche in cancer nurturing and treatment resistance</td>
<td>Jiaye LIU, Netherlands</td>
</tr>
<tr>
<td>FRI-489</td>
<td>C-Rel is a novel tumour suppressor and early prognostic indicator of hepatocellular carcinoma development</td>
<td>Jack LESLIE, United Kingdom</td>
</tr>
<tr>
<td>FRI-490</td>
<td>ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and paracrine signaling between tumor cells and cancer-associated fibroblasts</td>
<td>Javier VAQUERO, Spain</td>
</tr>
<tr>
<td>FRI-491</td>
<td>The role and mechanisms of high fat diet on the increased risk of hepatocellular carcinoma in hepatitis B virus transgenic mice</td>
<td>Jaw-Ching WU, Taiwan</td>
</tr>
<tr>
<td>FRI-492</td>
<td>DNA damage response protein checkpoint kinase 2 (CHK2) links chromosomal instability to cellular metabolism in hepatocellular carcinoma (HCC)</td>
<td>Krista ROMBOUTS, United Kingdom</td>
</tr>
<tr>
<td>FRI-493</td>
<td>Interplay of PNPLA and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients</td>
<td>Carla DE BENEDITTIS, Italy</td>
</tr>
<tr>
<td>FRI-494</td>
<td>Alisporivir, a cyclophilin inhibitor, reduces fibrosis and tumor burden derived from non-alcoholic steatohepatitis in a mouse model</td>
<td>Joseph KUO, United States</td>
</tr>
<tr>
<td>FRI-495</td>
<td>2-deoxy-D-glucose encapsulated PLGA nanoparticles suppress hepatocellular carcinoma through cytotoxic effect and activation of antitumor immunity</td>
<td>Kyo SASAKI, Japan</td>
</tr>
</tbody>
</table>
Liver tumours: Experimental and pathophysiology (Cont.)

FRI-496  SPARC negatively correlates with prognosis after transarterial chemoembolization and facilitates growth and metastasis of hepatocellular carcinoma via ERK/MMP signaling pathways  
Yao LIU, China

FRI-497  Patient-derived ECM-scaffolds of colorectal cancer and liver metastases as organotypic 3D model of liver metastatic colonization  
Luca URBANI, United Kingdom

FRI-498  Interplay between O-GlcNAc transferase and enhancer of zeste homolog 2 in hepatocellular carcinoma  
Margot THIRION, France

FRI-499  The metabolic plasticity of neoplastic cholangiocytes: perspective for target therapy in intrahepatic cholangiocarcinoma.  
Michela Anna POLIDORO, Italy

FRI-500  Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma  
Mirella PASTORE, Italy

FRI-501  Engineering of immunosuppressant-resistant HBV-redirected TCR T cells for post-transplant HBV-HCC immunotherapy  
Morteza HAFEZI, Singapore

FRI-502  NEDD8 specific protease 1 (NEDP1) as a tumor suppressor in hepatocellular carcinoma  
Marina SERRANO-MACIA, Spain

FRI-503  Piddosome-controlled liver ploidy is predictive for HCC outcome  
Nataliya ROHR-UDILOVA, Austria

FRI-504  TERT promoter mutations and liver carcinogenesis: identification and quantification of mutation status by digital PCR analysis on formol-fixed paraffin-embedded samples  
Paisley SARAH, France

FRI-505  The role of insulin degrading enzyme in gender disparity of hepatocellular carcinoma progression and sorafenib response  
Yu PAN, China

FRI-507  A pro-inflammatory variant in the TLR5 gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis.  
Philipp LUTZ, Germany
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-508</td>
<td>Deleting in vivo beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or mesenchymal hepatoblastoma similarly to APC loss-of-function</td>
<td>Robin LOESCH, France</td>
<td></td>
</tr>
<tr>
<td>FRI-509</td>
<td>Hepatitis B virus surface antigen inactivates the hippo pathway and thereby increases the hepatic expression of oncogene BMI1</td>
<td>Ruth BROERING, Germany</td>
<td></td>
</tr>
<tr>
<td>FRI-510</td>
<td>Natural killer cells target XP01: a therapeutic opportunity for HCC</td>
<td>Salim KHAJKOO, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>FRI-511</td>
<td>Myeloid IRE1a deletion alters hepatic macrophage phenotype and attenuates experimental non-alcoholic steatohepatitis-related hepatocellular carcinoma</td>
<td>Sanne VAN CAMPENHOUT, Belgium</td>
<td></td>
</tr>
<tr>
<td>FRI-512</td>
<td>TAK1 is a novel therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance</td>
<td>Shunjie XIA, China</td>
<td></td>
</tr>
<tr>
<td>FRI-513</td>
<td>Exposing the regulation of MDM2 expression by ADAR-mediated A-to-I editing in human hepatocellular carcinoma: application of a large-scale on-step predicting platform in oncology research</td>
<td>Guangqi SONG, China</td>
<td></td>
</tr>
<tr>
<td>FRI-514</td>
<td>Androgen receptor sensitized sorafenib efficacy via enriched EPCAM stemness in hepatocellular carcinoma</td>
<td>Hsueh-Chou LAI, Taiwan</td>
<td></td>
</tr>
<tr>
<td>FRI-515</td>
<td>BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features</td>
<td>Theo HIRSCH, France</td>
<td></td>
</tr>
<tr>
<td>FRI-516</td>
<td>PPEF2 suppresses hepatocellular carcinoma by inhibiting c-Myc signal pathway</td>
<td>Nuoqing WENG, China</td>
<td></td>
</tr>
<tr>
<td>FRI-517</td>
<td>Transforming growth factor-beta and AXL causes neutrophil infiltration and activation of matrix metalloproteinase 2/9 in hepatocellular carcinoma</td>
<td>Wolfgang MIKULITS, Austria</td>
<td></td>
</tr>
<tr>
<td>FRI-519</td>
<td>Intracellular retention of HBV contributes to mitochondrial energy deprivation, lipid metabolism disorders and Warburg effect in HBV-associated HCC</td>
<td>Jenny Yuh-Jin LIANG, Taiwan</td>
<td></td>
</tr>
<tr>
<td>FRI-520</td>
<td>T cell exhaustion dynamics are linked to clinical outcomes in hepatocellular carcinoma</td>
<td>Zhen ZHANG, Germany</td>
<td></td>
</tr>
</tbody>
</table>
POSTERS
SAT-001 – SAT-520
Poster programme version as of 10.04.2020
**NAFLD: Experimental and pathophysiology**

**SAT-001**  
**YI**  
Lipoprotein lipase deletion induces a proinflammatory phenotype in liver-infiltrating monocytes during non-alcoholic steatohepatitis  
Anja KOOP, Germany

**SAT-002**  
**YI**  
A translational mouse model for NASH and advanced fibrosis in association with atherosclerosis  
Anita M. VAN DEN HOEK, Netherlands

**SAT-003**  
**YI**  
Aberrant hepatic protein tyrosine phosphatase receptor type delta expression is a driver of metabolic liver disease  
Armando Andres ROCA SUAREZ, France

**SAT-004**  
**YI**  
LncRNA-H19 as a marker of liver progression from steatosis to hepatocellular carcinoma  
Ángela ROJAS, Spain

**SAT-005**  
**YI**  
The lipid composition of the liver: assessing differences in obese patients with and without non-alcoholic steatohepatitis  
Anna HERNÁNDEZ-AGUILERA, Spain

**SAT-006**  
**YI**  
AXL inhibition prevents NAFLD progression in mice with soluble AXL as marker of the NAFLD to NASH transition  
Anna TUTUSAUS, Spain

**SAT-007**  
**YI**  
Efficacy and safety of an acetyl CoA carboxylase inhibitor are improved in combination with PPAR agonists in a dyslipidemic rat model  
Archana VIJAYAKUMAR, United States

**SAT-008**  
**YI**  
PBI-4050 restores liver and adipose tissue metabolic homeostasis, and decreases fibrosis in a high-fat-diet mouse model of non-alcoholic fatty liver disease  
Brigitte GROUIX, Canada

**SAT-009**  
**YI**  
Adipose tissue macrophages acquire a pro-inflammatory phenotype which is associated to liver fibrogenesis in an experimental model of NAFLD in mice  
Celia MARTÍNEZ SÁNCHEZ, Spain

**SAT-010**  
**Top 10%**  
Intermittent hypoxia featuring the obstructive sleep apnea syndrome contributes to hepatosteatosis by upregulating the intrahepatic expression of fatty acid translocase CD36 and lipogenic genes  
Carmelo GARCIA-MONZON, Spain

**SAT-011**  
**Top 10%**  
The symbiotic supplementation modulate gut microbiota, regulation beta-catenin expression and prevents weight gain in ob/ob mice with non-alcoholic fatty liver disease (NAFLD)  
Claudia OLIVEIRA, Brazil
| SAT-012 | Treatment with the endothelin receptor inhibitor bosentan alleviates the NAFLD-associated increased intrahepatic vascular resistance and reduces steatosis and liver damage in a rat model of early NAFLD  
Denise VAN DER GRAAFF, Belgium |
| SAT-013 | Liver sinusoidal endothelial cell-specific RUNX-1 gene knockdown decreases hepatic inflammation and myeloid cells infiltration in pre-clinical animal models non-alcoholic steatohepatitis  
Dinesh Mani TRIPATHI, India |
| SAT-014 | Identification of novel biomarkers and therapeutic targets for steatohepatitis and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD): an in silico analysis  
Douglas MAYA-MILES, Spain |
| SAT-015 | Liver-chip: a model for understanding diet-induced liver disease and drug efficacy assessment  
Dwayne CARTER, United States |
| SAT-017 | Propionate intervention attenuates NASH while negatively affecting cognition  
Eveline GART, Netherlands |
| SAT-018 | A shortcut from non-alcoholic fatty liver disease to HCC: c-Myc, a promising theranostic target  
Feifei GUO, Spain |
| SAT-019 | Sex differences of adipose tissue dynamic changes in NASH progression of morbid obese patients: a preliminary study  
Gerard BAIGES, Spain |
| SAT-020 | Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of non-alcoholic fatty liver disease (NAFLD)  
Giovanni DI MAIRA, Italy |
| SAT-021 | MicroRNAs involved in the progression of non-alcoholic fatty liver  
Guillermo Nahum LÓPEZ-SÁNCHEZ, Mexico |
| SAT-022 | Simultaneous intra-operative sampling from multiple anatomical sites reveals pro-inflammatory liver homing T cells in liver, adipose tissue and peripheral blood in patients with NASH  
James BRINDLEY, United Kingdom |
| SAT-023 | The influence of obesity, non-alcoholic steatohepatitis and bariatric surgery on plasma lipid profile  
Helena CASTAÑÉ, Spain |
| SAT-024 | Growth differentiation factor 11 promotes progression of non-alcoholic fatty liver disease  
Jan FRÖHLICH, Czech Republic |
### NAFLD: Experimental and pathophysiology (Cont.)

**SAT-025**  
**The influence of TRPM8 variant on brown adipose tissue activity and contribution to increased susceptibility to non-alcoholic fatty liver disease among South Asians**  
Jane GROVE, United Kingdom

**SAT-026**  
**Combinatorial effect of ezetimibe and empagliflozin in non-alcoholic fatty liver disease in a mouse model and a liver organoid for disease modeling of hepatic steatosis**  
Dongyun KIM, Korea, Rep. of South

**SAT-027**  
**Deviations of the peripheral blood and intrahepatic immune cell landscape between NAFLD patients and healthy controls**  
Julian SCHULZE ZUR WIESCH, Germany

**SAT-028**  
**High-throughput sequencing identified MIR-193a as a potential biomarker of non-alcoholic fatty liver disease activity**  
Katherine JOHNSON, United Kingdom

**SAT-029**  
**Ageing causes lipid metabolism imbalance and exacerbates steatohepatitis in high-fat diet-fed mice**  
Kazuyoshi KON, Japan

**SAT-030**  
**Assessment of the utility of soluble CD14 in discriminating non-alcoholic steatohepatitis in the early stage of fibrosis from non-alcoholic fatty liver disease**  
Kenichi MORIKAWA, Japan

**SAT-031**  
**Genome-wide in vivo functional genetic screen to identify novel modulators of non-alcoholic fatty liver disease**  
Puja KHANNA, Singapore

**SAT-032**  
**Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatitis model**  
Kevin KLUCHER, United States

**SAT-033**  
**Cognitive dysfunction occurs early in experimentally induced NAFLD and is associated with systemic inflammation**  
Kristoffer KJÆRGAARD, Denmark

**SAT-034**  
**Thr β-selective agonist MGL-3196 improves NAS score and plasma lipoprotein profile in the liver-humanized FRGN KO NASH model**  
Lander FOQUET, United States

**SAT-035**  
**TM6SF2/PNPLA3/MBOAT7 loss-of function genetic variants impact on NAFLD development and progression both in patients and in vitro models**  
Miriam LONGO, Italy
SAT-036  
**YI**  
Enhancing autophagy improves and slows the progression of non-alcoholic steatohepatitis disease  
Maria RUART, Spain

SAT-037  
**Top 10%**  
**YI**  
The PSRC1 rs599839 A>G variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients  
Marica MERONI, Italy

SAT-038  
**Top 10%**  
**YI**  
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH  
Marie O’FARRELL, United States

SAT-039  
**Top 10%**  
**YI**  
SERPINB3 inhibition as a novel target therapy for non-alcoholic steatohepatitis  
Andrea MARTINI, Italy

SAT-040  
**YI**  
Metabolism of human liver on a genome scale in non-alcoholic fatty liver disease  
Matej OREŠIČ, Sweden

SAT-041  
**YI**  
Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation in non-alcoholic fatty liver disease  
Marta B. AFONSO, Portugal

SAT-042  
**YI**  
A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models  
Mary CHAU, United States

SAT-043  
**Top 10%**  
Kupffer cell depletion and breakage of TLR4-mediated hepatic tolerance drive susceptibility to injury and infections in the early phases of non-alcoholic fatty liver disease  
Gustavo MENEZES, Brazil

SAT-044  
**YI**  
Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice  
Michihiro IWAKI, Japan

SAT-045  
**YI**  
The role of RIPK3 in non-alcoholic fatty liver disease: a multi-omics perspective  
Miguel MATEUS-PINHEIRO, Portugal

SAT-046  
**YI**  
Muscle fat is higher in NAFLD, and increases with fibrosis stage – a retrospective liver biopsy controlled magnetic resonance imaging-based body composition study  
Mikael FORSGREN, Sweden
NAFLD: Experimental and pathophysiology (Cont.)

SAT-047 Adoptive cell transfer of regulatory T cells causes an exacerbation of hepatic steatosis in high-fat high-fructose diet-fed mice
Mikhail VAN HERCK, Belgium

SAT-048 Synergic effect of a combined treatment with atorvastatin and ambrisentan in a rat model of NASH
Miren BRAVO, Spain

SAT-049 Obesity and non-alcoholic steatohepatitis: assessing lipid diversity in adipose tissue
Montserrat FIBLA SIMÓ, Spain

SAT-050 N1-methylnicotinamide ameliorates hepatic steatosis through not only sirtuin activation but also modulation of bile acid metabolism and microbiota
Shusuke MORIZONO, Japan

SAT-051 Blocking IL-1 signaling in hepatocytes undergoing metabolic stress protects against metabolic inflammation and attenuates pro-coagulant factors
Nadine GEHRKE, Germany

SAT-052 Monocyte chemotactic protein-induced protein 1 level negatively correlates with steatosis in fatty liver patients
Natalia PYDYN, Poland

SAT-053 Ultrastructural changes in perfusion-fixed human non-alcoholic fatty liver disease biopsies
Pauline VERHAEGH, Netherlands

SAT-054 m1R-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD
Pedro Miguel RODRIGUES, Spain

SAT-055 Inhibition of autotaxin-lysophosphatidic acid signaling pathway by a novel autotaxin inhibitor FP10.47 ameliorates non-alcoholic steatohepatitis in vivo
Richell BOOIJINK, Netherlands

SAT-056 Recombinant glutamine synthetase reduces ammonia and hepatic fibrosis in vitro and in vivo models of non-alcoholic fatty liver disease
Antria SIAKALLI, United Kingdom

SAT-057 Absence of histidine triad nucleotide binding protein-2 (HINT-2) triggers mitochondrial dysfunction and aggravates steatosis
Raviprasadh RAJASEKARAN, India

SAT-058 GPNMB modulates hepatic steatogenesis and liver cancer
Seddik HAMMAD, Germany
| SAT-059 | **TM6SF2 E167K variant increases the severity of NAFLD in high fat diet-fed mice**  
Shousheng LIU, China |
| SAT-060 | **Unrevealing the HDL lipidome in NAFLD: a possible explanation for the increased CVD risk of these patients**  
Sofia KARTSOLI, Greece |
| SAT-061 | **A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis**  
Stéphanie LE CORRE, France |
| SAT-062 | **Evaluation of pharmacological intervention using a deep learning approach for histopathological scoring in a diet-induced obese and biopsy-confirmed mouse model of NASH with fibrosis**  
Sanne VEIDAL, Denmark |
| SAT-063 | **MET409, a potent, non-bile acid sustained FXR agonist, improves NAFLD activity score and exerts anti-fibrotic effects in a diet-induced obese mouse model of biopsy-confirmed fibrosing NASH**  
Sanne VEIDAL, Denmark |
| SAT-064 | **S1pr2 is a key mediator of endoplasmic reticulum stress in NAFLD/NASH pathogenesis**  
Stefania VETRANO, Italy |
| SAT-065 | **Infiltrative monocyte derived adenosine deaminase 2 promotes liver fibrosis via signaling through extracellular inosine**  
Shilpa TIWARI HECKLER, United States |
| SAT-066 | **TERN-501, a potent and selective agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated pathology in rodent models**  
Thorsten KIRSCHBERG, United States |
| SAT-067 | **Western diet induced nuclear NFATC1 activates pro-apoptotic endoplasmic reticulum (ER) stress signaling, and progresses NAFLD to NASH**  
Muhammad Umair LATIF, Germany |
| SAT-068 | **Overproduction of ITIH1 after loss of G alpha 13 in liver exacerbates systemic insulin resistance**  
Won KIM, Korea, Rep. of South |
| SAT-069 | **Chorionic-plate-derived mesenchymal stem cells attenuate hepatic steatosis via restoration of mitochondrial function**  
Yun Bin LEE, Korea, Rep. of South |
SAT-070  Glucagon-like peptide 1 receptor is localized in hepatocytes with macrovesicular steatosis attached to monocyte in non-alcoholic steatohepatitis
Hiroaki YOKOMORI, Japan

SAT-071  Iron loss-induced mitophagy via mitochondria ferritin suppresses NASH-related hepatocellular carcinoma
Yuichi HARA, Japan
| SAT-076 | Application of the new GLIM criteria for the diagnosis of malnutrition in patients with liver cirrhosis and usefulness of three different screening tools | Diego CASAS DEZA, Spain |
| SAT-077 | Automated low flow ascites (ALFA) pump effectively reduces the number of large volume paracentesis – data from a real world cohort | Adam HERBER, Germany |
| SAT-078 | Covered TIPSS does not improve long term survival in refractory ascites – a single-centre experience | Amritpal DHALIWAL, United Kingdom |
| SAT-079 | Comparison of skeletal muscle index (SMI) and transversal psoas muscle thickness (TPMT) for the diagnosis of sarcopenia in cirrhosis | Alessandra PIGLIACELLI, Italy |
| SAT-080 | PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions | Alison BOYLE, United Kingdom |
| SAT-081 | Building a better mousetrap: can MELD-Na be improved? | Allison KWONG, United States |
| SAT-082 | Systemic inflammation is associated with cardiodynamic state in acute-on-chronic liver failure | Sofia MONTEIRO, Portugal |
| SAT-083 | Preliminary results of the effects of beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: a randomized controlled pilot study | Angelo BRUNI, Italy |
| SAT-084 | Optimizing nutrition in patients with cirrhosis may reduce hospital readmissions in medium and high risk groups: a quality improvement project | Angela LIAROS, United Kingdom |
| SAT-085 | Adipopenia, among the nutritional parameters, is the rapid screening tool that best correlates with mortality in decompensated cirrhotic patients: results of a prospective study | Anna LOMBARDI, Italy |
| SAT-086 | Leptin as a key player in insulin resistance of liver cirrhosis | Anna MRZLJAK, Croatia |
Cirrhosis and its complications: Clinical (Cont.)

SAT-087  Femur fractures are associated with high morbimortality in patients with cirrhosis  
Anna BRUJATS, Spain

SAT-088  The presence of infection during hospitalization is associated with an increased risk of procedure-related bleeding in cirrhosis  
Abhishek SHENOY, United States

SAT-089  Role of urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 and cystatin C as markers of mild kidney function impairment in patients with liver cirrhosis  
Anna SZYMANEK-PASTERNAK, Poland

SAT-090  Analysis of factors associated with the prognosis of cirrhotic patients who were treated with V2-receptor antagonist for hepatic edema  
Akemi TSUTSUI, Japan

SAT-091  Combination of meld and lactates predicts early death in patients treated by salvage tips for refractory variceal bleeding  
Aurélie WALTER, France

SAT-092  Esophageal varices recurrence after eradication: are there any predictors?  
Myriam AYARI, Tunisia

SAT-093  Sarcopenia is associated with lack of therapeutic response and higher mortality in hepatocellular carcinoma patients  
Hanaa BADRAN, Egypt

SAT-094  A telephone survey to screen for frailty pre-liver transplant evaluation: validation of an easy to use survey  
Bandar ALJUDAIBI, United States

SAT-095  Risk factors associated with mortality in upper gastrointestinal bleeding in cirrhotic patients  
Andra BARBULESCU, Romania

SAT-096  Epithelial cell death markers M65 and M30 are significantly up-regulated in decompensated liver cirrhosis and decreased by correction of portal hypertension  
Beatrice-Victoria JAHN, Germany

SAT-097  Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis  
Chiara BECCHETTI, Switzerland

SAT-098  Bacterial translocation-induced inflammation promotes liver fibrogenesis in patients with advanced chronic liver disease  
Benedikt SIMBRUNNER, Austria
<table>
<thead>
<tr>
<th>SAT-099</th>
<th>YI</th>
<th>Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Benedikt SIMBRUNNER, Austria</td>
</tr>
<tr>
<td>SAT-100</td>
<td>YI</td>
<td>Impact of extended- spectrum- beta- lactamase faecal carrier on cirrhotic patients: a retrospective study on clinical outcomes before and after liver transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bianca MAGRO, Italy</td>
</tr>
<tr>
<td>SAT-101</td>
<td>YI</td>
<td>A randomized, double-blind study to evaluate the safety and tolerability of KB174, a novel synthetic glycan, in patients with well-compensated cirrhosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Robert S MITLEMAN, United States</td>
</tr>
<tr>
<td>SAT-102</td>
<td>YI</td>
<td>Renal clearance measured by iohexol identifies cirrhotic patients with normal creatinine at risk of serious adverse events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carlos GONZÁLEZ-ALAYÓN, Spain</td>
</tr>
<tr>
<td>SAT-103</td>
<td></td>
<td>Clinical relevance of sarcopenia in liver transplant candidates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chiara MAZZARELLI, Italy</td>
</tr>
<tr>
<td>SAT-104</td>
<td>YI</td>
<td>Impact of non-selective beta-blockers on hepatic encephalopathy in patients with liver cirrhosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christian LABENZ, Germany</td>
</tr>
<tr>
<td>SAT-105</td>
<td>YI</td>
<td>Characterization of alterations in mechanical, thermal and pain sensitivity in cirrhotic patients with minimal hepatic encephalopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carmina MONTOLIU, Spain</td>
</tr>
<tr>
<td>SAT-106</td>
<td>YI</td>
<td>Role and prognostic value of routine doppler sonography in patients with severe liver disease – a prospective cohort study in an intensive care unit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Constantin MAIER-STOCKER, Germany</td>
</tr>
<tr>
<td>SAT-107</td>
<td>YI</td>
<td>Lack of evidence of significant tubular injury in patients with cirrhosis and persistent hepatorenal syndrome. Implications for liver transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cristina SOLÉ MARTÍ, Spain</td>
</tr>
<tr>
<td>SAT-108</td>
<td>YI</td>
<td>Hepatic and splenic elastography: are they predictors of recurrence of esophageal varices after complete eradication?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniela REIS, Portugal</td>
</tr>
<tr>
<td>SAT-109</td>
<td>YI</td>
<td>Risk of contrast-induced acute kidney injury in cirrhotic patients undergoing computed tomography: myth or reality?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniela CAMPION, Italy</td>
</tr>
<tr>
<td>SAT-110</td>
<td>YI</td>
<td>Flash glucose monitoring system: a required tool to improve glycaemic control in patients with liver cirrhosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dalila COSTA, Portugal</td>
</tr>
<tr>
<td>SAT-111</td>
<td>Incorporation of frailty estimated by gait speed within MELD and the predictive potential for mortality in cirrhosis</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td>You DENG, China</td>
<td></td>
</tr>
<tr>
<td>SAT-112</td>
<td>Serologically assessed fragments of type VI collagen are predictors of progression free survival and death in patients with hepatocellular carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diana Julie LEEMING, Denmark</td>
<td></td>
</tr>
<tr>
<td>SAT-113</td>
<td>Mechanical ventilation in patients with hepatopulmonary syndrome: prevalence, resource utilization, and prognosis: a nationwide analysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ahmad KHAN, United States</td>
<td></td>
</tr>
<tr>
<td>SAT-114</td>
<td>Acute kidney injury: a predictor of worse outcomes in variceal bleeding</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ahmad KHAN, United States</td>
<td></td>
</tr>
<tr>
<td>SAT-115</td>
<td>The prospective prognostic values of diabetic conditions based on 75g oral glucose tolerance test in cirrhotic patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moon Young KIM, Korea, Rep. of South</td>
<td></td>
</tr>
<tr>
<td>SAT-116</td>
<td>PROSPER study reveals reduction in bed days per hospitalisation and decreased risk of mortality for patients observed on rifaximin-alpha 550mg compared to a cohort on standard of care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dave WALKER, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>SAT-117</td>
<td>Hemodynamic effects of direct-acting antivirals in patients with hepatitis-C virus-associated cirrhosis and portal hypertension non responsive to beta-blockers</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td>Edilmar ALVARADO, Spain</td>
<td></td>
</tr>
<tr>
<td>SAT-118</td>
<td>Improving nutritional care in patients with liver cirrhosis: a quality improvement project</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td>Syazedd SYAMANI, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>SAT-119</td>
<td>90-day mortality is lower after as compared to before transjugular intrahepatic portosystemic shunt at the same model for end-stage liver disease score</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td>Laurie EICHER, Germany</td>
<td></td>
</tr>
<tr>
<td>SAT-120</td>
<td>Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td>Alessandra PIVETTI, Italy</td>
<td></td>
</tr>
<tr>
<td>SAT-121</td>
<td>First-line empirical antibiotics failed to control bacterial infections resistant to multi drugs in patients hospitalized with cirrhosis</td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td>Zhujun CAO, China</td>
<td></td>
</tr>
</tbody>
</table>
SAT-122 | The SALTYFOOD trial: a randomized, controlled trial of home-delivered low-sodium meals for the management of refractory ascites  
Elliot TAPPER, United States

SAT-123 | The diagnosis of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis  
Top 10%  
YI  
Nicoletta FABRINI, Italy

SAT-124 | Interest of echocardiography in the management of acute kidney injury in cirrhotic patients with ascites. Results of the prospective pilot cirren study  
YI  
Fanny LEBOSSE, France

SAT-125 | Effectiveness of probiotics in the secondary prevention of hepatic encephalopathy among cirrhotic patients  
Top 10%  
Muhammad Farooq HANIF, Pakistan

SAT-126 | Head to head comparison of liver stiffness measurement using transient elastography, 2D-shear wave elastography and magnetic resonance elastography for non-invasive evaluation of clinical significant portal hypertension  
YI  
Filipe ANDRADE, Portugal

SAT-127 | A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis  
YI  
Fanny TURON, Spain

SAT-128 | Comparison of the diagnostic quality of aspiration and core biopsy needles for transjugular liver biopsy  
YI  
Georg SEMMLER, Austria

SAT-129 | Spleen stiffness-based models can predict presence of esophageal varices in patients with compensated liver cirrhosis stratified by liver disease etiology  
YI  
Mauro GIUFFRÈ, Italy

SAT-130 | Ammonia is an independent biomarker of poor outcomes in patients with advanced cirrhosis  
YI  
Gonçalo ALEXANDRINO, Portugal

SAT-131 | Survival outcomes of SBP, BA and CNNA in a large Scottish cohort  
YI  
Malgorzata GRZELKA, United Kingdom

SAT-132 | Risk stratification and the effects of early tips among patients with Child-Pugh B cirrhosis and acute variceal bleeding  
YI  
Guohong HAN, China

SAT-133 | Risk factors for sarcopenia and its impacts on clinical outcome in patients with liver cirrhosis  
YI  
Tao HAN, China
<table>
<thead>
<tr>
<th>SAT-134</th>
<th>The burden of cirrhosis on the Canadian healthcare system: a comparison between alcoholic and non-alcoholic cirrhosis patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>YI</td>
<td>Hassan AZHARI, Canada</td>
</tr>
<tr>
<td>SAT-135</td>
<td>Developed and validated a prognostic nomogram incorporating body compositions for long-term mortality in cirrhosis: a sex-stratified analysis</td>
</tr>
<tr>
<td>YI</td>
<td>Lijun HOU, China</td>
</tr>
<tr>
<td>SAT-136</td>
<td>Collagen type XVIII is associated with platelet count and meld score in patients with trans-jugular intrahepatic portosystemic shunt</td>
</tr>
<tr>
<td>YI</td>
<td>Ida VILLESEN, Denmark</td>
</tr>
<tr>
<td>SAT-137</td>
<td>Terlipressin vs noradrenaline for the treatment of hepatorenal syndrome in patients with acute-on-chronic liver failure: a 5-year retrospective analysis</td>
</tr>
<tr>
<td>YI</td>
<td>Ilaria GIOVO, Italy</td>
</tr>
<tr>
<td>SAT-138</td>
<td>Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites</td>
</tr>
<tr>
<td>YI</td>
<td>Ioannis PETRIDIS, Italy</td>
</tr>
<tr>
<td>SAT-139</td>
<td>Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial</td>
</tr>
<tr>
<td>YI</td>
<td>Jasmohan BAJAJ, United States</td>
</tr>
<tr>
<td>SAT-140</td>
<td>Salivary and stool microbiota differences are related to differences in 90-day hospitalizations in Mexican compared to American patients with cirrhosis</td>
</tr>
<tr>
<td>YI</td>
<td>Jasmohan S BAJAJ, United States</td>
</tr>
<tr>
<td>SAT-141</td>
<td>Validation of encephalapp stroop for minimal hepatic encephalopathy diagnosis in elderly patients with cirrhosis: a multi-center study</td>
</tr>
<tr>
<td>YI</td>
<td>Jasmohan S BAJAJ, United States</td>
</tr>
<tr>
<td>SAT-142</td>
<td>Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial</td>
</tr>
<tr>
<td>YI</td>
<td>Jasmohan S BAJAJ, United States</td>
</tr>
<tr>
<td>SAT-143</td>
<td>Microbiome metabolic therapies reduce microbiota-associated ammonia in ex vivo fecal samples from healthy subjects and patients with minimal hepatic encephalopathy and demonstrate improved tolerability over lactulose in a clinical study</td>
</tr>
<tr>
<td>Top 10%</td>
<td>Jasmohan S BAJAJ, United States</td>
</tr>
</tbody>
</table>
SAT-144

Top 10%

KB174 reduces relative abundance of multidrug resistance (MDR) enterobacteriaceae in fecal samples from patients with cirrhosis in an ex vivo test system
Jasmohan S BAJAJ, United States

SAT-145

YI

Prevalence and clinical significance of portal vein thrombosis in cirrhotic patients with acute decompensation
Yan ZHANG, China

SAT-146

Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis
Juan Carlos GARCIA PAGAN, Spain

SAT-147

Increased risk of perinatal complications in women with cirrhosis: a population-based matched cohort study
Jennifer FLEMMING, Canada

SAT-148

YI

Does the wedge hepatic vein pressure estimates the portal pressure in patients with NASH cirrhosis?
José FERRUSQUÍA-ACOSTA, Spain

SAT-149

Clinical outcomes of sedation during emergency endoscopic band ligation for variceal bleeding: a multicenter retrospective cohort study
Jang Han JUNG, Korea, Rep. of South

SAT-150

Prediction of variceal eradication in decompensated liver cirrhosis: a novel model
Xing WANG, China

SAT-151

YI

A comparison of non-invasive methods for the screening of gastroesophageal varices in patients with compensated cirrhosis
Jonathan NG, Australia

SAT-152

YI

Pre-procedural blood product transfusion and bleeding predictors in patients with chronic liver disease undergoing elective invasive procedures at a tertiary liver unit
Jonathan DURBIN, United Kingdom

SAT-153

YI

Urinary liver fatty-acid binding protein (UL-FABP) predicts acute-on-chronic liver failure (ACLF) and mortality in patients with decompensated cirrhosis
Adria JUANOLA, Spain

SAT-154

Sarcopenia and liver cirrhosis: comparison of the European working group on sarcopenia criteria 2010 and 2019
Julia TRAUB, Austria

SAT-155

Validation of diagnostic usefulness of the spot urine Na/K ratio for replacement of 24-hour urine NA excretion in cirrhotic patients with ascites
Jinwook LEE, Korea, Rep. of South
<table>
<thead>
<tr>
<th>SAT-156</th>
<th>Proton pump inhibitor use is associated with an increased risk of hepatic encephalopathy in a large cohort of patients with cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>YI</td>
<td>Koos DE WIT, Netherlands</td>
</tr>
<tr>
<td>SAT-157</td>
<td>Quality improvement campaign led to higher surveillance rate for hepatocellular carcinoma in primary care clinic</td>
</tr>
<tr>
<td>YI</td>
<td>Kanit BUNNAG, Thailand</td>
</tr>
<tr>
<td>SAT-158</td>
<td>Calf circumference as an easy surrogate marker for the screening of Japanese patients with chronic liver disease</td>
</tr>
<tr>
<td></td>
<td>Kei ENDO, Japan</td>
</tr>
<tr>
<td>SAT-159</td>
<td>A novel method: can stapedial acoustic reflex have a role in the diagnosis of minimally hepatic encephalopathy?</td>
</tr>
<tr>
<td></td>
<td>Bugra Tolga KONDUK, Turkey</td>
</tr>
<tr>
<td>SAT-160</td>
<td>Real-world treatment patterns and outcomes in hepatorenal syndrome: results from a retrospective chart review study in the United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Katharina VERLEGER, Germany</td>
</tr>
<tr>
<td>SAT-161</td>
<td>Validation of HCC risk calculator in a UK centre and implications of thresholds for screening</td>
</tr>
<tr>
<td>YI</td>
<td>Laura ATKINS, United Kingdom</td>
</tr>
<tr>
<td>SAT-162</td>
<td>Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease in patients with portal hypertension</td>
</tr>
<tr>
<td></td>
<td>Laure ELKRIEF, France</td>
</tr>
<tr>
<td>SAT-163</td>
<td>The utilisation of palliative care in patients with end-stage liver disease</td>
</tr>
<tr>
<td></td>
<td>Lauren ANDERSSON, Australia</td>
</tr>
<tr>
<td>SAT-164</td>
<td>Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicenter study</td>
</tr>
<tr>
<td>YI</td>
<td>Beiling LI, China</td>
</tr>
<tr>
<td>SAT-165</td>
<td>Continuous infusion of terlipressin for hepatorenal syndrome therapy: evaluation of efficacy and safety in real-life setting</td>
</tr>
<tr>
<td></td>
<td>Fernanda S. LINHARES, Brazil</td>
</tr>
<tr>
<td>SAT-166</td>
<td>Frailty assessed by the liver frailty index (LFI) predicts poor health-related quality of life (QOL) in patients hospitalised with liver cirrhosis</td>
</tr>
<tr>
<td></td>
<td>Lubomir SKLADANY, Slovakia</td>
</tr>
<tr>
<td>SAT-167</td>
<td>A novel score to predict mortality after transjugular intrahepatic portosystemic shunt in patients with renal insufficiency</td>
</tr>
<tr>
<td>YI</td>
<td>Luisa FUERSCHUß, Austria</td>
</tr>
</tbody>
</table>
| SAT-168 | YI | Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension  
Lukas HARTL, Austria |
| SAT-169 | YI | Prospective study of magnetic resonance spectroscopy identifies specific metabolic changes in covert hepatic encephalopathy  
Mark DANTA, Australia |
| SAT-170 | YI | Bacterial infections correlate with poor prognosis in cirrhosis independently from liver disease severity  
Maria Corina PLAZ TORRES, Italy |
| SAT-171 | YI | Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment  
Manuel TUFONI, Italy |
| SAT-172 | YI | Subtle changes of serum creatinine and C-reactive protein during the index hospitalization predict early readmission in patients with decompensated cirrhosis  
Manuel TUFONI, Italy |
| SAT-173 | YI | Value of Hitachi shear wave elastography (SWE) for exclusion of esophageal varices in patients with compensated advanced liver disease  
Marcel RAZPOTNIK, Austria |
| SAT-174 | YI | Factors associated with the presence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria  
Marcel RAZPOTNIK, Austria |
| SAT-175 | YI | Prevalence of cirrhotic cardiomyopathy according to the old and new diagnostic criteria  
Marcel RAZPOTNIK, Austria |
| SAT-176 | YI | Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection  
Marco SENZOLO, Italy |
| SAT-177 | YI | Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis  
Marcus MÜCKE, Germany |
| SAT-178 | YI | Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis  
Mario ROMERO CRISTÓBAL, Spain |
| SAT-179 | YI | Zinc deficiency in cirrhosis predicts hepatic decompensation and mortality  
Marta HERNÁNDEZ CONDE, Spain |
Cirrhosis and its complications: Clinical (Cont.)

SAT-180  A nomogram as an indirect method to identify sarcopenia in patients with liver cirrhosis
YI Marta HERNÁNDEZ CONDE, Spain

SAT-181  Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response
Top 10%
YI Mathias JACHS, Austria

SAT-182  Protective effects of statin therapy in liver cirrhosis are limited by the common SLC01B1 variant
YI Melissa MERKEL, Germany

SAT-183  Shifting the focus of liver cirrhosis to prevention with the help of the SEAL program
YI Nagel MICHAEL, Germany

SAT-184  Algorithm to predict development of sarcopenia after transjugular intrahepatic portosystemic shunt in decompensated cirrhosis
YI Michael PRAKTIKNJO, Germany

SAT-185  In-hospital falls and fall-related injury in patients with liver-cirrhosis – malnutrition matters
YI Nada ABEDIN, Germany

SAT-186  Body composition parameters predict outcomes of acute kidney injury in patients with cirrhosis
YI Naomi LANGE, Switzerland

SAT-187  Usefulness of handgrip as a non-invasive tool to predict the outcome of patients with cirrhosis. A prospective study
YI Nesrine AMARI, Belgium

SAT-188  Longitudinal assessment of progressive decrease in platelet counts as a surrogate marker of liver fibrosis and portal hypertension
YI Neta GOTLIEB, Israel

SAT-189  Factor VIII/protein C and not ADAMTS13/VWF: Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score
YI Niccolò BITTO, Italy

SAT-190  Baveno VI criteria as a prognosis index for clinical complications in patients with cirrhosis
YI Nicolas ASESIO, France

SAT-191  Systemic and splanchnic hemodynamic features of patients with porto-sinusoidal disease as compared with cirrhosis
YI Nicolas DRILHON, France
<table>
<thead>
<tr>
<th>SAT-192</th>
<th>YI</th>
<th>Circulating microfibrillar-associated protein 4 is an independent predictor of transplant-free survival in compensated and decompensated cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nikolaj TORP, Denmark</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-193</th>
<th>YI</th>
<th>Tunnelated peritoneal catheter versus large volume paracentesis for refractory ascites in cirrhosis: a randomized controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nina KIMER, Denmark</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-194</th>
<th>YI</th>
<th>Different prognostic role of liver stiffness according to type of liver-related outcomes and etiology of liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joo HYUN OH, Korea, Rep. of South</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-195</th>
<th>YI</th>
<th>Prognostic value of nutritional status in patients with advanced chronic liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovidiu CALAPOD, Romania</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-196</th>
<th>YI</th>
<th>Efficacy of transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome – chronic kidney disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paola PONZO, Italy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-197</th>
<th>YI</th>
<th>The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 10%</td>
<td>Paul CALES, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-198</th>
<th>YI</th>
<th>Direct acting oral anticoagulant use in cirrhosis patients: real-world bleeding and discontinuation rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick NORTHUP, United States</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-199</th>
<th>YI</th>
<th>Fluency is associated with hepatic encephalopathy using a common and easy language task</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patricia BLOOM, United States</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-200</th>
<th>YI</th>
<th>A smartphone app is feasible for outpatient ascites management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patricia BLOOM, United States</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-201</th>
<th>YI</th>
<th>Comparative study between spontaneous fungal peritonitis and spontaneous bacterial peritonitis in patients with end stage liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohamed ELNADRY, Egypt</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-202</th>
<th>YI</th>
<th>Association between proton pump inhibitor use in hospitalized cirrhotics and development of hepatic encephalopathy and spontaneous bacterial peritonitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pearl TAN, Canada</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-203</th>
<th>YI</th>
<th>Sarcopenia increases the risk of post transjugular intrahepatic portosystemic shunt hepatic encephalopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puja Bhatia KAPOOR, India</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-204</th>
<th>YI</th>
<th>Distinct features of the portalhypertensive syndrome in patients with advanced chronic liver disease due to non-alcoholic steatohepatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rafael PATERNOSTRO, Austria</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Cirrhosis and its complications: Clinical (Cont.)

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT-205</td>
<td>A novel, smartphone-based scleral image capture technique accurately determines serum bilirubin level and can be used for home-based monitoring of patients discharged from hospital, after an episode of acute decompensation</td>
<td>Rahul KUMAR, <strong>Singapore</strong></td>
</tr>
<tr>
<td>SAT-206</td>
<td>Degree of portal and systemic hemodynamic alterations predict repeated episodes of acute kidney injury and chronic kidney disease in patients with cirrhosis</td>
<td>Rakhi MAIWALL, <strong>India</strong></td>
</tr>
<tr>
<td>SAT-207</td>
<td>Long-term 20% albumin administration normalizes the plasma albumin binding capacity in patients with decompensated cirrhosis</td>
<td>Raquel HORRILLO, <strong>Spain</strong></td>
</tr>
<tr>
<td>SAT-208</td>
<td>Aminoglycosides and metronidazole for the treatment of hepatic encephalopathy in adults with cirrhosis</td>
<td>Rebecca JAYARAJ, <strong>United Kingdom</strong></td>
</tr>
<tr>
<td>SAT-209</td>
<td>Spleen stiffness and liver stiffness for predicting high risk varices in patients with compensated liver cirrhosis</td>
<td>Renata FOFIU, <strong>Romania</strong></td>
</tr>
<tr>
<td>SAT-210</td>
<td>Natural history and outcomes of patients with liver cirrhosis complicated by hepatic hydrothorax</td>
<td>Sarah ROMERO, <strong>Australia</strong></td>
</tr>
<tr>
<td>SAT-211</td>
<td>Acute or recent portal vein thrombosis in cirrhosis predicts a hidden or upcoming diagnosis of hepatocellular carcinoma</td>
<td>Rifaat SAFADI, <strong>Israel</strong></td>
</tr>
<tr>
<td>SAT-212</td>
<td>The association of sarcopenia with myostatin, follistatin and irisin levels in cirrhotic patients: a multicenter cross-sectional study</td>
<td>Salih BOGA, <strong>Turkey</strong></td>
</tr>
<tr>
<td>SAT-213</td>
<td>A prospective evaluation of the Bristol prognostic score: poor sensitivity and specificity in a non-Bristol cohort</td>
<td>Sarah BOWERS, <strong>United Kingdom</strong></td>
</tr>
<tr>
<td>SAT-214</td>
<td>Blood and ascites pharmacokinetics of meropenem in patients with nosocomial spontaneous bacterial peritonitis and decompensated liver cirrhosis</td>
<td>Marie SCHULTALBERS, <strong>Germany</strong></td>
</tr>
<tr>
<td>SAT-215</td>
<td>Diagnostic performance of contrast-enhanced CT for the diagnosis of portosinusoidal vascular disease: a case-control study</td>
<td>Shantha VALAINATHAN, <strong>France</strong></td>
</tr>
<tr>
<td>SAT-216</td>
<td>Broad defect in energy metabolism drives immune dysfunction in cirrhosis and cirrhosis associated sepsis</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Shiv Kumar SARIN, India</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-217</th>
<th>A nurse-led albumin infusion service reduces the need for therapeutic paracentesis in the outpatient day procedure setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siddharth SOOD, Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-218</th>
<th>Increased levels of soluble mannose receptor are associated with poor outcome in cirrhosis: results from a 2-year longitudinal study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signe WIESE, Denmark</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-219</th>
<th>MRI-derived myocardial extracellular volume is closely associated with markers of collagen formation in cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signe WIESE, Denmark</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-220</th>
<th>FIB-4 and APRI-scores predict survival in patients with transjugular intrahepatic portosystemic stent shunts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simone Anna KEIMBURG, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-221</th>
<th>Real-world effectiveness of piperacillin/tazobactam-based therapies for spontaneous bacterial peritonitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stefanie QUICKERT, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-222</th>
<th>Etiology and diagnosis of ascites: contemporary cohort study in a secondary care setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohsan SUBHANI, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-223</th>
<th>Sarcopenia is not associated with poor outcomes after transjugular intrahepatic portosystemic shunt insertion for refractory ascites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas TRANAH, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-224</th>
<th>Impact of acute decompensation on prognosis in patients with hepatocellular carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takayuki KONDO, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-225</th>
<th>Serum cholinesterase is an independent predictor of hepatic encephalopathy, acute-on-chronic liver failure and mortality after transjugular intrahepatic portosystemic shunt insertion in patients with liver cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lena THÖLE, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-226</th>
<th>Transjugular intrahepatic portosystemic shunt in cirrhotic elderly patients with refractory ascites – to do or not to do?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lena THÖLE, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-227</th>
<th>Four weeks of aerobic and resistance training improves frailty in patients with liver cirrhosis-liver habilitation (Li-Hab) center outcome data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varsha SHASTHRY, India</td>
<td></td>
</tr>
</tbody>
</table>
### Cirrhosis and its complications: Clinical (Cont.)

| SAT-228 | Effect of rivaroxaban on hypercoagulopathy risk factors in liver cirrhosis patients with nonvalvular atrial fibrillation  
Nataliya VIRSTYUK, Ukraine |
|---|---|
| SAT-229 | Between rapid diagnosis and prediction of survival in minimal hepatic encephalopathy  
Vlad TARU, Romania |
| SAT-230 | Efficacy and safety of rivaroxaban in portal vein thrombosis in patients with liver decompensated cirrhosis  
Min WANG, China |
| SAT-231 | Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomized controlled trials  
Wayne BAI, Canada |
| SAT-232 | The survival effect of sarcopenia in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt: a single-center review  
Wei ZHANG, United States |
| SAT-233 | Comparison of MELD, MELD-Na and MELD-sarcopenia in predicting mortality in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt  
Wei ZHANG, United States |
| SAT-234 | Empirical carbapenem versus third-generation cephalosporin treatment for spontaneous bacterial peritonitis: a multicenter study  
Sun Woong KIM, Korea, Rep. of South |
| SAT-235 | Early albumin improves survival in cirrhotic patients on diuretic therapy who develop significant acute kidney injury: real-world evidence in the United States  
W. Ray KIM, United States |
| SAT-236 | Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomised controlled trials  
Wayne BAI, Canada |
| SAT-237 | Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts  
Isabelle OLLIVIER-HOURMAND, France |
| SAT-238 | Development and validation of a risk scoring system for screening high-risk varices  
Yuling YAN, China |
SAT-239 Effect of rifaximin or norfloxacin on hepatic venous pressure gradient in patients with cirrhosis: a systematic review and meta-analysis
Yuly Paulin MENDOZA, Switzerland

SAT-240 Repeated versus single treatment of esophageal variceal ligation after esophageal variceal bleeding
Young Youn CHO, Korea, Rep. of South
Non-invasive assessment of liver disease except NAFLD

SAT-241 Serum gamma-glutamyl transpeptidase as a simple and useful indicator for predicting significant fibrosis in patients with chronic hepatitis B
Jian WANG, China

SAT-242 The predictive value of MRI-based markers of liver disease on clinical outcomes in patients with cirrhosis
Christina LEVICK, United Kingdom

SAT-243 Elast q – 2D shear wave liver elastography correlates well with vibration controlled transient elastography in patients with different etiologies of chronic liver disease
David JM BAUER, Austria

SAT-244 Liver function assessment by 13C-methacetin test before and after placement of a transjugular portosystemic shunt: a prospective pilot study
David SEMELA, Switzerland

SAT-245 A novel diagnostic model using liver stiffness measurement and platelet count that accurately predicts the presence of portal hypertensive gastropathy in patients with cirrhosis
David LEE, United States

SAT-246 Endothelin-1 level at first presentation of hematemesis as indicator of recurrent bleeding within 5 days
Ahmed IBRAHIM, Egypt

SAT-247 Spleen acoustic radiation force impulse (ARFI) elastography predicts decompensation in patients with liver cirrhosis
Elba LLOP, Spain

SAT-248 Automatic high-risk fibrosis score prediction using computed tomography imaging
Elton REXHEPAJ, France

SAT-249 The variscreen algorithm using successively platelets, liver stiffness and INR improves and secures the screening of esophageal varices needing treatment
Federico RAVAIOLI, Italy

SAT-250 Breath-based monitoring of liver metabolism using exogenous volatile organic compounds – towards improved detection
Giuseppe FERRANDINO, United Kingdom

SAT-251 Intelligent liver function testing in action: a one-year review
Iain MACPHERSON, United Kingdom

SAT-252 ALT level in the diagnosis of chronic liver disease and advanced fibrosis
Iain MACPHERSON, United Kingdom
SAT-253 Multiparametric magnetic resonance imaging of liver and spleen is a reliable non-invasive predictor of clinically relevant hepatic venous pressure gradient thresholds and predicts failure of primary prophylaxis for variceal bleeding
Pik Eu Jason CHANG, Singapore

SAT-254 Serum keratin 19 (CYFRA 21-1) links ductal reaction with portal hypertension and outcome of advanced liver disease
Karim HAMESCH, Germany

SAT-255 Relationship between Laennec histological subclassification of cirrhosis and clinical stage, grade of portal hypertension and liver stiffness
Castera LAURENT, France

SAT-256 Evolving imaging in biliary disease: quantitative magnetic resonance cholangiopancreatography findings correlate with the modified Amsterdam score in patients with primary sclerosing cholangitis
Lin CHENG, United Kingdom

SAT-257 The tissue balance of liver fibrosis: identification of fibrosis resolution biomarkers and demonstration of increased tissue formation and degradation
Morten KARSDAL, Denmark

SAT-258 Systemic light chain AL with cardiac and liver involvement can be predicted by transient elastography
Speranta IACOB, Romania

SAT-259 Validating the Swansea criteria in a single-centre study with cohorts of patients with acute fatty liver of pregnancy and haemolysis, elevated liver enzymes and low platelets syndrome: is it time to modify the criteria?
Mussarat RAHIM, United Kingdom

SAT-260 Diagnostic performance of a new algorithm combining simple, non-invasive and inexpensive tests for predicting the presence of liver severe fibrosis and cirrhosis in patients with chronic hepatitis B
Jean NANA, France

SAT-261 Heat shock protein 47 is associated with fibrogenesis in alcoholic liver disease
Natasja GUDMANN, Denmark

SAT-262 Dysregulation of wound healing status and activity is associated with fibrosis and inflammation in early alcohol associated liver disease
Natasja GUDMANN, Denmark

SAT-263 Liver stiffness measurement using acoustic radiation force impulse elastography is a good predictor of hepatic decompensation in pregnant cirrhotic patients
Omar ELSHAARAWY, Germany
| SAT-264 | Reliability criteria will discriminate accuracy of blood liver fibrosis tests  
Paul CALES, France |
| SAT-265 | The usual blood liver markers provide a performant fibrosis test thanks to artificial intelligence  
Paul CALES, France |
| SAT-266 | A gut microbiota and liver co-metabolized biomarker to monitor liver cirrhosis progression with different etiologies in humans  
Jia-bo WANG, China |
| SAT-267 | Serum metabolic biomarkers for the differential diagnosis of distal cholangiocarcinoma and pancreas ductal adenocarcinoma  
Rocio IR MACIAS, Spain |
| SAT-268 | Proteomic identification of serum factors that correlate with reduction of HVPG following curative treatment for hepatitis C virus infection  
Shola RICHARDS, Switzerland |
| SAT-269 | Genome-wide association study (GWAS) of circulating liver enzymes identifies >300 novel variants with distinct tissue expression patterns and gene set enrichment  
Vincent CHEN, United States |
| SAT-270 | Virtual touch quantification using acoustic radiation force impulse technology versus transient elastography for the non-invasive assessment of liver fibrosis in patients with chronic hepatitis B or C using liver biopsy as gold standard  
Victor BALDEA, Romania |
| SAT-271 | Quantitative magnetic resonance cholangiopancreatography imaging in patients with primary sclerosing cholangitis – feasibility and preliminary analysis for prediction of clinical outcomes  
Vijay ARE, United States |
| SAT-272 | Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease  
Wenyi GU, Germany |
## Public Health

**SAT-273**  
Progress in hepatitis C testing as a part of the hepatitis C elimination program in Georgia  
Amiran GAMKRELIDZE, Georgia

**SAT-274**  
Evaluation of hepatitis B virus (HBV) epidemiology, vaccine impact and treatment eligibility: a census-based community serological survey in Blantyre, Malawi  
Alexander STOCKDALE, United Kingdom

**SAT-275**  
HCV in addiction care: different epidemiology, excellent treatment results  
Andrea AFONSO DÍAZ, Spain

**SAT-276**  
Modelling the cost of hepatitis C virus transmission in Pakistan  
Aaron G. LIM, United Kingdom

**SAT-277**  
The best strategy for retrieval of hepatitis C patients lost to follow up: randomized clinical trial  
Alberto HERNÁNDEZ BUSTABAD, Spain

**SAT-278**  
Is hospital admission an ideal condition for HCV screening? A survey from the Venetian area (north-east of Italy)  
Alessandro CAROLI, Italy

**SAT-279**  
A novel microsimulation model of chronic hepatitis B (HBV): validation of HBV viral dynamics and cumulative incidence of hepatocellular carcinoma  
Amir MOHAREB, United States

**SAT-280**  
Rapid test & treat programme successfully facilitating hepatitis C micro-elimination in a women’s prison  
Andrew USTIANOWSKI, United Kingdom

**SAT-281**  
Role of immigration in chronic HBV and HCV infection in our environment. Origin and characteristics of the patients  
Ángela SUÁREZ-NOYA, Spain

**SAT-282**  
From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations  
Adam PALAYEW, Canada

**SAT-283**  
Insights into hepatitis B prevalence and vaccination in the Northern Territory, Australia: a longitudinal study  
Ashleigh QAMA, Australia

**SAT-284**  
Treatment cascade of hepatitis C in a non-university hospital setting, that uses a hub-and-spoke model, in southern Switzerland  
Benedetta TERZIROLI, Switzerland
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT-285</td>
<td>A nurse led hepatitis C model of care in primary care and community services in Melbourne, Australia</td>
<td>Brendan HARNEY, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>SAT-286</td>
<td>Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy?</td>
<td>Peter BUGGISCH, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>SAT-287</td>
<td>Public health implications of stigma and discrimination towards people who inject drugs in Australia</td>
<td>Carla TRELOAR, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>SAT-288</td>
<td>Description of HBV-infected persons presenting late to specialist care in 10 Spanish centres: A retrospective registry review</td>
<td>Camila PICCHIO, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>SAT-289</td>
<td>The prevalence of hepatitis C amongst people who use performance and image enhancing drugs – a systematic review</td>
<td>Charlotte COOK, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>SAT-290</td>
<td>Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study)</td>
<td>Clotilde LEPERS, France</td>
<td>France</td>
</tr>
<tr>
<td>SAT-291</td>
<td>Hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington, USA</td>
<td>Maria CORCORRAN, United States</td>
<td>United States</td>
</tr>
<tr>
<td>SAT-292</td>
<td>Dried blood spots are a useful tool for hepatitis A screening in the pandemic areas with medical resource-limited condition</td>
<td>Chikako YAMAMOTO, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>SAT-293</td>
<td>Viral hepatitis in Belgian prisons: a first-time multicenter prevalence study</td>
<td>Dana BUSSCHOTS, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>SAT-294</td>
<td>Limburg is the first Belgian province on track for hepatitis C virus eradication in the most important group at risk: People who use drugs</td>
<td>Dana BUSSCHOTS, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>SAT-295</td>
<td>Early treatment of hepatitis C virus improves health outcomes and yields cost-savings: A modeling study in Argentina</td>
<td>Diego KANEVSKY, Argentina</td>
<td>Argentina</td>
</tr>
<tr>
<td>SAT-296</td>
<td>Tailored message interventions promote the number of participants in viral hepatitis screening for Japanese workers – multicenter trial of 1,127,596 general checkup applicants</td>
<td>Masaaki KORENAGA, Japan</td>
<td>Japan</td>
</tr>
</tbody>
</table>
| SAT-297 | Data from a large, public sector hepatitis C program in Punjab, India  
Gagandeep Singh GROVER, India |
| SAT-298 | Implementation of electronic monitoring and evaluation system for hepatitis C in Punjab, India  
Gagandeep Singh GROVER, India |
| SAT-299 | Hepatitis C elimination in hemodialysis population of a county – an innovative collaborative care model in Taiwan  
Tsung-Hui HU, Taiwan |
| SAT-300 | Unusual occurrence of hepatitis B infection in Upper Egypt  
Mahmoud S. ELZALABANY, Saudi Arabia |
| SAT-301 | A novel test and treat hepatitis C micro-elimination project among underserved communities in Islamabad, Pakistan  
Huma QURESHI, United States |
| SAT-302 | Classifying people living with hepatitis C virus using a population-level latent class analysis to inform optimal integration of health services  
Emilia CLEMENTI, Canada |
| SAT-303 | Comparison of risk factors for cirrhosis and hepatocellular carcinoma: a large prospective study of UK women  
Emily HE, Australia |
| SAT-304 | Hepatitis C virus testing and treatment in children: results from a global paediatric policy review  
Farihah MALIK, United Kingdom |
| SAT-305 | HCV screening strategies targeting prisoners and immigrants from endemic countries: are they cost-effective?  
Francesco MANCA, United Kingdom |
| SAT-306 | Relationship between metabolic syndrome and ALT level with normal range in the general population  
Won SOHN, Korea, Rep. of South |
| SAT-307 | Are UK NAFLD/NASH referral pathways ready to tackle the emerging epidemic? A rapid systematic public health evidence synthesis  
Hannah PHEASANT-OLDFIELD, United Kingdom |
| SAT-308 | The case for testing and treating all HBV patients  
Homie RAZAVI, United States |
| SAT-309 | Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study  
Heather VALERIO, Australia |
SAT-310  YI  Searching for patients lost in the system with chronic hepatitis C in a tertiary hospital: a problem still to be solved
Irene ANDALUZ, Spain

SAT-311  YI  Economic evaluation of the hepatitis C virus screening and treatment program in Georgia
Irina TSKHOMELIDZE, Georgia

SAT-312  Top 10%  YI  Assessing the level of detection of hepatitis C virus RNA in individuals with detectable viremia following treatment with direct acting antivirals: and opportunity for new testing technologies
Jake MORGAN, United States

SAT-313  YI  A population-based intervention to improve care cascade of patients with hepatitis C infection
John D SCOTT, United States

SAT-314  Top 10%  YI  Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission
Jeffrey LAZARUS, Spain

SAT-315  YI  Validation of a novel rapid point-of-care ALT test in patients with viral hepatitis
Jessica HOWELL, Australia

SAT-316  YI  Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic hepatitis C virus in low- and middle-income settings
Josephine WALKER, United Kingdom

SAT-317  YI  Cross-sectional associations between suspected non-alcoholic fatty liver disease, diabetes, and hypertension in hispanic adults living in the San Juan metropolitan area
Josheili LLAVONA-ORTIZ, Puerto Rico

SAT-318  YI  HCV care cascade of PWID enrolled in methadone substitution treatment program in Georgia – is this the first group of population in which hepatitis C will be eliminated in Georgia?
Ketevan STVILIA, Georgia

SAT-319  YI  Screening and linkage to care of prisoners with HCV infection: the resist-HCV project
Lorenza DI MARCO, Italy

SAT-320  YI  Frequency of prenatal hepatitis C screening and diagnosis in British Columbia, 2008-2018
Margo PEARCE, Canada
| SAT-321 YI | Re-capturing a lost population – the benefits of a nurse-delivered HCV community cirrhosis clinic  
Maryam NOEMAN, United Kingdom |
| SAT-322 | Strengthening HCV elimination policies through community-based research  
Maria DONATELLI KLINGER, France |
| SAT-323 | Preliminary results of the prevalence of non-alcoholic fatty liver disease among the greater Toronto area population  
Magdy ELKHASHAB, Canada |
| SAT-324 | Suboptimal linkage to care after identification of serum hepatitis B surface antigen-positive individuals in territory-wide screening: a need for educational and public health policies  
KL KO, Hong Kong |
| SAT-325 Top 10% YI | Changes in the hepatitis C cascade of care among individuals attending primary and community health services before and after the introduction of direct-acting antiviral treatment in Australia  
Michael TRAEGER, Australia |
| SAT-326 | Microelimination of chronic hepatitis C in Romania – another pathway to achieve national elimination goals by HepC ALERT project  
Speranta IACOB, Romania |
| SAT-327 | What is required for achieving HCV elimination in Singapore? A modeling study  
Natasha MARTIN, United States |
| SAT-328 | Hepatitis C virus screening of people with severe mental illness: a cost-effectiveness analysis  
Nathalie VERNAZ, Switzerland |
| SAT-329 | Incidence of HCV infection among gbMSM in British Columbia, Canada: a population-based cohort study  
Naveed JANJUA, Canada |
| SAT-330 | An OST (opiate substitution therapy)-based hepatology service facility (OHSF) with access to chronic hepatitis C treatment: the example of an one stop shop as a practical step towards HCV elimination in patients who use drugs (PWUD)  
Nikolaos PAPADOPOULOS, Greece |
| SAT-331 | Recent decline in hepatocellular carcinoma rates in the United States  
Thomas OBRIEN, United States |
| SAT-332 | HCV screening and linkage to care of homeless people in a major European city. Data from a mobile screening unit (MSU)  
Pablo RYAN, Spain |
Public Health (Cont.)

SAT-333  Development of a supportive needs assessment tool for cirrhosis (SNAC)
Patricia VALERY, Australia

SAT-334  Inequities in presentation and outcomes for indigenous Australians hospitalised for cirrhosis
Patricia VALERY, Australia

SAT-335  Leveraging direct-to-patient messaging: electronic record assimilation and subsequent eradication of hepatitis C (Erase-C)
Paul KWO, United States

SAT-336  Catalytic funding of viral hepatitis elimination program in Uzbekistan
Rick DUNN, United States

SAT-337  Meta-analysis: accuracy of the enhanced liver fibrosis (ELF) test in detection of advanced fibrosis or cirrhosis
Richard PARKER, United Kingdom

SAT-338  Risk factors for liver disease cluster geographically: precision public health analysis of a UK city
Richard PARKER, United Kingdom

SAT-339  Updated estimate for prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin
Robert WONG, United States

SAT-340  Improving access to care for serologically positive hepatitis C blood donors in private sector
Sabeen SHAH, Pakistan

SAT-341  Comparison of costs of different HCV screening and linkage to care interventions across Europe
Sandra BIVEGETE, United Kingdom

SAT-342  High patient acceptability for a hepatitis C mobile outreach service targeting ‘vulnerable’ homeless communities – an important component for elimination?
Sarah MONTAGUE, United Kingdom

SAT-343  Health and economic burden due to alcohol related liver diseases in New Delhi, India: a Markov probabilistic modelling approach
Shiv Kumar SARIN, India

SAT-344  No restrictions should be placed on future treatment for patients who discontinue DAAAs on their first or second attempt. A real world experience from the TraP HepC initiative in Iceland
Sigurdur OLAFSSON, Iceland
SAT-345  National survey among people who use drugs (PWUD) on opioid substitution treatment (OST) on their knowledge of hepatitis C virus (HCV) infection and barriers for treatment in Bulgaria
Marieta SIMONOVA, Bulgaria

SAT-346  Demonstration of the feasibility of two innovative models of HCV testing and treatment in two unique populations in Punjab and Delhi, India-head-start project, India
Sonjelle SHILTON, Switzerland

SAT-347  Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US
Pimsiri SRIPONGPUN, United States

SAT-348  From emergency department automated hepatitis B & C screening to care and cure in a primary care practice
Su WANG, United States

SAT-349  Prevention of liver diseases through universal coverage with hepatitis B vaccination in India
Umesh KAPIL, India

SAT-350  Deleterious impact of advanced non-alcoholic steatohepatitis on multiple patient-relevant outcomes: an international, cross-sectional, real-world study
Victoria HIGGINS, United Kingdom

SAT-351  Factors associated with failure to link people who inject drugs to HCV care and treatment: results from a community-based seek-test-treat program in Athens, Greece (ARISTOTLE HCV-HIV)
Vana SYPSA, Greece

SAT-352  Clinical and economic consequences of antiviral treatment for hepatitis C chronic infection in Europe: analysis of England, Italy, Romania and Spain data
Xhimi TATA, Albania

SAT-353  The head-start project: introduction of rapid diagnostic tests for hepatitis C screening in primary healthcare sites as a first step towards decentralizing hepatitis C care in Malaysia
Xiaohui SEM, Switzerland

SAT-354  Enhancing the hepatitis B care cascade in Australia using a country-based testing program targeting new migrants: a cost-effectiveness model
Yinzong XIAO, Australia

SAT-355  Cost-effectiveness of mass screening for HCV in an Irish prison
Zoe WARD, United Kingdom
**Viral Hepatitis A, B, C, D, E: Virology**

**SAT-356**  Hormone replacement therapy is associated with reduced liver cirrhosis risk and improved survival in treatment-naive hepatitis B- and/or C- infected postmenopausal women: a nationwide long-term population-based cohort study  
Yuan-Tsung TSENG, Taiwan

**SAT-357**  Hepatitis B virus core protein variants observed in a first-in-human placebo-controlled study of a core protein inhibitor  
Amy C.H. LEE, United States

**SAT-358**  Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection  
Avista WAHID, Germany

**SAT-359**  Establishment of human induced pluripotent stem cell-derived hepatocyte-like cells permissive for serum-originated hepatitis B virus infection and allowing for covalently closed circular DNA inhibitor drug screening  
Chau-Ting YEH, Taiwan

**SAT-360**  Farnesoid X receptor alpha ligands inhibit hepatitis delta virus replication in vitro independently of their effect on hepatitis B virus  
Christophe RAMIÈRE, France

**SAT-361**  Analysis of hepatitis B virus quasispecies in circulating viral DNA and RNA: are genotype and complexity different?  
Cristina GODOY CRUZ, Spain

**SAT-362**  Mitochondrial DNA damage and mitochondrial dysfunction in patients with chronic hepatitis B  
Dimitri LOUREIRO, France

**SAT-363**  Differential HBV RNA and quantitative HBsAg kinetics between HBeAg(+) and HBeAg(-) patients with chronic hepatitis B on nucleos(t)ide analogues (NA)  
Daryl LAU, United States

**SAT-364**  Role of hepatitis C virus core antigen in HIV-HCV co-infected and chronic kidney disease patients on hemodialysis: expanding the HCV horizon of diagnostics  
Ekta GUPTA, India

**SAT-365**  Characterization of acute hepatitis C virus infection and transmission clusters by next-generation sequencing among people who inject drugs in Catalonia  
Elisa MARTRÓ, Spain
<table>
<thead>
<tr>
<th>SAT-366</th>
<th>Mathematical modeling of early hepatitis D virus kinetics in transgenic-hNTCP mice</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Harel DAHARI, United States</td>
</tr>
<tr>
<td>SAT-367</td>
<td>Prospective study of viral hepatitis in pregnancy and its vertical transmission in the northeast region of India</td>
</tr>
<tr>
<td></td>
<td>Harpreet KAUR, India</td>
</tr>
<tr>
<td>SAT-368</td>
<td>Usefulness of dried plasma spots using a plasma separation card for serological diagnosis of chronic hepatitis B and C and reflex viral load testing</td>
</tr>
<tr>
<td></td>
<td>Joan MARTINEZ, Spain</td>
</tr>
<tr>
<td>SAT-369</td>
<td>Validity of a point-of-care viral load kit for hepatitis B in a low-income setting</td>
</tr>
<tr>
<td></td>
<td>Asgeir JOHANNESSEN, Norway</td>
</tr>
<tr>
<td>SAT-370</td>
<td>Antisense oligonucleosides with immunomodulatory SB 9000 for chronic hepatitis B therapy</td>
</tr>
<tr>
<td></td>
<td>Radhakrishnan IYER, United States</td>
</tr>
<tr>
<td>SAT-371</td>
<td>Top 10% Mechanism of action studies of inarigivir, a novel immunomodulator against chronic hepatitis B</td>
</tr>
<tr>
<td></td>
<td>Radhakrishnan IYER, United States</td>
</tr>
<tr>
<td>SAT-372</td>
<td>A systematic assessment of acute viral hepatitis and chronic liver diseases in northeast India with special reference to strengthening of laboratories in the region</td>
</tr>
<tr>
<td></td>
<td>Vijaya Kumar KARRA, India</td>
</tr>
<tr>
<td>SAT-373</td>
<td>From in vivo to in vitro: ex vivo studies using primary human hepatocytes from chronically diseased liver-humanized FRG® KO mice</td>
</tr>
<tr>
<td></td>
<td>Lander FOQUET, United States</td>
</tr>
<tr>
<td>SAT-374</td>
<td>The head-start project Georgia: a three-armed, cluster, non-randomised trial of the effectiveness of two novel models of HCV confirmatory testing in harm reduction sites (HRS) in Georgia</td>
</tr>
<tr>
<td></td>
<td>Maia JAPARIDZE, Georgia</td>
</tr>
<tr>
<td>SAT-375</td>
<td>HBeAg seroconversion during treatment with peginterferon-alfa2a (PEG-IFN) is preceded by selection of hepatitis B virus basal core promoter and pre-core variants which are associated with decreased HBV replication</td>
</tr>
<tr>
<td></td>
<td>Maria PFEFFERKORN, Germany</td>
</tr>
<tr>
<td>SAT-376</td>
<td>Targeting hepatitis B virus with CRISPR/Cas9 approach</td>
</tr>
<tr>
<td></td>
<td>Maria Guadalupe MARTINEZ, France</td>
</tr>
<tr>
<td>SAT-377</td>
<td>Evolution of full-length hepatitis B virus quasispecies in HBeAg-negative patients during spontaneous viral reactivation and remission</td>
</tr>
<tr>
<td></td>
<td>Guan Huei LEE, Singapore</td>
</tr>
</tbody>
</table>
**Viral Hepatitis A, B, C, D, E: Virology (Cont.)**

**SAT-378** The correlations between HBV markers and HBV cccDNA in the patients during Na treatment  
Matsui TAKESHI, Japan

**SAT-379** Delineating HBV transcripts from integrated viral DNA using target enrichment and long read sequencing  
Nicholas VAN BUUREN, United States

**SAT-380** Prospective study of hepatitis B virus infection and its genotypes in the north-eastern India region  
Premashis KAR, India

**SAT-381** Hepatitis D virus entry, replication and assembly in stem cell-derived hepatocytes  
Bingqian QU, Germany

**SAT-382** Crispr/cas9-tailored hepatitis B-x protein knockdown inhibits cellular hyperplasia, invasion and tumorigenicity of HBV-infected hepatoma cells.  
Preety RAWAL, India

**SAT-383** Cryptic HBV viremia in anti-HBC positive/HBsAg negative patients with HIV infection is frequently revealed by applying an ultrasensitive droplet digital PCR assay  
Romina SALPINI, Italy

**SAT-384** Osteopontin drives HBV replication and HBV-driven fibrogenesis and represents a novel therapeutic target to achieve functional cure in chronic hepatitis B  
Sandra PHILLIPS, United Kingdom

**SAT-385** Toll-like receptor 7 and 8 agonists as potent inhibitors of hepatitis delta virus infection  
Sandra WESTHAUS, Germany

**SAT-386** Viral compartmentalization and carcinogenesis at single-cell level in HBV-induced hepatocellular carcinoma  
Antonio SAVIANO, France

**SAT-387** Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C  
Steven FLAMM, United States

**SAT-388** A novel intrahepatic restriction factor, HMGA1, contributes to hepatitis B virus (HBV) replication in immune tolerant phase, serving as an anti-HBV target  
Zhongliang SHEN, China
SAT-389  **Multivariant surface quasispecies in a hepatitis B virus chronically infected individual with concomitant and continually positive surface antigen and anti-HBS biomarkers**
Suzane Kioko ONO, Brazil

SAT-390  **Evaluation of the introduction of hepatitis C core antigen as a routine test to detect viraemia among patients with anti-HCV antibodies**
Stephen BARCLAY, United Kingdom

SAT-391  **Virologic causes for DAA treatment failure of chronic hepatitis C**
Chun-Jen LIU, Taiwan

SAT-392  **Impact of direct antiviral agents (DAAs) on the HBV virologic profile in HCV+ but HBsAg- and HBCAb+ patients**
Régine TRUCHI, France

SAT-393  **Usefulness of HEV antigen determination in the diagnosis of acute hepatitis E**
Víctor J BELTRÁN, Spain

SAT-394  **Hepatitis V virus (HBV) cccDNA mini-chromosome transposase-accessible chromatin by atac-sec in infected primary human hepatocytes (PHHs)**
Vincenzo ALFANO, France

SAT-395  **Resistance monitoring data from treatment-naive chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator R07049389 monotherapy**
Xue ZHOU, China

SAT-396  **Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing**
Yang LIU, United States

SAT-397  **Novel mutations within hepatitis B virus antigen promoter correlate with viral relapse through increasing covalently closed circular DNA accumulation**
Demin YU, China

SAT-398  **Impact of antiviral therapy for blocking mother-to-child transmission on virus quasispecies in pregnant women with chronic HBV infection**
Zhihua LIU, China
## Viral hepatitis A/E: Clinical aspects

| SAT-399 | Significant compartment-specific impact of the RNA extraction and quantification method on the sensitivity of hepatitis E virus detection: implications for clinical care? | Patrick BEHRENDT, Germany |
| SAT-400 | Effectiveness of hepatitis A vaccination in human immunodeficiency virus-infected men who have sex with men during an outbreak of hepatitis A in Osaka, Japan | Hiroki BESSHO, Japan |
| SAT-401 | Histopathology of hepatitis E is associated with patients’ immune status and preexisting liver condition | Daniela LENGGENHAGER, Switzerland |
| SAT-402 | Epidemiology of fulminant hepatitis A cases in Vienna – an informative case series | David JM BAUER, Austria |
| SAT-403 | Epidemiology of fulminant hepatitis E cases in Vienna – an informative case series | David JM BAUER, Austria |
| SAT-404 | Impact of acute kidney injury in patients with acute hepatitis A | Ahmad KHAN, United States |
| SAT-405 | Are we aligned with WHO international strategy to eliminate hepatitis C by 2030: real-world data from Khyber Pakhtunkhwa, Pakistan | Bakht BILAND, Pakistan |
| SAT-406 | Hepatitis E seroprevalence and rate of viremia in immunocompromised patients – a systematic review and meta-analysis | Gustav BUESCHER, Germany |
| SAT-407 | Therapeutic window for ribavirin therapy in transplant recipients with chronic hepatitis E virus infection | Midas MULDER, Netherlands |
| SAT-408 | Does glucose-6-phosphate dehydrogenase deficiency affects morbidity in acute viral hepatitis? A case control study from a tertiary care hospital in Karachi, Pakistan | Mahrukh ALI, Pakistan |
| SAT-409 | Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010-2018 | Michael PEETERS, Belgium |
SAT-410  Hepatitis E virus infection in liver transplant recipients in Sweden  
Miriam KARLSSON, Sweden

SAT-411  Hepatitis E virus shedding in semen of chronically, but not acute HEV infected individuals  
Thomas HORVATITS, Germany
Viral hepatitis B/D: Therapy

SAT-412 Pradefovir in naive or experienced adult patients with chronic infection of hepatitis B virus: week24 results from 23 multicentre, double-blind, randomised, non-inferiority, phase2 trials
Yanhang GAO, China

SAT-413 Combination of NA, PEG-IFN alpha-2b and GM-CSF enhanced hbsab production in NA experienced CHB patients (the anchor a study): an interim analysis
Di WU, China

SAT-414 Efficacy and safety of treatment interruption in patients with HBeAg negative chronic hepatitis B
Teresa BROQUETAS, Spain

SAT-415 Pegylated interferon beta strongly reduces all serological and intrahepatic hepatitis B virus parameters in immunodeficient humanized mice
Andrea PIROSU, Germany

SAT-416 hzVSF, a novel HBV therapeutic candidate, shows WHsAg loss in woodchuck hepatitis model and safety in phase I clinical study
Byoung AHN, Korea, Rep. of South

SAT-417 Safety and efficacy of up to 76 weeks 10mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis
Alessandro LOGLIO, Italy

SAT-418 Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure
Alessandro LOGLIO, Italy

SAT-419 The establishment of hepatitis B care and treatment clinics with viral load testing capacity in the United Republic of Tanzania: a demonstration project following WHO guidelines, Zanzibar, 2017-2019
Ali SALIM, Tanzania

SAT-420 Nucleos(t)ide analogue therapy decreases the HBeAg loss rate in HBeAg positive chronic hepatitis B patients with hepatitis flare: a propensity score matching study
Chien-Wei PENG, Taiwan

SAT-421 Long-term risk of primary liver cancers in tenofovir versus entecavir treatment for chronic hepatitis B
Chao-Hung HUNG, Taiwan

SAT-422 ATI-2173, a novel phosphoramidate nucleoside prodrug for HBV cure regimens
Douglas MAYERS, United States
SAT-423  The role of HBV genotypes in HBV relapse after cessation of entecavir or tenofovir in HBeAg-negative patients without cirrhosis
Chien-Hung CHEN, Taiwan

SAT-424  Impact of ESC+ technology on the hepatic safety profile of GalNAc-delivered, HBV-targeting RNAi therapeutics
Edward GANE, New Zealand

SAT-425  A once-per-week or every-two-week dosing regimen is more efficacious for the TIR7 agonist JNJ-64794964 (JNJ-4964) to induce an anti-hepatitis B virus (HBV) effect and HBV-specific immune responses in AAV-HBV mice
Florence HERSCHKE, Belgium

SAT-426  In vitro and in vivo characterization of VIR-2218, an investigational RNAi therapeutic targeting hepatitis B virus
Florian LEMPP, United States

SAT-427  Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF)
George PAPATHEODORIDIS, Greece

SAT-428  Early PEG-interferon-related ALT flares of high magnitude lead to HBsAg decline and loss. A study of 639 chronic hepatitis B patients
Hannah S.J. CHOI, Canada

SAT-429  Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study
Harry JANSSEN, Canada

SAT-430  Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study
Heiner WEDEMEYER, Germany

SAT-431  Combination drug interactions of hepatitis B virus (HBV) S-antigen transport – inhibiting oligonucleotide polymers in vitro
Hua TAN, United States

SAT-432  Bile acid derivatives inhibit hepatitis B virus infection in vitro and in vivo
Kiyokai ITO, Japan

SAT-433  Early on-treatment ALT normalization in patients with chronic hepatitis B is associated with lower risk of hepatocellular carcinoma development
Jong Eun YEON, Korea, Rep. of South

SAT-434  Best in class hepatitis B virus anti-sense oligonucleotides: next generation bridged nucleic acid chemistries significantly improve the therapeutic index by reducing hepatotoxicity and increasing in vivo efficacy in a mouse model
Jin HONG, United States
## Viral hepatitis B/D: Therapy (Cont.)

| SAT-435 | Association between hepatitis B virus flare and overall survival in hepatitis B virus-related hepatocellular carcinoma in patients with undetectable serum HBV DNA levels | Jong-In CHANG, Korea, Rep. of South |
| SAT-436 | The first report of phase 1b study of a novel inhibitor of apoptosis proteins (IAPs) antagonist APG-1387 in patients with chronic hepatitis B: an interim analysis | Jinlin HOU, China |
| SAT-437 | The establishment of hepatitis B care and treatment clinics with viral load testing capacity in the United Republic of Tanzania: a demonstration project following WHO guidelines, Dar es Salaam, 2017-2019 | John RWEGASHA, Tanzania |
| SAT-438 | Solving the cold chain problem – development of a heat-stable therapeutic vaccine to combat chronic hepatitis B | Julia SACHERL, Germany |
| SAT-439 | Multicistronic DNA-based therapeutic vaccine as a promising candidate to treat chronic hepatitis B virus (HBV) infection | Helene KERTH, Germany |
| SAT-440 | EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: preliminary results of a phase 1 study in healthy adult subjects | Kajal LARSON, United States |
| SAT-441 | Novel cell culture 3D model for HBV/HIV co-infection and antiviral evaluation | Leda BASSIT, United States |
| SAT-442 | Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study | Young-Suk LIM, Korea, Rep. of South |
| SAT-443 | Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir | Lucio BOGLIONE, Italy |
| SAT-444 | Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study) | Milan SONNEVELD, Netherlands |
| SAT-445 | Silencing HBV expression using LNA gapmers: preliminary data of a new promising strategy | Maria Francesca CORTESE, Spain |
SAT-446  The composition of HBsAg during peginterferon-alfa2a treatment can predict treatment response in HBV/HDV-coinfection
Maria PFEPPEKORN, Germany

SAT-447  All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment-naive chronic hepatitis B patients in British Columbia, Canada
Mawuena BINKA, Canada

SAT-448  Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice
Michael CURRY, United States

SAT-449  Structural requirements for S-antigen transport-inhibiting oligonucleotide polymer inhibition of hepatitis B surface antigen secretion
Megan FITZGERALD, United States

SAT-450  Low hepatitis B surface antigen at baseline and increased ALT levels during treatment predicts significant HBsAg decline in peginterferon alfa added to long-term nucleos(t)ide analogue. Results from two randomized controlled trials in 165 patients
Mina FARAG, Canada

SAT-451  Efficacy and safety of switching to tenofovir alafenamide for chronic hepatitis B patients with advanced fibrosis and partial virologic response to oral nucleos(t)ide analogues (ESTAB-AFPVR) – an interim report
Ming-Lun YEH, Taiwan

SAT-452  Efficacy and safety of GLS4/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study
Mingyuan ZHANG, China

SAT-453  Long-term efficacy of generic antiviral drugs (tenofovir and entecavir) in suppression of viral replication in chronic hepatitis B
Marta CASADO, Spain

SAT-454  Guideline change for antiviral therapy reduced the risk of HBV-related HCC development among cirrhotic patients in South Korea
David KIM, Korea, Rep. of South

SAT-455  ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B
Qingling ZHANG, United States

SAT-456  Longer consolidation duration is required to reduce 1-year clinical relapse rate after stopping tenofovir in HBeAg negative CHB patients
Rachel Wen-Juei JENG, Taiwan
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT-457</td>
<td>Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression</td>
<td>Rajender REDDY, United States</td>
</tr>
<tr>
<td>SAT-458</td>
<td>Immtav, a novel immunotherapy approach to eliminate hepatitis B virus</td>
<td>Ruth MARTINEZ HAGUE, United Kingdom</td>
</tr>
<tr>
<td>SAT-459</td>
<td>HBV RNA decline without concomitant HBsAg decrease is associated with a low probability of sustained response and HBsAg loss</td>
<td>Sylvia BRAKENHOFF, Netherlands</td>
</tr>
<tr>
<td>SAT-460</td>
<td>HBV specific ImmTAV induce a broad immune response enabling the elimination of HBV positive cells</td>
<td>Sarah LEONARD, United Kingdom</td>
</tr>
<tr>
<td>SAT-461</td>
<td>Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials</td>
<td>Scott FUNG, Canada</td>
</tr>
<tr>
<td>SAT-462</td>
<td>Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers</td>
<td>Sneha V. GUPTA, United States</td>
</tr>
<tr>
<td>SAT-463</td>
<td>Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a therapeutic agent targeting persisting HBV infection</td>
<td>Zhongliang SHEN, China</td>
</tr>
<tr>
<td>SAT-464</td>
<td>Optimising delivery of therapeutic hepatitis B vaccines to induce resident memory T cells in the liver</td>
<td>Tamsin CARGILL, United Kingdom</td>
</tr>
<tr>
<td>SAT-465</td>
<td>Entecavir versus lamivudine as antiviral prophylaxis for patients with hepatitis B infection undergoing anticancer cytotoxic chemotherapy: a randomized multicenter clinical trial</td>
<td>Won KIM, Korea, Rep. of South</td>
</tr>
<tr>
<td>SAT-466</td>
<td>Functional cure based on pegylated interferon ? in long-term nucleoside analog suppressed HBcAg negative chronic hepatitis B: a multicenter real-world study (Everest project in China), an interim report</td>
<td>Ze-Qian WU, China</td>
</tr>
<tr>
<td>SAT-467</td>
<td>Occurrence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment: a multicenter study in Taiwan</td>
<td>Yi-Hsiang HUANG, Taiwan</td>
</tr>
</tbody>
</table>
**SAT-468**  Anti-HBS induction and HBsAg reduction by nasal administration of a therapeutic vaccine containing HBsAg and HBCaG (NASVAC) in patients with chronic HBV infection
Osamu YOSHIDA, Japan

**SAT-469**  The development and application of a prognosis prediction model for children with chronic hepatitis B
Yanwei ZHONG, China
Liver tumours: Therapy

**SAT-473**  
Pre-operative gamma-glutamyltransferase to lymphocyte ratio predicts long-term outcomes for intrahepatic cholangiocarcinoma following hepatic resection  
Jinju WANG, China

**SAT-474**  
LXR agonism potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription  
Zhongjie LIN, China

**SAT-475**  
Ivermectin inhibits cholangiocarcinoma proliferation via induction of endoplasmic reticulum stress in vitro and vivo  
Zhe WAN, China

**SAT-476**  
Percutaneous microwave ablation versus open surgical resection for colorectal cancer liver metastasis  
Lei CHEN, China

**SAT-477**  
5-aminolevulinic acid mediated photodynamic therapy: pathing the way towards a new therapeutic modality for hepatocellular carcinoma  
Abhishek KUMAR, France

**SAT-479**  
Transarterial radioembolization versus systemic treatment for the management of hepatocellular carcinoma with vascular invasion: analysis of the US national cancer database  
Joseph AHN, United States

**SAT-480**  
ALBI grade is a good predictive parameter for prognosis in advanced HCC patients with nivolumab therapy  
Wei TENG, Taiwan

**SAT-481**  
Early changes in circulating FGF19 and ANG-2 levels as a possible predictive biomarker for lenvatinib therapy in hepatocellular carcinoma  
Makoto CHUMA, Japan

**SAT-482**  
The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib  
Claudia CAMPANI, Italy

**SAT-483**  
Alcoholic liver disease is associated with a poorer survival after radioembolisation for hepatocellular carcinoma  
Clemens SCHOTTEN, Germany

**SAT-484**  
HBsAg relapse after living donor liver transplantation in hepatocellular carcinoma patients with hepatitis D virus infection may result in hepatocellular carcinoma relapse  
Adil BASKIRAN, Turkey
SAT-485 13C-methacetine breath test for the prediction of liver damage caused by transarterial chemoembolization in patients with hepatocellular carcinoma
Florian VAN BÖMMEL, Germany

SAT-486 Influence of acute kidney injury on the prognosis of patients receiving transarterial transembolisation for hepatocellular carcinoma: based on ICA-AKI criteria
Won SOHN, Korea, Rep. of South

SAT-487 Radiofrequency versus microwave ablation for hepatocellular carcinoma within the Milan criteria in challenging locations: a retrospective controlled study
Xue HAN, China

SAT-488 Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: analysis in real-life settings
Heechul NAM, Korea, Rep. of South

SAT-489 Intrahepatic HBV replication markers associated with tumor recurrence after surgical resection in patients with HBV-related hepatocellular carcinoma
I-Cheng LEE, Taiwan

SAT-490 Mutations in circulating tumor DNA predict primary resistance to systemic therapies in patients with advanced hepatocellular carcinoma
Johann VON FELDEN, Germany

SAT-491 Diagnostic value of brush cytology alone and in combination with tumor marker in malignant biliary stricture
Jaseem ANSARI, India

SAT-492 miR-486-3p mediates sorafenib resistance through targeting FGFR4 and EGFR in hepatocellular carcinoma
Lin Ji, China

SAT-494 Treatment strategy for single small T1/T2 hepatocellular carcinoma patients with Child-Turcotte Pugh class A; a nationwide cohort study in South Korea
Young-Joo JIN, Korea, Rep. of South

SAT-495 Safety and efficacy of lenvatinib in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice
Katsuaki OGUSHI, Japan

SAT-496 Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization before designing clinical trials comparing transarterial chemoembolization and immune checkpoint inhibitor-based therapies
Keisuke KOROKI, Japan
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT-497</td>
<td>High rate of hepatitis B virus S-integrated human extra spindle pole bodies like 1 fusion gene is detected in hepatitis B virus-related liver cancer patients: a Chinese case-control study</td>
<td>Rongming WANG</td>
<td>China</td>
</tr>
<tr>
<td>SAT-498</td>
<td>Treatment decision for hepatocellular carcinoma ≤5cm: surgical resection or microwave ablation</td>
<td>Ping LIANG</td>
<td>China</td>
</tr>
<tr>
<td>SAT-499</td>
<td>Chlorogenic acid decreases malignant characteristics of hepatocellular carcinoma cells by inhibiting DNMT1 expression</td>
<td>Yao LIU</td>
<td>China</td>
</tr>
<tr>
<td>SAT-500</td>
<td>Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma</td>
<td>Luca IELASI</td>
<td>Italy</td>
</tr>
<tr>
<td>SAT-501</td>
<td>A lncRNA-associated ceRNA regulatory network in MVI positive hepatocellular carcinoma influences their sensitivity to sorafenib</td>
<td>Zhiwen LUO</td>
<td>China</td>
</tr>
<tr>
<td>SAT-502</td>
<td>In vivo performance of PEG-coated gold nanoparticles mediated ultrasound guided radiofrequency ablation: a pilot study in swine</td>
<td>Tudor MOCAN</td>
<td>Romania</td>
</tr>
<tr>
<td>SAT-503</td>
<td>The «six-and-twelve» score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule</td>
<td>Marco SANDUZZI ZAMPARELLI</td>
<td>Spain</td>
</tr>
<tr>
<td>SAT-504</td>
<td>Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib monotherapy in advanced hepatocellular carcinoma: a systemic review and meta-analysis</td>
<td>Zhiyuan YAO</td>
<td>China</td>
</tr>
<tr>
<td>SAT-505</td>
<td>Dexamethasone prophylaxis of postembolization syndrome after transcatheter arterial chemoembolization: a randomized, double-blind, placebo-controlled study</td>
<td>Panot SAINAMTHIP</td>
<td>Thailand</td>
</tr>
<tr>
<td>SAT-506</td>
<td>Relative dose intensity and response in real-world treatment with lenvatinib for advanced hepatocellular carcinoma</td>
<td>Ryu SASAKI</td>
<td>Japan</td>
</tr>
<tr>
<td>SAT-507</td>
<td>Association between curative treatment after transarterial radioembolization and better survival outcomes in patients with hepatocellular carcinoma</td>
<td>Yoon Ah KIM</td>
<td>Korea, Rep. of South</td>
</tr>
</tbody>
</table>
SAT-509  The real-world systemic sequential therapy of sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
Yoonseok LEE, Korea, Rep. of South

SAT-510  Multicenter, real-world experience with lenvatinib for patients with advanced hepatocellular carcinoma in Japan
Takuya SHO, Japan

SAT-511  Prognostic value of alpha-fetoprotein in patients achieving complete response to transarterial chemoembolisation for hepatocellular carcinoma
Jae Seung LEE, Korea, Rep. of South

SAT-512  Quantitative high-thought small-molecule screening identified MEK inhibitor PD198306 synergize with sorafenib in treatment for hepatocellular carcinoma (HCC) via ERK-dependent up-regulation of Bim and ERK-independent down regulation of MCL1
Junjie HONG, China

SAT-513  Updated data from an ongoing study with ADP-A2AFP spear T-cells
Tim MEYER, United Kingdom

SAT-514  A nationwide multicenter study of Japanese patients with unresectable hepatocellular carcinoma treated with regorafenib in real-world practice
Kaoru TSUCHIYA, Japan

SAT-515  Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma
Tsuguru HAYASHI, Japan

SAT-516  No risk of hepatitis B reactivation in hepatocellular carcinoma patients with HBV-DNA > 100 iu/ml undergoing immune checkpoint inhibitor immunotherapy by pre-emptive strategy
Pei-Chang LEE, Taiwan

SAT-517  Effect of antibiotics, proton pump inhibitors and steroids on survival and response to immune-checkpoint inhibitors in patients with hepatocellular carcinoma
Pei-Chang LEE, Taiwan

SAT-518  Nucleos(t)ide analogs reduces hepatocellular carcinoma mortality in patients with low HBV-DNA levels
ZhiYun YANG, China

SAT-519  Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure
Yun Bin LEE, Korea, Rep. of South

SAT-520  Zinc phthalocyanine/sorafenib-conjugated bovine serum albumin nanoparticles provide effective synergistic therapy against hepatocellular carcinoma
Ji-Min ZHU, China